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Part I :  Methodologies for attaching polypyridyl ligands 
into amino acid side chains 
Chapter 1. Introduction 
 One of the biggest challenges encountered by medicinal chemists is to gain specificity to 
avoid off-target side effects. Ideally the drug should only target the organism or organ affected 
by the condition. Many potential solutions have been proposed by numerous researchers working 
in the field, but a final answer has still not been found. One interesting and elegant method 
consists of attaching the potential drug molecule to a vector molecule which provides specificity 
for a class of tissues, cells or organs. Vectors are usually (bio)molecules such as nutrients for 
cells (sugars, amino acids, etc.), cofactors (Vitamin B12), antibodies or others.
1
 
 Although metals have been used as medicines for the last 4500 years, it’s only the 
serendipitous discovery of a few metal-based drugs in the late 20th century such as Auranofin or 
cisplatin
2
 that triggered a rational design of drugs based on metals. In early examples, researchers 
have exploited these early discoveries to design second generation drugs. Advances in inorganic  
chemistry, ligand synthesis and biochemistry have enabled the construction of novel metal based 
drugs for alternative targets such as thiol-containing proteins, redox processes, reactive oxygen 
species (ROS)
3
 and others. 
 In an effort to combine those two ideas and mimic nature’s use of metalloproteins, 
bioinorganic chemists developed metal-peptide conjugates and explored them as potential 
medicinal agents, catalysts and in de novo proteins.
4-6
 They found numerous applications as 
2 
 
radiopharmaceuticals
7-9
, imaging agents,
10-12
 anticancer or antibacterial agents
1
 or DNA/protein 
inactivating agents.
13-15
 
 In spite of a great interest in attaching metals or metal ligands to peptides, there is a lack 
of methods that would enable an easy construction of ligands based on nitrogen-containing 
heterocycles attached to peptides. Previous studies present ways to append 2 or 3 atom donor 
ligands to peptides
16-19
 but methodologies using polydentate ligands beyond 3 are scarce.
20
 The 
Kodanko group recently showed the use of polydentate non-heme ligands and the corresponding 
iron or cobalt complexes as agents that can cleave or oxidize amino acids,
21, 22
 have anticancer 
properties through carbon monoxide release,
23
 inhibit the purified 20S proteasome
24
 or mimic 
glutathionylcobalamin (GSCbl).
25
 Tethering those complexes to peptides with the aim of specific 
delivery should first improve their activity and second enable a more in depth study of their 
modes of action. We sought to develop a divergent strategy for attaching such polypyridyl 
ligands to peptides through amino acid side chains through the synthesis of novel unnatural 
amino acids and applying them using solid phase synthesis (SPPS) in order to build their 
corresponding metal complexes. The divergency of the methodology would consist in 
introducing the ligand diversity as late as possible. 
 My contributions while in the Kodanko group towards the synthesis of those novel 
unnatural amino acids and their application through SPPS to accessing novel metal-peptide 
conjugates will be discussed in the first part of this dissertation. The first chapter will give a brief 
introduction on the different possibilities of building metal peptide conjugates and their 
applications, ferryl complexes and solid phase synthesis. Methodologies giving access to 
unnatural amino acids will be discussed with a special emphasis on enantioselective alkylation of 
benzophenone imine. The second chapter will present the conjoint development, with fellow 
3 
 
coworkers from the Kodanko group, Dr. Nitinkumar Jabre and M. Sc. Selma Ulku, of a novel 
divergent strategy for the synthesis of peptide polypyridyl ligand conjugates and its applications 
to SPPS. The third chapter will present the development of an optimal substrate for the 
enantioselective benzophenone glycine imine alkylation reaction enabling the use of acid 
sensitive substrates. The final chapter will present the conclusions of this first part of the 
dissertation, state the achievements and their importance and present future goals. 
I.1.A. Peptide ligand conjugates 
 This section will give a brief overview of the different possibilities for attaching metal 
ligands to peptides. A more in depth description can be found in Dr. Nitinkumar Jabre’s 
dissertation entitled: “Synthesis of peptide-ligand conjugates and their applications”.26 
 
Figure 1: Strategies for attaching metals to peptides by SPPS  
In principle there are two different strategies for attaching a metal to a peptide chain. The 
metal could either be covalently attached while the peptide is being built by SPPS or after 
4 
 
cleavage from resin and purification. The first strategy has the advantages of the synthesis being 
completed on resin and should in theory require less purification efforts. It has the inconvenience 
that the metal-peptide conjugate must survive the conditions used to cleave the peptide from 
resin.
1
 For this reason we have chosen to focus on the second strategy only. The ligand peptide 
conjugate will be first synthesized in solution or by SPPS, purified and characterized before the 
metal complex is formed (Figure 1). Many different modes for the attachment of the metal ligand 
to the peptide can be imagined. The reactivities of the functional groups on both the C-, and 
N-termini can be used to covalently attach metal ligands to the peptide. Using a similar approach 
the ligands can be incorporated in the backbone as well. Other functional groups that can be 
found on some of the side-chains from the natural amino acids (lysine, glutamic and aspartic 
acid, tyrosine, phenylalanine) have been used to tether ligands through the side chain. Finally 
unnatural amino acids already having ligands attached to them, or having functional groups that 
can be used towards this goal can be synthesized (Figure 2). 
In the next two sections, details about tethering ligands through the side-chains of natural 
amino acids and methodologies for the synthesis of novel unnatural amino acids will be given. 
We have chosen these two modes as the most pertinent because they enable the most flexibility 
in which position within the peptide the metal complex will be placed. For all the other modes of 
attachment please refer to Dr. Jabre’s dissertation entitled “Synthesis of peptide-ligand 
conjugates and their applications”.26 
5 
 
 
Figure 2: Different modes of attachment of metal ligands to peptides 
I.1.A.a. Ligand attachment through amino acid side chains 
 Among the twenty natural amino acids, lysine’s primary amine has been the most used 
side chain functional group to attach ligands to amino acids. The amino group can participate in 
reductive aminations, alkylation reactions giving the corresponding secondary or tertiary amines, 
amide bond formations, or can be transformed into the corresponding azide functionality to be 
further conjugated through “click” chemistry. 
6 
 
 
Figure 3: Examples of amino acids bearing metal ligands prepared from lysine 
 The Vaillant group prepared the single amino acid chelates (SAAC) containing bpa (2,2-
bis(pyridylmethyl)amine) (1)
27, 28
 or bqa (2,2-bis(quinoleylmethyl)amine) (2)
7, 29
 using the 
reductive amination reaction between Fmoc-protected lysine and 2-pyridinecarboxaldehyde or 
quinoline-2-aldehyde, followed by reduction with a borohydride (Figure 3).  
 Aminodiacetic acid residues can be introduced into peptides by direct N-alkylation of 
lysine with benzyl-2-bromoacetate to give Boc-Ada4-OH (3) according to the work of the 
Hopkins group.
30
 Other amino acids bearing the same aminodiacetic acid motif could be 
prepared in a similar fashion if unnatural amino acids resembling lysine, but with shorter linkers 
(1-3 carbons) between the backbone and the amino functionality, were used (Figure 3). 
 Lysine can also participate in amide bond formation reactions. The Sherry group 
explored this reactivity to prepare Fmoc-Lysine-DOTA-OH (4). Bromoacetyl bromide was used 
to make the amide bond, and the resulting bromide was displaced with triprotected DO3A-(tBu3) 
(Figure 3).
31
 
 Although lysine has been the most used natural amino acid to attach ligands to peptides, 
other amino acids such as glutamic and aspartic acids, tyrosine and phenylalanine have also been 
used. The Hovinen group used glutamic acid to attach a lanthanide (III) chelate through a peptide 
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bond formation reaction to make unnatural amino acid (5).
32
 In a very similar fashion, p-
Aminoobenzyl-EDTA has been attached to aspartic acid by the Rana group (6) (Figure 4).
33
 
 
Figure 4: Examples of amino acids bearing metal ligands prepared from natural amino acids 
 The Smith group used tyrosine to attach two bpa (2,2-bis(pyridylmethyl)amine) units in a 
very short and clever way. The iminium ion, resulting from the Mannich reaction between 
dipicolylamine and paraformaldehyde, was reacted with tyrosine following an electrophilic 
aromatic substitution reaction to give zinc (II) chelator (7) (Figure 4).
34
 
I.1.A.b. Preparation of metal chelating unnatural amino acids 
 A different approach consists of preparing unnatural amino acids which bear 
metal-binding units directly attached to the peptide backbone. Most of the amino acids prepared 
this way have been incorporated into peptides using Fmoc based SPPS. Reactive functional 
groups are usually protected using acid sensitive protecting groups that are cleaved under the 
acid-mediated cleavage from resin. 
 The Imperiali group explored the Zn
II
 affinity of different bipyridine or phenanthroline 
containing alanine derivatives synthesized by asymmetric alkylation of benzophenone glycine 
imine. Molecules 8-12
17-19, 35
 showed different metal binding affinities depending on the 
bipyridine moiety. Other bidentate or tridentate ligands featuring pyridoxal coenzyme (13)
16
 or 
quinoxaline
36
 have also been prepared using the same synthetic method (Figure 5). 
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The Scrimin group used electrophilic serine β-lactone derivatives to directly attach the 
triazacyclononane (tacn) group to the β-carbon of alanine (16).37, 38 A different approach has 
been used by the Diederichsen group to attach the same tacn unit. “Click” chemistry has been 
employed to form a triazole linker by reacting Fmoc protected propargylglycine and an azide 
containing tacn unit (17).
39
 The Yu group used the basicity of cyclen to N-alkylate 
bromo-homoserine to give cyclen containing amino acid 18 that could be easily coupled to other 
peptides (Figure 5).
40
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Figure 5: Examples of unnatural amino acids bearing metal ligands attached to the backbone 
I.1.B. Biomedical applications of peptide ligand conjugates 
Peptide metal ligand conjugates have found various applications in different areas such as 
biomedicinal chemistry and biology, catalysis of chemical and biological reactions and de novo 
synthesis of metallopeptides. The focus of this section will be on applications related to the 
biomedical field with a particular emphasis on peptide-based radiopharmaceuticals and imaging 
agents as well as therapeutic agents (inactivation of biomolecules, anticancer or antibacterial 
activity). 
10 
 
Receptor binding peptides have become an attractive target for vectoring metal-based 
radioimaging agents and therapeutic agents. Conjugation of the metal based “warheads” to 
specific peptides that can bind overexpressed receptors in cancer cells has opened new 
possibilities for targeted radiotherapy and cancer treatment.
1, 9, 10, 41
 Some of the most common 
peptide vectors are somatostatin, bombesin, gastrin, neurotensin and LHRH (luteinizing 
hormone-releasing hormone). In 1994, a specific example of a peptide based radioimaging agent 
has been authorized by the FDA for cancer diagnosis (
111
In-DTPA-octreotide or OctreoScan®) 
and became a “golden standard” in the field (Figure 6). The development of new radiolabelling 
techniques and chemical modifications of the peptide vectors to gain more specificity, avoid 
short half lives (due to peptidase degradation), and enhance pharmacokinetics were the main 
researched areas. They gave rise to many new agents that have been tested in clinical trials, and 
for some, approved by the FDA. A few examples will be presented in the next paragraph. 
 
Figure 6: 
111
In-DTPA-octreotide or OctreoScan®: the first FDA approved radiolabelled peptide 
for cancer imaging 
 The foundation of peptide-based radiolabelling agents lies in the identification of a 
molecular receptor (target) that is overexpressed on the surface of cancer cells and that is a target 
of an agonist peptide. The latter peptide is synthetically modified to improve its stability to 
peptidases and pharmacokinetics in a way that the binding affinity to the receptor is preserved. 
11 
 
The radiometal is covalently attached to the peptide using a metal-binding ligand and a spacer. 
Many aspects need to be optimized for the peptide-based radiolabelling agent to be successful 
such as accumulation in target and non target cells, in vivo stability, clearance, toxicology, etc. A 
few examples of peptide receptors expressed in human tumors
1, 9, 10, 41
 are listed below: 
 Somatostatin: expressed in neuroendocrine tumors, melanomas, breast, brain and small 
lung cancers 
 Bombesin: expressed in prostate, breast, pancreas and colorectal cancers 
 Gastrin: expressed in thyroid cancer and stromal ovarian cancers 
 LHRH: (luteinizing hormone-releasing hormone) expressed in prostate, breast and 
ovarian carcinomas 
 
Figure 7: Commonly used radiometal chelators 
The choice of the metal chelator and the radiometal itself depends on many factors and 
many metal-ligand partners are being used. The nature of the decay of the radiometal will 
12 
 
determine the imaging technique that can be used. The half life of the radiometal and the ease 
and cost of its preparation are also extremely important factors.  
Some of the metals used are: 
99Tc (γ emission, no α or β radiation, low cost and easy 
access), 
111In (γ emission, longer half life, suitable for delayed imaging, high cost), 64Cu (β 
emissions, can be used for both imaging and radiotherapy, high cost), 
66/67/68Ga (suitable for γ 
scintography and PET imaging, high cost but excellent physical properties). Because of its low 
cost and ease of preparation, 
99
Tc is used in 80% of cases in clinical applications. Representative 
examples of the most commonly used chelators and how they can be attached to the peptide are 
shown in Figure 7. 
In the same manner, metal based “warheads” can be conjugated to peptides in order to 
inactivate biomolecules. The Shally
42
 group has attached known and clinically used 
antiproliferative metal complexes cisplatin [cis-diamminedichloroplatinum(II)] and 
transbis(salicylaldoximato)copper(II) to LHRH peptides through a D-Lysine linker and showed 
an increase of cytotoxic activity inhibition of [
3
H]thymidine incorporation in human prostate 
cells ranging up to 73%. 
In a different approach the Kodadek group has attached a singlet oxygen generating 
Ru(II)(tris-bipyridyl)
2+
 complex to a highly selective VEGF (vascular endothelial growth factor) 
peptoid antagonist GU40C.
43
 Upon irradiation the CALI (chromophore-assisted light 
inactivation) reagent was up to 1000 times more active at inhibiting the activity of the VEGF 
receptor than compared to the same reagent left in the dark. In summary, the metal complex was 
used in this case to mask (and trigger using light) the action of the antagonist peptoid GU40C 
(Figure 8). 
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Figure 8: VEGF antagonist (Ru
II
(bpy)3
2+
)-GU40C metal peptoid conjugate 
Numerous other examples of peptide metal conjugates, where both the peptide and metal 
can play different roles have been synthesiszed. This type of conjugation became popular in the 
recent years with the development of solid phase chemistry that enables quick and easy synthesis 
of the peptides. The development of inorganic and bioinorganic complexes as well as the 
discovery and further understanding of the overexpression of peptide receptors on different type 
of cells including cancer cells have also contributed to the popularity of this strategy. 
The Kodanko group has been interested in the study of peptide ferryl conjugates. Studies 
to understand the oxidative reactions between ferryls, amino acids and peptides have been 
undertaken, as well as the potential use of those conjugates in a therapeutic way through 
oxidative protein inactivation. Ferryl chemistry will be discussed in the next section. 
I.1.C. Ferryl chemistry 
Nature uses different oxygen activating metalloenzymes to selectively oxidize different 
substrates. Some of them use iron as the central red/ox unit. The most studied, known and 
understood iron containing enzymes are heme-iron cytochrome P-450, which uses a 
protoporphyrin to bind Fe(II)
44
 and non-heme iron enzyme methane monooxygenase (MMO).
45
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Since the discovery of Fe(IV) complexes as active species in biological systems, many research 
groups have been trying to model them and prepare synthetic equivalents. Most research has 
focused on two different families of ligand structures, namely heme based structures as in the 
cytochrome P-450 or non-heme ligands. Non-heme ligands that can support iron-oxo species 
have mainly N-donor ligand frameworks consisting of tertiary amines, pyridines or cyclams. The 
first full characterization of a synthetic ferryl came in 2003
46
 and five crystal structures have 
been reported since. The subject has been extensively covered in the literature and thorough 
reviews by Que
47, 48
 and Nam
49
 have been published. Former graduate students from the 
Kodanko laboratory, Dr. Ahmed Abouelatta
50
 and Dr. Ashley Campanali
51
 have discussed ferryl 
chemistry in their PhD dissertations, and for these reasons the description here will only briefly 
introduce the main aspects of non-heme iron-oxo chemistry. 
In 2000 the Wieghardt group used oxone to oxidize [Fe
III
(cyclam-acetato)(CF3SO3]
2+
 at  
-80ºC and characterized the product by Mössbauer spectroscopy.
52
 Three years later the Que 
group obtained a crystal structure of the ferryl complex [Fe
IV
(O)(TMC)(MeCN]
2+
. Many more 
complexes have been synthesized and characterized since then, and the usual synthetic strategy 
consist in reacting Fe(II) complexes with oxidants such as peracids,
46, 53-55
 PhIO,
56
 KHSO5,
57
 
ozone,
58
 NaOCl
59
 or others. The oxidation of the iron center proceeds through a two-electron 
process for single oxygen donors or through a homolytic cleavage of an O-O bond for two 
oxygen donors such as hydroperoxide.
60
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Figure 9: The oxidation chemistry of ferryl complexes 
The Fe-O bond has characteristics of a double bond with a length of around 1.64 Å. The 
chemistry of ferryl complexes includes redox reactions and C-H activation. As noted before, 
most ferryls are obtained by oxidation from the corresponding Fe
II
 complexes. Once formed, the 
ferryls are prone to oxidizing numerous functional groups. In early studies, ferryls were used to 
oxidize functional groups that are prone to oxidation including phosphines,
46
 alkenes,
53
 or 
sulfides.
61
 An impressive result demonstrated that N4Py and Bn-TPEN derived ferryl complexes 
are able to oxidize C-H bonds (both activated and non-activated) with bond energies between  
81 and 99 kcal/mol.
62
 
The Kodanko group has been interested in exploring the reactivity of ferryl groups with 
biologically relevant species. In a first study, the ferryl complex [Fe
IV
(O)(N4Py)]
2+
 was reacted 
with all 20 natural amino acids (protected as the Ac-AA-NHtBu). It was shown that different 
oxidation patterns exist depending on the nature of the amino acid submitted to the reaction with 
the ferryl.
21, 22
 Complex and rigorous kinetic and mechanistic studies have also shown a very 
broad array of reactivities with rate constants for the most reactive amino acid (cysteine) being 
28,000 times higher than the one of the unreactive amino acids. Five amino acids (Gly, Met, Trp, 
Tyr and Cys, in increasing reactivity order respectively) were substantially more reactive than 
the other 15 and all reacted with different KIEs (kinetic isotope effect) and mechanisms.
21, 22
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In a subsequent study, the intramolecular reaction of a ferryl complex within a 
peptide-ferryl conjugate was studied.
63
 The results showed that reactivity is controlled by a 
remote benzyl ester that is situated 11 atoms away from the metal center. 
Further studies with other biologically relevant systems have shown that N4Py derived 
ferryl complexes can oxidize glutathione (GSH) to its dimer form GSSG (the disulfide dimer).
64
 
Serine proteases, trypsin and chymotrypsin, can be inactivated by ferryl complexes of N4Py 
having a pendant guanidinium group. The inactivation occurs by oxidation of the side chain and 
not oxidative cleavage of the backbone.
65
 
Further investigations of both ferrous and ferryl complexes reactivities with short 
peptides and proteins were undertaken during my time in the Kodanko laboratory. The use of 
those complexes as potential inhibitory agents when tethered to vector peptides has also been 
studied by members of the Kodanko group. All these studies require efficient ways of attaching 
polypyridyl ligands to peptides. A new strategy developed with fellow students from the 
Kodanko laboratory, Dr. Jabre and M.Sc Ulku will be described in Chapter 2 of this thesis. The 
next sections will describe the use of solid phase synthesis for the preparation of peptides and 
synthetic strategies used to build new, unnatural amino acids. 
I.1.D. Solid phase chemistry/peptide synthesis 
The idea of solid phase synthesis came from the Merrifield laboratory in the early 
1960s.
66
 The process was based on the use of a polymeric resin bead cross linked to a growing 
chain of the peptide (through synthetic steps). The use of excess reagents (monomers, coupling 
reagents and deprotection cocktails, same as in a classical solution phase sequence) had the aim 
to force reactions to completion. The excess material could potentially be removed by simple 
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filtration leaving the growing peptide attached to the insoluble bead in the reaction flask. The 
whole process was based on 3 requirements: 
 The polymeric support for the synthesis had to be inert to the conditions used to both 
building the peptide and the final cleavage from the resin 
 A strategy of orthogonal protection and deprotection of the reactive amino acid functional 
groups had to ensure the ability to easily build the peptide and reduce the number of 
manipulations. Reactive side chains needed to be protected in a way that their reactivity 
was only uncovered during the final cleavage from resin or through an additional and 
final step (for example hydrogenolysis). 
 The growing peptide needed to be attached to the resin bead in a way that a final reaction 
would cleave the final product from the bead and enable its isolation.  
 The first published example of a successful peptide syntheis using SPPS came from the 
Merrifield laboratory in 1963.
66
 A Cbz protected amino acid (free C-terminus) was attached 
to the polystyrene resin bead through an ester bond. The Cbz protecting group was 
selectively removed using an HBr/HOAc mixture unveiling a reactive amino group. The 
latter could be reacted with a second Cbz protected amino acid using DCC coupling 
conditions. The Cbz group could be once again removed using the same HBr/HOAc cocktail 
and the sequence of reactions repeated until the desired peptide was fully constructed. The 
unreacted reagents were filtered off between reactions, leaving the insoluble resin bead in the 
flask. The final peptide was liberated from the resin by NaOH saponification of the first ester 
bond (Figure 10). Changes to the initial sequence were made by the Merrifield group to make 
the method more robust and enable better deprotection yields and selectivity by replacing the 
Cbz protecting group by a tert-butoxycarbonyl group (BOC) and the nitropolysterene bead 
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by a 2% crosslinked polystyrene. Those efforts enabled the group to disclose the successful 
synthesis of bovine insulin in 1966
67
  
 
Figure 10: Merrifield’s first solid phase synthesis sequence of a tetrapeptide 
Despite the synthetic successes of these early solid phase syntheses, the community was 
very skeptical on the potential use of the method. In 1973 Max Brenner described the discovery 
of SPPS with the following words: “The invention of the solid-phase method looked like an 
ingenious trick to overcome some of the unpleasant features of the classical methods. As we 
know today, the ingenuity of the trick remains, but only a large investment of heavy real effort 
will eventually, if ever, work it into a real progress over the classical approach.”68 A “large 
investment of heavy effort” made solid phase synthesis one of the most, if not the most, robust 
methodology to build not only peptides but also DNA, RNA and others and was recognized by a 
Nobel Prize for Merrifield in 1984.
69
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Since its invention, SPPS has evolved and all parameters have been modified and 
optimized starting from the resin beads, the use of different linkers,
70
 protecting groups and 
subsequent deprotecting cocktails as well as coupling agents. Automated systems are common 
synthetic laboratory equipment all over the world. All aspects have been thoroughly reviewed 
and only the main aspects relevant to the work presented in Chapters 2 and 3 of this dissertation 
will be explained in the following paragraphs. 
One of the disadvantages of the BOC strategy is the use of either HF or TFA for the final 
cleavage step. HF is highly toxic and can react with standard glassware equipment (etching) so 
special equipment needs to be used. To circumvent those issues a different strategy, namely 
Fmoc SPPS can be adapted (Figure 11). In this case the amino acids are protected with the Fmoc 
protecting group that can be easily removed using a 20-50% secondary amine solution (such as 
piperidine) or DBU. The drawbacks of this method are higher aggregation of longer peptide 
compared to the BOC strategy, and racemization of Cys containing peptides. 
PAM resin was introduced to circumvent losses of larger peptides from the Merrifield 
resin during the TFA mediated BOC deprotection.
71
 It offers better stability to TFA but also 
requires harsher conditions for the final cleavage often requiring the use of HF. 
Wang resin, introduced in 1973 by the Wang group, has become the most used resin for 
the Fmoc SPPS. The linker attached to the polystyrene bead is a 4-hydroxybenzyl alcohol group 
through a phenyl ether bond.
72
 The peptide can be cleaved through acid-assisted ether bond 
cleavage (usually a TFA mixture with scavengers) to give the corresponding carboxylic acid 
product. 
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Figure 11: Boc and Fmoc deprotection 
 
Figure 12: Commonly used resins and linkers in SPPS 
If a C-terminal peptide amide is desired, the Rink amide
73
 or PAL resin can be used. 
Similar to the Wang resin, the peptide is linked to the polystyrene bead through a phenyl ether 
linker that can be cleaved under TFA conditions.  
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Many other resins offering either a wide variety of cleavage conditions, such as the trityl 
and 2-chlorotrityl resins
74
 (acetic acid mediated cleavage), HMBA
75
 (hydroxymethyl benzoic 
acid linked resin) (base mediated cleavage) or the preparation of specific terminal groups such as 
the DHP resin
76
 (for the preparation of alcohols) or the Weinreb aminomethyl resin to prepare 
terminal aldehydes
77
 have also been developed. 
 
Figure 13: Formation of an intermediate oxazolone that epimerizes the R2 α-carbon geometry 
while building a peptide from the N-terminus (example on PEG resin) 
The coupling step has also seen a number of optimizations (known also from standard 
solution phase synthesis). As in all peptide synthesis, peptides are built from C-to N-terminus 
using SPPS. Building a peptide in the opposite direction presents a risk of epimerization of the α-
carbon. Amides are indeed known for closing on an activated ester to form a five membered 
oxazolone where chirality is lost. When building a peptide from the C-terminus, the N-terminus 
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of a new peptide is protected as a carbamate (Fmoc, or Boc), and carbamates are known for not 
cyclizing in a similar fashion (Figure 13, Figure 14). 
 
Figure 14: Absence of formation of an intermediate oxazolone while peptide is built from the C-
terminus (use of carbamate protection) (example on PEG resin) 
 The other potential risk for epimerization comes from a slow reacting amino acid in the 
peptide bond formation reaction. Upon activation of the C-terminus as an active-ester, an 
intermediate ketene can be formed by deprotonation of the α-carbon leading to epimerization. 
The ketene is still reactive in the peptide bond forming reaction, leading to an epimerized 
peptide. This problem is recurrent with carbodiimide activated esters (and DCC in particular). To 
circumvent this problem, HOBt (1-hydroxybenzatriazole) can be added in stoichiometric fashion. 
HOBt reacts with the activated ester to give a new ester. The latter is still reactive in the peptide 
bond formation reaction but does not lead to ketene formation. 
Modern coupling phosphonium-based reagents like BOP (Benzotriazol-1-
yloxy)tris(dimethylamino)phosphonium hexafluorophosphate ) or aminium-based such as HBTU 
(O-(Benzotriazol-1-yl)-N,N,N’,N’-tetramethyluroniumhexafluorophosphate) or HATU have OBt 
incorporated in them as a leaving group leading to the formation of the HOBt ester in situ, thus 
23 
 
facilitating synthesis. Many other coupling reagents have been developed for special, difficult to 
make, peptide bonds (Figure 15). 
 
Figure 15: Commonly used peptide coupling agents 
 In order to use SPPS for the construction of metal peptide conjugates, new unnatural 
amino acids need to be prepared. The following section presents synthetic methods to prepare 
such amino acids. 
I.1.E. Unnatural amino acid synthesis strategies 
The α-amino acids (AAs) are one of the most important chiral building blocks for both 
medicinal and synthetic chemists. Methods for the isolation of enantiomerically enriched α-
amino acids have evolved over the years. The high demand for new unnatural amino acids has 
motivated synthetic chemists to discover new methodologies for the construction of α-AAs, 
marking a switch from the classical methods. Historically, α-AAs were either isolated from 
natural sources or resolved either chemically or enzymatically. The last 20 years have seen an 
emergence of catalytic asymmetric syntheses of α-AAs. The next sections will present some of 
the methodologies in each of the approaches used to synthesisze α-AAs with a special emphasis 
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on enantioselective alkylations of glycine derivatives. More specific information can be found in 
the numerous review articles devoted to the subject.
78-82
 
Two main approaches are available for the enantioselective construction of an α-AA. The 
first one is the asymmetric introduction of the α-hydrogen. The main types of reactions that 
belong to this group of transformations are enantioselective hydrogenations of α-β carbon-carbon 
double bonds and the analogous hydrogenation (or hydride addition) of nitrogen-carbon bonds.
83
 
All the other strategies, aim at introducing one of the constituents of an amino acid, namely an α-
amino group, or the α-side chain or the carboxy group (Figure 16).80 Only a few examples will 
be given to illustrate each strategy as hundreds of methods, catalyst and ligands exist for each 
transformation (Figure 16). A more in depth description of the asymmetric alkylation of glycine 
imines using quaternary ammonium salts will be given in the following section.  
Asymmetric hydrogenation is one of the most employed and researched catalytic 
transformations in organic chemistry. Since the work on the synthesis of L-Dopa by Knowles
84
 
and early efforts by Noyori and Kagan (recognized by the Nobel Prize in 2001 for Knowles and 
Noyori), numerous applications have emerged including the synthesis of α-AAs. Both 
monodentate and bidentate ligands can induce high levels of enantioselectivity using mostly Rh 
and Ir complexes. 
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Figure 16: Different approaches to build α-AAs80 
Rhodium complexes with different families of monodentate ligands including 
phosphines, phosphonium salts, phosphonites, aminophosphonites, phosphoramidites and 
phosphites systematically induce levels of ee (enantiomeric excess) higher than 90% in the 
asymmetric reduction of α-β-dehydro α-AAs 35.85-89 Examples of some of these ligands are 
shown in Figure 17. 
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Figure 17: Asymmetric hydrogenation of α-β-dehydro α-AAs with Rh complexes 
Analogous bidentate ligand-Rh complexes have been found to be even more efficient 
than mondentate systems, enabling lower levels of ligand to be used (catalytic turnover often as 
high as 10,000). Interestingly, bidentate phosphines are also great ligands for the asymmetric 
hydrogenation of α-β carbon-nitrogen double bonds as in α-imines 3790 or hydrazones 3991 
(Figure 18).  
 
Figure 18: Asymmetric hydrogenation of α-β carbon-nitrogen double bonds with bidentate 
phoshine ligand-metal complexes 
 The Strecker reaction is one of the oldest amino acid synthesis methods, where an 
aldehyde or ketone is reacted with potassium cyanide in the presence of ammonium chloride to 
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give an amino acid after hydrolysis. Although discovered in 1850, the reaction was only a source 
of racemic α-AAs until recent development of its asymmetric catalytic analogue in the 1990s. 
Asymmetric Strecker type reactions can be catalyzed by both metal and organocatalysts. The 
Vilaivan group has shown that the catalytic addition of TMSCN to imine 41 in the presence of a 
titanium complex gives the product with good yields and up to 90% ee (Figure 19).
92
  
 
Figure 19: Strecker type asymetric α-AA synthesis 
 In a similar fashion, aldimines such as tosylimines derived from aliphatic aldehydes can 
undergo a cyanide addition catalyzed by quaternary ammonium iodides to give the 
corresponding products in good yields and excellent enantioselectivities (% ee > 98%).
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 The introduction of the α-side chain to glycine analogues is one of the most versatile 
methods of building α-AAs. Most methodologies use phase transfer catalysis to alkylate glycine 
imine derivatives. The next section will present the historical discovery of this type of reactions 
and give a perspective on this very robust method. 
I.1.F. Enantioselective alkylation of glycine imine derivatives 
I.1.F.a. Strategies 
Phase transfer catalysts (PTCs) are ionic compounds that ease the migration of molecules 
between the aqueous and organic phase in a biphasic solution. They are known to highly 
accelerate the rate of reaction of heterogeneous reactions. 
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The high acidity of α-hydrogens of α-aminoacid ester imines 43 enables easy access to 
highly nucleophilic enolate derivatives 44 in situ. PTCs permit a controlled delivery of the 
enolate into the electrophile-containing phase, offering many advantages. Reactions are usually 
more selective due to controlled delivery. Nucleophiles are often more reactive due to higher 
charge separation of the phase transfer catalyst-nucleophile ion pairs. A wide array of solvents is 
allowed, giving easy solutions for the isolation and recovery of products and catalysts. The 
catalysts are often organic quaternary ammonium salts which facilitate reactions compared to 
water-and air-sensitive transition metal catalysts. All these points make asymmetric phase 
transfer catalysis a very attractive methodology that has seen increasing attention and widespread 
applications. Numerous review papers describe the different aspects of the subject.
82, 94-97
 
 
Figure 20: Phase transfer catalysis of α-aminoacid ester imines 
 The next section will describe some of the optimization work dedicated to substrate and 
catalysts for the phase transfer catalysis of glycine imines. Other applications are included in 
previous review articles and will not be discussed.
87, 99-102
 
I.1.F.b. Substrate and catalyst optimization 
O’Donnell was the first to report the use of chiral PTC for the asymmetric alkylation of 
glycine imine esters in 1989.
98
 The catalyst used was an N-benzyl ammonium salt derived from 
the natural alkaloid Cinchonine. Low to moderate levels of enantioselectivity were obtained 
ranging from 42% to 66% ee in favor of the (R) enantiomer. Interestingly, the (S) enantiomer 
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could be obtained if a stereoisomer and pseudo-enantiomer of the catalyst derived from 
Cinchonidine was used, with the same levels of enantioselectivity. The optimized conditions 
used a tert-butyl ester benzophenone imine as the substrate, a 50% NaOH/CH2Cl2 solvent system 
and high stirring for 24 hours at RT (Figure 21).  
 
Figure 21: First example of Cinchona derived PTC of glycine imines by O’Donnell 
 A major breakthrough for this subject was registered almost at the same time (submitted 
within a week) from two independent labs in 1997. The Corey group hypothesis stated that 
increased steric hindrance on the bridgedhead nitrogen atom should increase the shielding of 
three of the four quadrant phases of the pseudo tetrahedron, thus enabling a closer ion-pair 
contact of the catalyst with the substrate and higher levels of enantioselectivity. To prove their 
hypothesis the Corey group built a new catalyst using a 9-anthracenylmethyl group to construct a 
Cinchonidine derived quaternary ammonium salt. The secondary alcohol was also transformed 
into an allyl ether. The alkylation reaction using O’Donnell’s substrate with solid CsOH gave 
good yields and excellent levels of enantioselectivity (92-99% ee).
99, 100
 The Lygo group 
conducted a very similar analysis, and prepared the analogous catalyst with the exception of 
leaving the free alcohol (which is believed to get alkylated during the reaction and does not seem 
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to have an influence on the levels of ee). Their levels of enantioselectivity were slightly lower 
than that of Corey, but the reactions were conducted at RT (Figure 22).
101
 
 
Figure 22: Optimized cinchonidinum PTC for the asymmetric alkylation of glycine imines 
 Since the simultaneous discovery of this new catalyst by Corey and Lygo, most 
optimizations have focused on the nature of the catalyst. The most interesting modifications have 
been the use of organic bases such as the Schwesinger BTTP or BEMP showing no loss of % ee 
in homogenous catalysis
102
 and the attachment of the catalyst to different type of SPPS resins
103, 
104
 to enable the synthesis of amino acids using that technology or higher order oligomers
105, 106
 
(dimers and trimers of the Cinchona catalyst) that could improve the levels of enantioselectivity. 
 Only minimal attention has been given to substrate optimization. The original O’Donnell 
paper mentions that benzyl protected ester gives only 28% ee compared to 66% when the tert-
butyl protected ester imine is used. In 2003, the Lygo group presented a short study on the 
influence of the size of the ester protecting group. Surprisingly, the ethyl group could induce 
levels of ee between 73% and 87% compared to 79% for the benzyl ester and 63% for the 
benzhydryl ester.
107
 Nonetheless, the tert-butyl ester protected benzophenone imine is the only 
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substrate to date to consistently induce high levels of enantioselectivity with the Cinchona 
derived catalysts. 
 Spiro type C2-symmetric quaternary salts derived from (R)-or (S)-Binol are the other 
family of PTCs that have been successfully developed for the alkylation of glycine imines. Their 
synthesis is more difficult as they are purely synthetic (compared to derivatives of the Cinchona 
family natural alkaloids), which also enabled a huge variety of analogues and room for 
optimization. The levels of enantioselectivity induction are comparable or even higher than with 
the Cinchona derived PTCs. Examples of such catalysts are given in Figure 23.
87, 99-102
 
 
Figure 23: C2-symmetric quaternary salts derived from (R)-or (S)-Binol 
I.1.G. Thesis statement (Part I) 
The use of peptides as vectors for therapeutic agents is a very efficient and elegant way of 
gaining specificity. Concurrently metal complexes are finding more and more medicinal 
applications as both imaging and therapeutic agents. It seemed natural to combine those two 
areas and build metal peptide conjugates, and research in this field has been recently dynamic. 
Despite these facts, there is a lack of efficient and divergent strategies to build such peptide 
metal conjugates. A great improvement for the fast synthesis and evaluation of such species 
would be to develop a SPPS “friendly” and divergent method that would enable both modularity 
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on where within the peptide to attach the metal binding unit and also vary its structure. Ideally, 
the structural diversity would be introduced late in the synthetic sequence and from a common 
precursor, limiting the number of reactions for each compound. 
The goals for this first part of this dissertation were first to develop a SPPS friendly, 
divergent methodology for the attachment of non-heme polypyridyl ligands to peptides through a 
novel unnatural amino acid. Solution phase methodologies and unnatural amino acids suitable 
for the construction of such metal-peptide conjugates have been synthesized previously in the 
Kodanko group in standard solution phase chemistry.
63
 The translation from solution phase to 
SPPS prior to my investigations had been unsuccessful. 
The second goal was to develop a new and optimized substrate for the asymmetric, phase 
transfer catalyzed alkylation reaction of benzophenone imine. The current methodology suffers 
from the fact that the only substrate to date to consistently induce high levels of 
enantioselectivity with the Cinchona derived catalysts is the tert-butyl ester benzophenone imine. 
With the first goal in mind, namely the use of Fmoc SPPS for the construction of metal peptide 
conjugates it becomes clear that large amounts of Fmoc unnatural amino acids would be needed. 
Amino acids for Fmoc SPPS with their side chains protected with acid-labile protecting groups 
(that are disclosed during the final acid mediated cleavage from resin) are not easily synthesized 
(or require extra protecting group manipulation steps) using the phase transfer Cinchona 
catalyzed alkylation of glycine benzophenone imine, because the tert-butyl ester deprotection 
(acid mediated) also removes the side chain protecting groups. There is a clear need for a 
substrate having an orthogonal protecting group with the side chain’s protecting group that 
would induce high levels of enantioselectivity. 
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Strategies to complete each of the goals, as well as all relevant experimental data, will be 
discussed in the next two chapters. Conclusions and future directions will be presented at the end 
of this Part I of the dissertation. 
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Chapter 2. Novel, divergent strategy for the synthesis of peptide 
polypyridyl ligand conjugates and its applications to SPPS 
I.2.A. Background and project design 
The Kodanko group demonstrated that ferryl complexes derived from N4Py can cleave 
peptide backbones and oxidize side chains when reacted with single, protected amino acids.
21, 22
 
With the aim of studying ferryl complexes attached to peptides, a divergent strategy has been 
developed and applied to the construction of a short peptide incorporating polypyridyl ligands. 
The work of Dr. Jabre has shown that the pyridyl ring being a core element of numerous 
non-heme polypyridyl ligands, a pyridylmethyl containing unnatural amino acid is a perfect 
anchor for a divergent synthesis of such peptide-ferryl conjugates. The clever design of the 
Fmoc-HPA(OTBS)-OH unnatural amino acid (HPA: 2-hydroxymethyl-5-pyridyl alanine) 
enabled a quick synthesis of a ferryl containing dipeptide Ac-HPA(Fe
IV
(O)(N3Py))-Gly-OBn in 
solution phase (Figure 24) (for the synthesis of Fmoc-HPA(OTBS)-OH, please refer to Chapter 
3, Scheme 9).
63
 The decomposition of the oxo species was shown to be controlled by the ester 
moiety located 11 atoms away from the iron center. 
 
Figure 24: Design of the HPA(OTBS) unnatural amino acid leading to the synthesis of dipeptide 
Ac-HPA(Fe
IV
(O)(N3Py))-Gly-OBn 
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In order to broaden the investigation of the stability of peptide ferryl conjugates, two new 
unnatural amino acids have been designed. S. Ulku, a colleague from the Kodanko laboratory, 
envisioned an analogous unnatural amino acid to HPA, but having a three hydrocarbon linker 
between the backbone and the pyridyl moiety, namely HPN ((2-hydroxymethyl-5-pyridyl 
norvaline) (for the synthesis of Fmoc-HPN(OTBS)-OH, please refer to Chapter 3, Scheme 10). 
To ease the synthesis of the third unnatural amino acid, we sought a synthesis that would start 
from a natural amino acid, with the hope of not having to build a new chiral center. We 
hypothesized that serine could be the starting amino acid leading to unnatural amino acid HPMA 
((2-hydroxymethyl-5-pyridyl methyloxy)-3-alanine) (Figure 25). 
 
Figure 25: Design of the second generation unnatural amino acids HPN and HPMA 
Most importantly, the full potential of this methodology could only be obtained if the 
synthesis of peptide ferryl conjugates could be adapted to SPPS with a more combinatorial and 
divergent approach (Figure 26). N. Jabre demonstrated that polypyridyl ligands and 
corresponding ferryl conjugates could by synthesized using the HPA unnatural amino acid in 
solution phase but the transition to SPPS had to be established. 
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Figure 26: Solid phase, divergent and combinatorial, synthesis of peptide-ferryl conjugates 
I.2.B. Results and discussion 
I.2.B.a. Fmoc-HPMA-OH 
The new HPMA ((2-hydroxymethyl-5-pyridyl methyloxy)-3-alanine) amino acid has 
been designed so that the chirality of the α-center could be inherited from commercially 
available and enantiomerically enriched L-serine. This presents a great advantage compared to 
the synthesis of HPA and HPN, in which the geometry is introduced using a chiral catalyst 
(results do not exceed 92% ee and the catalyst needs to be synthesized). Scheme 1 presents the 
retrosynthetic approach towards HPMA that uses L-serine as a starting material. The key step in 
that sequence is the O-alkylation of a serine derivative with 2,5-dibromo-substituted pyridine 
derivative to give TBS protected HPMA. 
37 
 
 
Scheme 1: Retrosynthetic approach to HPMA using L-serine as a starting material 
 The synthesis of the 2,5-dibromo-substituted pyridine derivative starting with pyridine-
2,5-dicarboxylic acid 63 has been developed by N. Jabre in our laboratory and was used without 
any changes (Scheme 2). 
 
Scheme 2: Synthesis of the 2,5-substituted pyridine derivatives 
Methods where the serine derivative plays the nucleophilic role were the first methods of 
choice because the O-alkylation of benzyl bromide or its derivatives with the serine-derived 
alkoxide is described in the literature.
108, 109
 The only drawback of this approach is that 58 
decomposes within a day so it has to be prepared and used immediately in the alkylation trials. 
The standard procedure to alkylate the β-alcohol of serine uses two equivalents of NaH to 
make the alkoxide dianion, which is quenched with an electrophile such as benzyl bromide. 
Following this procedure, the serine dianion alkoxide was quenched with 58 but only gave 
decomposition products (Scheme 3, Table 1). 
A screening of different temperatures, number of equivalents, bases and solvents 
produced only decomposition products or starting materials. We hypothesize that either the 
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acid-base reaction is faster than the SN2 type displacement reaction or the harsh anionic 
conditions are incompatible with the rather unstable nature of 58. 
 
Scheme 3: Serine as the nucleophilic partner in one phase alkylation reactions  
Entry 65a-c base solvent conditions yield 
      
1 65a PG=Boc NaH 1 equiv THF -78°C to RT Decomposition 
2  NaH 2 equiv THF -78°C to RT Decomposition 
3  DIPEA DMF -78°C to RT No reaction 
4  TEA DMF -78°C to RT No reaction 
5  K2CO3 DMF -78°C to RT No reaction 
      
6 65b PG=Cbz NaH 1 equiv THF -78°C to RT Decomposition 
7  NaH 2 equiv THF -78°C to RT Decomposition 
8  Ag2O DMF RT No reaction 
      
9 65c PG=Trt NaHMDS THF -78°C to RT Decomposition 
10  KHMDS THF -78°C to RT Decomposition 
      
Table 1: O-Alkylation of protected serine derivatives in a homogenous solution 
Alternatively, silver oxide was tried to lengthen the carbon-bromide bond and promote an 
SN1 type reaction.
110
 Unfortunately, those conditions led to no reaction between partners 58 and 
65b (Scheme 3, Table 1, entry 8). 
Gratifyingly, O-alkylation can be achieved using PTC conditions.
108, 109, 111
 Our first trials 
with 58 and 65 were unsuccessful and it was decided to optimize the alkylation using benzyl 
bromide. A screen of starting material partners suggested that the trityl protecting group was 
better suited for the reaction compared to more classical Boc or Cbz protecting groups (Scheme 
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4, Table 2, entries 1-3, 4). The optimized conditions, where an excess of concentrated aqueous 
NaOH (at least 5 equiv, 40% NaOH; 20% NaOH gave lower yields), vigorous stirring (1000 
rpm), and either DCM or benzene associated with TBAB or TEBAC gave yields between 49 and 
66%. Specific literature on PTC also confirmed that the amount of base, vigorous stirring as well 
as the trityl protecting group
112
 are key in this type of reaction.
113-115
 
 
Scheme 4: Serine as the nucleophilic partner in PTC alkylation trials 
Entry 65a-c base catalyst solvent conditions yield 
       
1 65a 
PG=Boc 
K2CO3 1 equiv TBAB 10% Toluene RT, 24 h No reaction 
       
2 65b 
PG=Cbz 
KOH 1.5 equiv Aliquat 336 DCM RT, 24 h No reaction 
3  CsOH 1 equiv TBAS DCM RT, 24 h No reaction 
       
4 65c 
PG=Trt 
10 equiv NaOH 40%  TBAB DCM RT, 24 h 26% 
5  10 equiv NaOH 40%  TBAB Benzene RT, 24 h 66% 
6  10 equiv NaOH 40%  TEBAC DCM RT, 24 h 40% 
7  10 equiv NaOH 40% TEBAC Benzene RT, 24 h 49% 
       
 Table 2: O-Alkylation of protected serine derivatives in a heterogeneous solution using 
PTC 
The conditions found using benzyl bromide were then tested with 58 as the electrophilic 
partner with both TBAB and TEBAC as catalysts and 40% aqueous NaOH associated with either 
DCM or benzene. The combination of TBAB and benzene gave the best results (66c isolated 
with a 66% yield on a multigram scale). 
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With the alkylation adduct in hand, Fmoc-HPMA(OTBS)-OH was in sight, just 
protecting group manipulations away. Our plan was to remove both protecting groups at the 
same time and telescope that reaction with Fmoc reprotection. Two choices were available, 
acid-mediated trityl and benzyl ester removal (probably requiring fairly harsh conditions that 
would also certainly remove the TBS group) or hydrogenolysis. We decided that the latter would 
be a better option. 
 
Scheme 5: Hydrogenation of the O-alkylation product 66c and subsequent Fmoc protection 
Entry catalyst solvent conditions yield 
     
1 Pd/C 10%w/w EtOH NH4+HCO2 
15 equiv 
slow partial reduction 
     
2 Pd/C 10% w/w MeOH H2 gas 1.0 atm partial reduction 
3 Pd/C 10% w/w MeOH H2 gas 2.5 atm partial reduction 
4 Pd/C 10% w/w EtOH H2 gas 1.0 atm partial reduction 
5 Pd/C 10% w/w EtOAc H2 gas 1.0 atm slow partial reduction 
     
6 Pd(OAc)2 10% 
w/w 
MeOH H2 gas 1.0 atm reaction completed after 24 h 
     
7 Pd(OH)2 5% 
w/w 
MeOH H2 gas 1.0 atm reaction completed after 4 h 
     
Table 3: Hydrogenation of the O-alkylation product 66c 
Pd/C was the first catalyst screened associated with either hydrogen gas or ammonium 
formate as hydrogen donors.
116-118
 None of the conditions using Pd/C (with different solvents and 
different hydrogen pressures) gave complete removal of the trityl protecting group (Scheme 5, 
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Table 3, Entries 1-5). Other catalysts were screened and Pd(OH)2 was found to be suitable for 
this transformation at 10% w/w loading, H2 at atmospheric pressure and methanol as solvent 
(Scheme 5, Table 3, Entries 6-7). The catalyst loading could be lowered to 5% w/w on a 
multigram scale, giving 99% yields after catalyst filtration and solvent removal. 
 Purification of the free amino acid was not attempted due to the polarity of the 
unprotected HPMA amino acid. Triphenylmethane being the only byproduct (toluene was 
removed under reduced pressure) the crude material was subjected to an Fmoc protection 
reaction with pyridine acting as a base and solvent to give Fmoc-HPMA(OTBS)-OH 61 in an 
acceptable yield (55% isolated yield after chromatography over the 2 steps, Scheme 5). 
I.2.B.b. Applications to SPPS 
 The Kodanko laboratory had previously tried to incorporate N4Py onto peptides under 
SPPS conditions with Wang resins without success. It was decided to switch the type of resin in 
favor of the Rink amide resin. This resin affords a terminal amide after cleavage that should be 
more compatible with the different nitrogen based ligands and their synthesis. The Rink amide 
resin has been then applied to the synthesis of different peptides with all three synthetic amino 
acids developed by our laboratory (HPA, HPN and HPMA). 
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Scheme 6: Construction of polypyridyl ligand-peptide conjugates by SPPS on Rink amide resin 
 The synthesis started with Fmoc-protected glycine Rink resin (the initial glycine can be 
loaded manually as well). After Fmoc deprotection under standard 20% piperidine conditions, 
coupling with all three unnatural Fmoc protected synthetic amino acids 60-62 was achieved. 
After a second Fmoc deprotection the free amine was acetylated to give acetylated dipeptides 
69-71 on resin. TBS deprotection and chlorination reactions had been previously developed on 
SPPS with the Wang resin by our laboratory and were applied here. Desilylation occured 
smoothly under TBAF/acetic acid conditions and a same second cycle was performed to ensure 
complete deprotection. The resulting alcohols were chlorinated under LiCl/TsCl conditions. The 
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efficiency of this step was checked by deprotection of a minimal amount of product from resin 
and assessed by NMR. The N-alkylation reactions with the desired secondary amines were 
performed in a classical manner on resin. After 24 hours the beads were transferred back to the 
SPPS reactor to wash out the unreacted starting materials before a final TFA/H2O deprotection. 
The final products were purified on HPLC under basic conditions (0.01% NH4OH) (Scheme 6). 
N-alkylation leading to both TPA and N4Py containing conjugates were investigated. The 
introduction of TPA was successful with all three unnatural amino acids leading to dipeptides 
Ac-HPA/HPN/HPMA(N2Py)-Gly-NH2 73, 75 and 76. The crude purities after final cleavage 
were greater than 80% giving the final products in pure form after HPLC purification. The 
introduction of N4Py was successful on HPA-and HPN-containing dipeptides giving dipeptides 
Ac-HPA/HPN/(N3Py)-Gly-NH2 72 and 74. The HPMA containing dipeptide was not compatible 
with N4Py, despite trying numerous conditions. Nonetheless, the proof of concept for this SPPS 
divergent methodology for the construction of peptide ligand conjugates was achieved (Scheme 
6). S. Ulku has expanded this methodology for building conjugates with multiple binding units 
(structures not shown).
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To expand the scope of this methodology, and check functional group compatibility with 
the N-alkylation and resin cleavage conditions, the heptapeptide Ac-Trp-HPN(N2Py)-Leu-Met-
Val-Asn-Gly-NH2 77 was prepared. First, the pentapeptide Fmoc-Leu-Met-Val-Asn(Trt)-Gly 
bound to Rink resin was synthesized on an automated peptide synthesizer. The beads were then 
transferred into a SPPS reactor, the Fmoc group was removed manually, and coupling with 
Fmoc-HPN(OTBS)-OH was performed. A a full cycle of coupling with Fmoc-Trp(BOC)-OH 
completed the building phase of the peptide before the installation of the TPA ligand. The same 
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conditions as for compounds 72-76 were used, and TPA was incorporated to give compound 77 
(Scheme 7). 
 
Scheme 7: Construction of heptapeptide 77 by SPPS 
I.2.C. Conclusion 
A new unnatural amino acid has been synthesized. Its synthesis can be easily scaled up to 
furnish multigram quantities of Fmoc-HPMA-OH. A crucial O-alkylation reaction under phase 
transfer conditions had to be used in order to take advantage of the chirality inherited from L-
serine. Although the introduction of N4Py is problematic into peptide conjugates containing 
HPMA, other smaller ligands like TPA have been introduced successfully. 
 Finally, this divergent methodology has been successfully transferred onto SPPS that 
greatly accelerates the synthesis of new peptide conjugates. The possibility of using SPPS for the 
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construction of peptide ligand conjugates with the possibility of placing one or more metal 
ligands within the peptide, at any desirable position, should enable the synthesis of a wide array 
of new peptide-metal ligand conjugates. Moreover, the ligand diversity is introduced in the last 
step of the sequence (other than the cleavage from resin) making this methodology highly 
divergent. The robustness of this methodology has been demonstrated with the construction of 
the TPA containing heptapeptide 77. The use of this methodology for the construction of 
biologically active agents is also being explored in the Kodanko laboratory. 
The work presented in this chapter was published in the Journal of Organic Chemistry: 
Jabre, N. D., Respondek, T., Ulku, S., Korostelova N., Kodanko, J. J. "A Divergent Strategy for 
Attaching Polypyridyl Ligands to Peptides", J. Org. Chem., 2010, 75(3), 650-659.
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I.2.D. Experimental section 
I.2.D.a. General considerations 
All reagents were purchased from commercial suppliers and used as received. NMR 
spectra were recorded on a Varian FT-NMR Mercury-300, 400 or 500 MHz Spectrometer. Low-
resolution mass spectra were recorded on a Waters ZQ2000 single quadrupole mass spectrometer 
using an electrospray ionization source, while high-resolution mass spectra were recorded on a 
Waters-Micromass LCT Premier XE time of flight mass spectrometer. IR spectra were recorded 
on a Nicolet FT-IR spectrophotometer. Optical rotations were obtained by using a PERKIN-
ELMER 241-MC Polarimeter. HPLC was performed on an Agilent 1200 preparative purification 
system equipped with a multi-wavelength detector. Column purifications were performed using 
silica gel flash chromatography unless mentioned otherwise. All reactions were performed under 
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ambient atmosphere unless otherwise noted. Anaerobic reactions were performed in Schlenk 
tubes. All NMR spectra and chromatographs can be found in the Appendix section. 
I.2.D.b. Experimental procedures and tabulated characterization data 
(6-((tert-butyldimethylsilyloxy)methyl)pyridin-3-yl)methanol (64): 
 
To a solution of pyridine-2,5-dicarboxylic acid (20.0 g, 0.12 mmol) in 120 ml of CH3OH 
(31.25 equiv) was slowly added H2SO4 (40.0 ml, 0.75 mmol, 6.25 equiv). The solution was 
temporarily placed in an ice bath to control the exotherm. After completing the addition the 
resulting solution was heated to reflux for 24 h. The crude was worked up by slow addition of 50 
ml of water (the solution is placed in an ice bath to control the exotherm and Na2CO3 is added to 
get a pH~9-10 (need to control the speed of addition and avoid emulsion, some additional water 
addition is needed)). The basic aqueous solution is extracted with CHCl3 (3 250 mL). The 
organic layers are combined, dried over Na2SO4 and concentrated to give dimethylpyridine-2,5-
dicarboxylate as a white to yellow solid (19.9 g, 83% isolated yield): 
1
HNMR (CDCl3 δ 7.27) : 
δ 9.31 (d, 1H, J=1.62Hz), 8.44-8.47 (dd, 1H, J1=8.11Hz, J2=1.62Hz), 8.20-8.23 (d, 1H, 
J=8.11Hz), 4.04 (s, 3H). 
 Dimethylpyridine-2,5-dicarboxylate (1.00 g, 5.12 mmol, 1.0 equiv) was dissolved in 
dry THF/EtOH (45 ml, 1/2) under Argon. CaCl2 (2.27 g, 20.50 mmol, 4.0 equiv) is added and the 
solution cooled down to 0°C. NaBH4 (485 mg, 12.8 mmol, 2.5 equiv) is added in small portions 
and the resulting solution is stirred at 0 °C for 6-8 h. After completion of the reaction (as judged 
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by TLC), 60 ml of water are added drop wise. The resulting solution is extracted with CHCl3 
(3 60 mL). The organic layers are combined, dried over Na2SO4 and concentrated to give 
methyl-6-(hydroxymethyl)nicotinate as a white to yellow oil (0.78 g, 93% isolated yield): 
1
HNMR (CDCl3 δ 7.27) : δ 9.15 (d, 1H, J=1.62Hz), 8.28-8.30 (dd, 1H, J1=8.11Hz, J2=1.62Hz), 
7.37-7.39 (d, 1H, J=8.11Hz), 4.83 (s, 2H), 3.96 (s, 3H) 
To a solution of methyl-6-(hydroxymethyl)nicotinate (0.778 g, 4.65 mmol, 1.0 equiv) 
in 10 mL of DMF was added imidazole (477 mg, 7.0 mmol, 1. 4.0 equiv) and TBS-Cl (771 mg, 
5.12 mmol, 1.1 equiv) at RT. The resulting solution was stirred for 2 h. After completion of the 
reaction (as judged by TLC), 25 mL of water are added drop wise. The resulting solution is 
extracted with EtOAc (3 25 mL). The organic layers are combined, dried over Na2SO4 to give 
methyl-6-((tert-butyldimethylsilyloxy)methyl)nicotinate as a white to yellow oil (1.248g, 95% 
isolated yield): 
1
HNMR (CDCl3 δ 7.27) : δ 9.10-9.11 (d, 1H, J=2.43Hz), 8.30-8.32 (dd, 1H, 
J1=8.11Hz, J2=2.43Hz), 7.60-7.62 (d, 1H, J=8.11Hz), 4.88 (s, 2H), 3.94 (s, 3H), 0.96 (s, 9H), 
0.13 (s, 6H) 
A mixture of methyl-6-((tert-butyldimethylsilyloxy)methyl)nicotinate (5.00 g, 17.8 
mmol) and dry THF (125 mL) was cooled to 0 °C under a nitrogen atmosphere. A solution of 
NaAlH2(OCH2CH2OMe) in toluene (65% w/w) (12.7 mL, 40.8 mmol) was added dropwise over 
30 min, resulting in an orange solution. The solution was maintained at 0 °C for 1.5 h. After 
consumption of the starting material, as judged by TLC analysis, the reaction mixture was 
quenched by dropwise addition of MeOH (4.5 mL) followed by addition of a 0.1M NaOH 
solution (10 mL). The reaction mixture was combined with H2O (200 mL) and the aqueous layer 
was extracted with EtOAc (3 75 mL). The combined organic layer was dried over anhydrous 
Na2SO4 and concentrated to give a yellow viscous oil which upon crystallization from cold 
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hexanes (10 mL) furnished 64 as a white crystalline solid (3.50 g, 78%): mp = 50-51 °C; 
1
H 
NMR (400 MHz, CDCl3)  8.34 (brs, 1H), 7.69 (d, J = 8.1 Hz, 1H), 7.46 (d, J = 8.1 Hz, 1H), 
4.76 (s, 2H), 4.64 (s, 2H), 3.57 (b, 1H), 0.91 (s, 9H), 0.07 (s, 6H); 
13
C NMR (100 MHz, CDCl3) 
 160.4, 147.2, 135.8, 134.7, 119.9, 65.7, 62.2, 25.9, 18.3, -5.4; IR (thin film) 3211 (b), 2953, 
2927, 2856, 1604, 1573, 1491, 1458, 1399, 1377, 1358, 1341, 1255, 1102, 1060, 1031, 1006, 
860, 839, 776, 670, 647 cm
-1
; LRMS (ESMS) calculated for C13H24NO2Si (M+H)
+
 254, found: 
254. 
5-(bromomethyl)-2-((tert-butyldimethylsilyloxy)methyl)pyridine (58): 
 
To a solution of (6-((tert-butyldimethylsilyloxy)methyl)pyridin-3-yl)methanol 64 (1013 
mg, 4.0 mmol, 1.0 equiv) in 20 ml of CH2Cl2 dried over molecular sieves under Argon at RT 
were added NBS (783 mg, 4.4 mmol, 1.1 equiv) and PPh3 (1.15 g, 4.4 mmol, 1.1 equiv). The 
reaction was stirred at RT for 90 min. After completion of the reaction (as judged by TLC), 
CH2Cl2 is removed on Rotavap and the crude is purified by flash chromatography (9/1 to 8/2 
hexanes/EtOAc) and 58 was obtained as a white oil (1.12 g, 88% isolated yield). The product 
decomposes within a day (turns pinkish and then purple): 
1
HNMR (CDCl3 δ 7.27): δ 8.52-8.53 
(d, 1H, J=2.44Hz), 7.74-7.77 (dd, 1H, J1=7.94Hz, J2=2.44Hz), 7.51-7.53 (d, 1H, J=7.94Hz) 4.84 
(s, 2H), 4.49 (s, 2H), 0.97 (s, 9H), 0.13 (s, 6H);
13
CNMR (CDCl3 δ 77.00): δ 161.62148.70, 
137.22,. 131.67, 119.98, 65.85, 29.80, 25.88, 18.34, -5.41; LRMS (ESMS): calculated for 
C13H22BrNOSi (M+H)
+
: 317, found: 317 (M+H)
+
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(S)-benzyl 3-((6-((2,3,3-trimethylbutan-2-yloxy)methyl)pyridin-3-yl)methoxy)-2-
(tritylamino)propanoate (66c): 
 
To a solution of 5-(bromomethyl)-2-((tert-butyldimethylsilyloxy)methyl)pyridine 58 (95 
mg, 0.3 mmol, 1.0 equiv) in 1 mL of benzene at RT were added (S)-benzyl 3-hydroxy-2-
(tritylamino)propanoate 65c (131 mg, 0.3 mmol, 1.0 equiv) in 1.0 mL of benzene. To the 
resulting solution were added TBAB (97 mg, 0.3 mmol, 1.0 equiv) and 10 equiv of 40% NaOH 
(300 mg, 3.0 mmol, 10 equiv). The reaction was stirred at 1000 rpm for 24 h. After completion 
of the reaction (as judged by TLC,), 2 mL of water were added and the resulting solution was 
extracted with EtOAc (3 5 mL).The organic layers were combined, dried over Na2SO4 and 
concentrated. The resulting crude was purified by flash chromatography (9/1 to 8/2 
hexanes/EtOAc) and 66c was obtained as a white oil (118 mg, 59% isolated yield): 
1
HNMR 
(MeOD δ 3.31) : δ 8.30 (d, 1H, J=1.62Hz), 7.59-7.62 (dd, 1H, J1=8.11Hz, J2=1.62Hz), 7.45-7.46 
(m, 7H), 7.13-7.23 (m, 14H), 4.78 (s, 2H), 4.72-4.76 (d, 1H, J=12.97Hz), 4.50-4.53 (d, 1H, 
J=12.97Hz), 4.38-4.46 (d, 2H, 7.30), 3.68-3.71 (dd, 1H J1=8.92Hz, J2=4.05Hz ), 0.96 (s, 9H), 
0.12 (s, 6H), 3.47-3.56 (m, 2H); 
13
CNMR (MeOD δ 48.94) : δ 175.19, 161.57, 154.08, 148.65, 
147.39, 138.45, 137.20, 134.07, 130.05, 129.55, 129.30, 129.25, 129.09, 127.80, 121.72, 75.54, 
73.88, 71.28, 67.81, 66.65, 57.99, 26.54, 19.35, -5.08; IR (KBr): 3061, 3032, 2955, 2928, 2887, 
2854, 1734, 1601, 1489, 1471, 1456, 1448, 1371, 1362, 1254, 1182, 1174, 1128, 1101, 837, 777, 
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746, 706 cm
-1
; LRMS (ESI): calculated for C42H48N2O4Si (M+H)
+
: 673, found: 673(M+H)
+
, 695 
(M+Na)
+
 
(S)-2-(((9H-fluoren-9-yl)methoxy)carbonylamino)-3-((6-((tert-butyldimethyl-
silyloxy)methyl)pyridin-3-yl)methoxy)propanoic acid (61): 
 
A mixture of compound 66c (2.10 g, 3.12 mmol), Pd(OH)2/C (525 mg, 5% w/w) and 
MeOH (210 mL) was stirred at RT under H2 (1 atm) for 12 h. The reaction mixture was filtered 
through a celite bed to remove Pd/C and the filtrate was concentrated to give a colorless solid. A 
mixture of the latter colorless solid (100 mg, 0.17 mmol), FmocOSu (69 mg, 0.21 mmol) and 
pyridine (2.8 mL) was maintained at RT for 12 h. The reaction mixture was concentrated to 
obtain the crude product. The crude product was dissolved in water (10 mL) and acidified with 
5% aqueous citric acid (pH= 5-6). The aqueous layer was extracted with CH2Cl2 (3 30 mL). The 
combined organic layer was dried over anhydrous Na2SO4 and concentrated to obtain the crude 
product. The resulting crude was purified by silica gel chromatography (0% to 10% 
MeOH:CH2Cl2) to obtain 61 as a colorless amorphous solid (53 mg, 55%): 
1
H NMR (400 MHz, 
CD3OD) δ 8.40 (s, 1H), 7.79 (d, J = 8.1 Hz, 1H), 7.76 (d, J = 7.3 Hz, 2H), 7.63 (dd, J = 6.9, 3.2 
Hz, 2H), 7.47 (d, J = 8.1 Hz, 1H), 7.36 (t, J = 7.3 Hz, 2H), 7.26 (t, J = 6.9 Hz, 2H), 4.75 (s, 2H), 
7.58-7.51 (m, 2H), 4.38 (dd, J = 10.5, 7.3 Hz, 2H), 4.31-4.23 (m, 2H), 4.18 (t, J = 6.5 Hz, 1H), 
3.91-3.79 (m, 2H), 0.93 (s, 9H), 0.10 (s, 6H); 
13
CNMR (100 MHz CD3OD) δ 175.7, 160.2, 
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157.2, 147.4, 144.2, 144.1, 141.4, 137.2, 127.6, 127.0, 125.1, 125.0, 120.4, 119.8, 70.9, 70.0, 
66.8, 65.3, 47.2, 25.2, 18.0, -6.5; IR (thin film) 3340 (b) 2953, 2856, 1716, 1606, 1506, 1450, 
1253, 1105, 910, 839, 779, 759, 738 cm
-1
; [ ] = +11.3
°
 (c = 0.97, MeOH); HRMS (ESMS) 
calculatedd for C31H37N2O6SiNa2 (M-H+2Na)
+
, 607.2216, found: 607.2209. 
Solid phase peptide synthesis general considerations: 
All peptides were synthesized on a 0.12-0.40 mmol scale by solid phase peptide synthesis 
methods using N -9-fluorenylmethyloxy-carbonyl (Fmoc) amino acids with HBTU-activated 
ester chemistry in a Peptide Synthesis Vessel (ChemGlass CG-1860). Burrell Model 75 Wrist 
Action Lab Shaker was used for shaking the reaction mixture. Commercially available starting 
materials and reagents were purchased from ChemPep.Inc., AnaSpec.Inc. and Chem Impex. 
Solid phase peptide synthesis procedures: 
Fmoc-Gly-Rink Amide MBHA Resin (0.32 mmol/g) or Rink Amide MBHA Resin (0.75 
mmol/g) was used to afford C-terminal amides. Typical protocols for coupling a residue involved 
1-4 h coupling cycles with 3-4 equiv of amino acid. However, for the unnatural amino acids 
HPA, HPN and HPMA only 2 equiv were used. Activated esters were formed in situ using 
HBTU and i-Pr2EtN in DMF. After coupling, Fmoc deprotection as well as washing steps, 
solutions were filtered manually through a CG-1860 Peptide Synthesis Vessel. The Fmoc 
deprotection was performed using 20% Piperidine/DMF with three cycles 10-20 min each. After 
constructing the desired length of a peptide chain, the N-terminal was acetylated using acetic 
anhydride (50 equiv) and i-Pr2EtN (50 equiv) in DMF for 2 h. After each reaction step, the resin 
was washed with DMF, i-Pr2EtN and CH2Cl2. Kaiser test was used to monitor the coupling 
reactions and deprotection of the Fmoc-group. Standard SPPS steps were summarized in Table 4. 
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Operation Reagent Vol Time 
    
Fmoc deprotection 20% Piperidine/DMF 7 mL 3  15 min  
    
 
Drain and wash 
DMF 
IPA 
CH2Cl2 
4 mL 
4 mL 
4 mL 
2 min 
    
 
Coupling with Gly or 
Ala 
Fmoc-AA-OH (0.3 mmol) 
HBTU (0.3 mmol) 
i-Pr2EtN (0.3 mmol) 
 
2 mL DMF 
 
1-2 h 
    
Coupling with HPN, 
HPA or HPMA 
Fmoc-AA-OH (0.2 mmol) 
HBTU (0.2 mmol) 
i-Pr2EtN (0.2 mmol) 
 
1.5 mL DMF 
 
3-4 h 
    
Capping Ac2O   (5 mmol) 
i-Pr2EtN (5 mmol) 
2.5 mL DMF 1 h 
    
Table 4: Standard Solid Phase Peptide Synthesis (0.1 mmol scale) 
General Procedure for Chlorination: 
Cleavage of the silyloxyether group of compounds 69-71 were performed by shaking a 
mixture of the corresponding intermediate with acetic acid (1 equiv) and TBAF (4 equiv) in THF 
at RT for 1 h. The cleavage procedure was repeated to ensure complete cleavage of the 
silyloxyether group. After applying the standard washing procedure, resin was dried under 
vacuum. A mixture of the dried resin, flame dried LiCl (50 equiv), MeCN and i-Pr2EtN (15 
equiv) was purged under nitrogen atmosphere for 5-10 min and TsCl (10 equiv) was added. The 
reaction mixture was shaken at RT for 6 h. The color of the resin changed from pale yellow to 
red. At least one water washing was included in the standard washing protocol. Finally, the resin 
was dried under vacuum. At this point, % conversion to the chloride can be checked by cleaving 
a small amount of the peptide from the resin using TFA/H2O (95:5) and analyzing the crude 
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peptide by 
1
H NMR and ESMS. In some cases, it was necessary to resubject the resin-bound 
peptide to the chlorination conditions (LiCl, TsCl, i-Pr2EtN) to observe complete conversion to 
the chloride. 
General Procedure for N-Alkylation: 
A mixture of the resin containing the chlorinated adduct, MeCN, i-Pr2EtN (12 equiv), 
sodium iodide (0.2 equiv) and the corresponding secondary amine (10 equiv) was heated at 55 
°C for 24 h. The reaction mixture was washed using the standard washing procedure and the 
peptides were cleaved from the resin by treatment with TFA/H2O (95:5) for 2 h. In the case of 
compound 77, Reagent K was used for cleavage of the peptide from the resin. The resin was 
filtered, washed with TFA, and the combined filtrate was concentrated to 1-2 mL and strirred 
with ether/hexanes. The supernatant was decanted and remaining residue was purified by 
preparative HPLC. 
Operation Reagent Vol Time Temperature 
     
TBS- Cleavage TBAF (1M in THF, 0.4 
mmol) 
AcOH (0.1 mmol) 
4 mL THF 2  1 h  RT 
     
 
Chlorination 
LiCl (5 mmol) 
TsCl (1 mmol) 
i-Pr2EtN (1.5 mmol) 
 
4 mL CH3CN 
 
1  6 h 
 
RT 
     
 
N-Alkylation 
NaI (0.02 mmol) 
R
1
R
2
NH (1 mmol) 
i-Pr2EtN  (1.2 mmol)  
 
2 mL CH3CN 
 
1  12-24 h 
 
55 °C 
     
Table 5: Reactions on the side chain (0.1 mmol scale) 
2-acetamido-N-(2-amino-2-oxoethyl)-3-(6-(((dipyridin-2-ylmethyl)(pyridin-2- 
ylmethyl)amino)methyl)pyridin-3-yl)propanamide (72). 
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 The crude product was purified by preparative HPLC. HPLC column: Phenomenex 
LUNA C18 (2) 100 Å 250 × 21.2 mm; Mobile phase: 0.01% aq NH4OH and MeOH; Flow rate = 
20 mL/min; Gradient elution 0-4 min 5-20% MeOH in aq NH4OH, 4-25min 20-95% MeOH in 
aq NH4OH, RT = 16.3 min. 
1
H NMR (400 MHz, CD3OD) δ 8.47 (d, J = 4.9 Hz, 2H), 8.37 (d, J = 
4.9 Hz, 1H), 8.27 (d, J = 1.6 Hz, 1H), 7.83-7.73 (m, 5H), 7.73-7.68 (m, 1H), 7.68-7.61 (m, 2H), 
7.31-7.26 (m, 2H), 7.25-7.20 (m, 1H), 5.32 (s, 1H), 4.50 (dd, J = 8.9, 6.5 Hz, 1H), 3.95 (s, 2H), 
3.90 (s, 2H), 3.86 (d, J = 17.0 Hz, 1H), 3.69 (d, J = 17.0 Hz, 1H), 3.14 (dd, J = 14.2, 6.1 Hz, 1H), 
2.91 (dd, J = 13.8, 8.9 Hz, 1H), 1.91 (s, 3H); 
13
C NMR (100 MHz CD3OD) δ 172.9, 172.5, 
172.4, 159.6, 159.3, 157.7, 148.9, 148.7, 148.3, 137.9, 137.3, 137.2, 131.9, 124.5, 123.5, 123.2, 
122.8, 122.4, 72.8, 57.2, 56.9, 54.9, 41.9, 34.0, 21.2; IR (KBr) 3431, 2918, 2850, 1662, 1594, 
1571, 1541, 1471, 1435, 1293, 1092, 1004, 770, 692, 561, 459 cm
-1
; HRMS (ESMS) calculated 
for C30H32N8O3Na (M+Na)
+
: 575.2495, found: 575.2501 
2-acetamido-N-(2-amino-2-oxoethyl)-3-(6-((bis(pyridin-2-ylmethyl)amino)- 
methyl)pyridin-3-yl)propanamide (73). 
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 The crude product was purified by preparative HPLC. HPLC column: Phenomenex 
LUNA C18 (2) 100 Å 250 × 21.2 mm; Mobile phase: 0.01% aq NH4OH and MeOH; Flow rate = 
20 mL/min; Gradient elution 0-4 min 5-20% MeOH in aq NH4OH, 4-25 min 20-75% MeOH in 
aq NH4OH, RT = 19.8 min. 
1
H NMR (400 MHz, CD3OD) δ 8.34 (d, J = 4.9 Hz, 2H), 8.32 (d, J = 
2.4 Hz, 1H), 7.79 (td, J = 7.7, 1.6 Hz, 2H), 7.71 (dd, J =8.1, 1.6 Hz, 1H), 7.66 (d, J = 8.1 Hz, 
2H), 7.61 (d, J = 8.1 Hz, 1H), 7.28 (dd, J = 6.5, 4.9 Hz, 2H), 4.53 (dd, J = 8.9, 6.5 Hz, 1H), 3.86 
(d, J = 17.0 Hz, 1H), 3.83 (s, 4H), 3.82 (s, 2H), 3.69 (d, J = 16.2 Hz, 1H), 3.16 (dd J = 14.2, 6.1 
Hz, 1H), 2.93 (dd, J = 14.6, 8.9 Hz, 1H), 1.90 (s, 3H); 
13
C NMR (100 MHz, CD3OD) δ 172.9, 
172.4, 172.3, 158.6, 157.0, 148.9, 148.3, 138.3, 137.6, 132.4, 123.8, 123.4, 122.8, 59.7, 59.5, 
54.8, 41.9, 34.1, 21.2; IR (KBr) 3435, 2927, 2850, 1669, 1595, 1570, 1541, 1436, 1374, 1294, 
1203, 1129, 1050, 1003, 836, 768, 600 cm
-1
; HRMS (ESMS) calculated for C25H29N7O3Na 
(M+Na)
+
: 498.2230, found: 498.2229 
(S)-2-acetamido-N-(2-amino-2-oxoethyl)-5-(6-(((dipyridin-2-ylmethyl)(pyridin-2- 
ylmethyl)amino)methyl)pyridin-3-yl)pentanamide (74). 
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 The crude product was purified by preparative HPLC. HPLC column: Phenomenex 
LUNA C18 (2) 100 Å 250 × 21.2 mm; Mobile phase: 0.01% aq NH4OH and MeOH; Flow rate = 
20 mL/min; Gradient elution 0-4 min 5-20% MeOH in aq NH4OH, 4-25 min 20-95% MeOH in 
aq NH4OH, RT = 16.7 min. 
1
H NMR (400 MHz, CD3OD) δ 8.47 (d, J = 4.9 Hz, 2H), 8.35 (d, J = 
4.9 Hz, 1H), 8.20 (s, 1H), 7.82-7.73 (m, 4H), 7.72 (dd, J= 7.3, 1.6 Hz, 1H), 7.70-7.66 (m, 1H), 
7.62-7.55 (m, 2H), 7.31-7.25 (m, 2H), 7.23-7.18 (m, 1H), 5.32 (s, 1H), 4.23 (dd, J = 7.3, 5.7 Hz, 
1H), 3.95 (s, 2H), 3.93 (s, 2H), 3.88 (d, J= 17.0 Hz, 1H), 3. 76 (d, J = 17.0 Hz, 1H), 2.62 (dd, J = 
7.3, 5.7 Hz, 2H), 1.99 (s, 3H), 1.87-1.70 (m, 1H), 1.75-1.60 (m, 3H); 
13
C NMR (100 MHz 
CD3OD) δ 173.7, 173.1, 172.7, 159.7, 159.4, 156.7, 137.3, 137.2, 136.3, 124.4, 123.5, 123.3, 
122.8, 122.4, 73.1, 57.4, 57.2, 54.1, 42.0, 31.8, 30.9, 27.3, 21.2; IR (KBr) 3435, 2924, 2852, 
1659, 1594, 1571, 1541, 1471, 1435, 1384, 1088, 1003, 773, 693, 459 cm
-1
; [α] = +2.5° (c = 
0.60, MeOH); HRMS (ESMS) calculated for C32H36N8O3Na (M+Na)
+
: 603.2808, found: 
603.2810 
(S)-2-acetamido-N-(2-amino-2-oxoethyl)-5-(6-((bis(pyridin-2-ylmethyl)amino)- 
methyl)pyridin-3-yl)pentanamide (75). 
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 The crude product was purified by preparative HPLC. HPLC column: Phenomenex 
LUNA C18 (2) 100 Å 250 × 21.2 mm; Mobile phase: 0.01% aq NH4OH and MeOH; Flow rate = 
20 mL/min; Gradient elution 0-4 min 5-20% MeOH in aq NH4OH, 4-25 min 20-75% MeOH in 
aq NH4OH, RT = 21.5 min. 
1
H NMR (400 MHz, CD3OD) δ 8.42 (d, J = 4.9 Hz, 2H), 8.28 (s, 
1H), 7.78 (td, J = 7.5, 2.0 Hz, 2H), 7.66 (d, J = 8.1 Hz, 2H), 7.62 (d, J = 2.4 Hz, 1H), 7.56 (d, J = 
8.1 Hz, 1H), 7.27 (t, J = 6.5 Hz, 2H), 4.24 (t, J = 6.5 Hz, 1H), 3.87 (d, J = 17.0 Hz, 1H), 3.84 (s, 
4H), 3.82 (s, 2H), 3.76 (d, J = 17.0 Hz, 1H), 2.65 (t, J = 6.5 Hz, 2H), 1.98 (s, 3H), 1.87-1.77 (m, 
1H), 1.75-1.62 (m, 3H); 
13
C NMR (100 MHz, CD3OD) δ 173.7, 173.1, 172.7, 158.9, 156.4, 
148.3, 148.2, 137.5, 136.6, 123.7, 123.4, 122.7, 60.0, 59.7, 54.1, 42.0, 31.8, 30.9, 27.2, 21.2; IR 
(KBr) 3439, 2925, 2851, 1660, 1595, 1570, 1541, 1436, 1374, 1311, 1258, 1124, 1051, 1003, 
768, 603 cm
-1
; [α] = +3.0° (c = 0.75, MeOH); HRMS (ESMS) calculated for C27H33N7O3Na 
(M+Na)
+
: 526.2543, found: 526.2552 
(S)-2-acetamido-N-(2-amino-2-oxoethyl)-3-((6-((bis(pyridin-2-ylmethyl)amino)- 
methyl)pyridin-3-yl)methoxy)propanamide (76) 
58 
 
 
 The crude product was purified by preparative HPLC. HPLC column: Phenomenex 
LUNA C18 (2) 100 Å 250 × 21.2 mm; Mobile phase: 0.01% aq NH4OH and MeOH; Flow rate = 
20 mL/min; Gradient elution 0-4 min 5-20% MeOH in aq NH4OH, 4-25 min 20-75% MeOH in 
aq NH4OH, RT = 19.3 min. 
1
H NMR (400 MHz, CD3OD) δ 8.44 (d, J = 4.9 Hz, 2H), 8.42 (d, J = 
1.6 Hz, 1H), 7.83-7.76 (m, 3H), 7.69-7.64 (m, 3H), 7.30-7.25 (m, 3H), 4.62-4.54 (m, 2H), 4.51 
(t, J = 5.3 Hz, 1H), 3.89-3.79 (m, 8H), 3.82 (dd, 3.74 (J = 9.7, 5.7 Hz, 1H), 3.74 (dd, J = 9.7, 4.9 
Hz, 1H), 2.02 (s, 3H); 
13
C NMR (100 MHz CD3OD) δ 173.0, 172.8, 171.5, 158.8, 158.4, 148.3, 
147.8, 137.5, 137.0, 132.8, 123.7, 123.4, 122.7, 70.2, 69.6, 59.7, 54.3, 42.1, 21.3; IR (KBr) 3440 
(b), 2919, 2849, 1678, 1541, 1435, 1384, 1204, 1181, 1122, 837, 800, 773, 722, 693, 467; [α] = 
+4.5° (c= 0.37, MeOH); HRMS (ESMS) calculated for C26H31N7O4Na (M+Na)
+
: 528.2335, 
found: 528.2332 
Heptapeptide Ac-Trp-HPN(N2Py)-Leu-Met-Val-Asn-Gly-NH2 (77): 
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 The crude product was purified by preparative HPLC. HPLC column: Phenomenex 
LUNA C18 (2) 100 Å 250 × 21.2 mm; Mobile phase: 0.01% aq NH4OH and MeOH; Flow rate = 
20 mL/min; Gradient elution 0-25 min 50-95% MeOH in aq NH4OH, RT = 22.4 min. See 
Appendix for NMR spectrum. HRMS (ESMS) calculated for C58H78N14O9Na (M+Na)
+
: 
1169.5695, found: 1169.5750. 
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Chapter 3. Development of an “optimal substrate” for the 
enantioselective alkylation of benzophenone imine 
I.3.A. Background and project design 
The divergent methodology for the incorporation of polypyridyl ligands into peptides 
developed and presented in the previous chapter is based on the use of unnatural amino acids 
bearing a pyridine moiety as an anchoring group. Three unnatural amino acids had been designed 
by the Kodanko group (the synthesis of the HPMA unnatural amino acid was presented in 
Chapter 2, Scheme 4 and Scheme 5) whereas the syntheses of HPA and HPN had been 
developed by fellow group members N. Jabre and S. Ulku. In these two latter syntheses an 
asymmetric alkylation of a benzophenone glycine imine derivative was the key step (Scheme 8).  
 
Scheme 8: Retrosynthetic analysis of HPA and HPN unnatural amino acids 
N. Jabre’s synthesis of HPA started with the phase transfer catalyzed alkylation of 
benzophenone glycine imine 78 with partner 58. Because the Cinchona derived catalysts used to 
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catalyze the former alkylation reaction require the tert-butyl ester protecting group for the 
C-terminus in order to achieve high ee levels (enantiomeric excess), a 6 N HCl hydrolysis had to 
be used to remove the latter protecting group. Those harsh conditions were also responsible for 
the removal of the TBS group that had to be reintroduced leading to Fmoc-HPA(OTBS)-OH 
after Fmoc protection (Scheme 9). 
 
Scheme 9: N. Jabre’s synthesis of Fmoc-HPA(OTBS)-OH 62 
Similarly, S. Ulku’s synthesis of HPN utilized the analogous phase transfer catalyzed 
alkylation reaction of benzophenone glycine imine 78 with partner 81. Once again, protecting 
groups were removed under acid mediated hydrolysis conditions. After Sonogashira coupling 
between partners 79 and 80, the imine was cleaved using citric acid. After hydrogenation of the 
alkyne moiety, the tert-butyl ester was removed under 6 N HCl hydrolysis conditions, resulting 
in the need to reintroduce the TBS group, finally leading to Fmoc-HPN(OTBS)-OH after Fmoc 
protection (Scheme 10). 
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Scheme 10: S. Ulku’s synthesis of Fmoc-HPN(OTBS)-OH 60 
Those two first generation syntheses, although granting access to needed unnatural amino 
acids HPA and HPN, are not atom economical or well suited for mutligram quatntities because 
of the numerous protecting group manipulation steps.  
On a larger perspective, the Cinchona catalyzed alkylation of glycine imine is one of the 
most used methodologies for the synthesis of enantiomerically enriched amino acids but is not 
compatible  with acid sensitive substrates due to the fact that it requires the use of the tert-butyl 
ester as the protecting group for the C-terminus (or requires extra protecting group manipulation 
steps as in the examples explained above). The tert-butyl ester forces the use of harsh acidic 
conditions in the deprotection step. Newer classes of catalysts based on biphenyl or binaphthyl 
motifs
121, 122
 enable high levels of enantioselectivity with a variety of glycine C-terminal 
protecting groups. Their main drawback is a difficult multistep synthesis. In the view of Fmoc-
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based SPPS, where acid-labile protecting groups are typically used for the protection of reactive 
side chains, new methods needed to be developed. 
 
Figure 27: Examples of phase transfer catalysts used in the alkylation of glycine benzophenone 
imine reaction 
 To solve this problem we decided to pursue a substrate for the asymmetric alkylation of 
benzophenone glycine imine that leads to high ee and is orthogonal to acid-labile protecting 
groups. We hypothesized that the cumyl ester protected glycine imine would have enough steric 
hindrance on the C-terminus to maintain high levels of enantioselectivity and be removable 
under mild conditions by hydrogenolysis.
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I.3.B. Results and discussion 
I.3.B.a. Synthesis of cumyl ester protected benzophenone imine 
Our initial retrosynthetic plan for the synthesis of the cumyl ester benzophenone imine 
started with Fmoc-protected glycine that was esterified with 2-phenyl-2-propanol. The plan then 
envisioned a transamination with diphenyl ketimine after Fmoc removal. The direct esterification 
of Fmoc protected glycine with DCC and DMAP proceeded in 38% yield.
124
 Such a low yield in 
the first step of our synthesis was unacceptable, so a trichloacetimidate intermediate was 
proposed to access the cumyl ester (Scheme 11).
125, 126
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Scheme 11: Synthesis of cumyl ester protected benzophenone imine 
 The synthesis started with the NaH catalyzed preparation of the trichloroacetimidate 
derived from 2-phenyl-2-propanol 86. The reaction proceeded cleanly and the 
trichloroacetimidate could be stored on a multigram scale in cyclohexanes for two months.
125, 126
 
Upon exposure to bromoacetic acid, ester 87 was obtained with a 90% yield over two steps after 
chromatography. Alkylation of 87 with diphenyl ketimine
127
 afforded compound 88 in 85% yield 
after purification on silica gel.
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 Our proposed substrate for the enantioselective alkylation of benzophenone imine could 
be accessed in three steps and 77% overall yield from commercially available 2-phenyl-2-
propanol. With 88 in hand, the exploration of the alkylation reaction and resulting 
enantioselectivities obtained with the use of 52 as the catalyst could be started. It was decided to 
optimize the conditions using benzyl bromide. 
I.3.B.b. Enantioselective alkylation conditions optimization 
The enantioselective alkylation of 88 was optimized with benzyl bromide. In DCM or 
mixtures of toluene and DCM, the reaction proceeded cleanly with average yields (48-67 %) and 
good levels of ee (87-91%) with CsOH as the base at low temperatures (-50 °C to -78 °C). 
Changing the solvent system to toluene/chloroform (7:3) raised the ee to 94% (all ee were 
determined by chiral HPLC by comparison with the racemic product). We also observed that 
benzyl bromide was not completely consumed at the end of the reaction, due probably to a slight 
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instability of the imine moiety in 88. Raising the number of equivalents of 88 to 1.4 enabled 
higher yields (86% based on benzyl bromide) (Scheme 12, Table 6). 
 
Scheme 12: Optimization of the asymmetric alkylation conditions with the cumyl ester 88 
Entry Equiv of 88 Solvent Temp (°C) yield (%) ee % 
      
1 1.0 CH2Cl2 -50 67 87 
2 1.0 CH2Cl2 -78 52 91 
3 1.0 Toluene/CH2Cl2 (7:3) -78 48 90 
4 1.0 Toluene/CHCl3 (7:3) -50 62 94 
5 1.0 Toluene/CHCl3 (7:3) -78 42 89 
6 1.4 Toluene/CHCl3 (7:3) -50 86 94 
      
Table 6: Optimization of the asymmetric alkylation conditions with the cumyl ester 88 
I.3.B.c. Reaction scope 
Having found optimized conditions for the enantioselective alkylation of 88, the reaction 
scope was investigated. Before screening electrophiles, it was decided to run a control 
experiment to ensure that high levels of enantioselectivity with the new substrate are not solely 
due to optimized reaction conditions but rather to the nature of the substrate. To prove our 
hypothesis, benzyl protected glycine benzophenone imine was used in the alkylation reaction 
with 58 under the same optimized conditions which provided an ee of only 80%. The analogous 
reaction between 88 and 58 provided the product with 94% ee. This proved that the new cumyl 
protected substrate, and not the optimized conditions, are the reason for the high levels of ee. At 
that point the use of different electrophiles, varying in size and electronic nature (sp
3
, sp
2
 and sp 
hybridized) was investigated. Levels of ee were high in all cases. EtI (Table 7, entry 4, 85% ee), 
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was the only example showing levels of ee lower than 90%. Good yields and excellent 
enantioselectivities were obtained with all other electrophiles (Table 7, yields ranging from 56 to 
91% and ee from 91 to 94%). 
 
Scheme 13: Scope of the asymmetric alkylation reaction with the cumyl ester 88 
Entry PG RX Product yield (%) ee % 
      
 
1 
 
OBn (90) 
  
91 
 
70 
 
80 
 
2 
 
Ocumyl (88) 
  
89b 
 
79 
 
94 
3 OCumyl MeI 89c 56 92 
      
4 OCumyl EtI 89d 77 85 
      
 
5 
 
OCumyl 
  
89e 
 
85 
 
91 
 
6 
 
OCumyl 
  
89f 
 
91 
 
92 
      
Table 7: Scope of the asymmetric alkylation reaction with the cumyl ester 88 
 Finally, during the initial development of the HPA amino acid, N. Jabre showed that the 
alkylation of the tert-butyl ester protected glycine with 58 gives the corresponding product with 
80% yield and 93% ee. No loss in yield or enantioselectivity is observed with the new method 
(Table 7, entry 2).
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 The results presented above were very promising, as no loss of ee was observed between 
the new method and the methods previously developed by Corey, Lygo and others. The potential 
novelty associated with the use of the cumyl ester protected glycine imine versus the established 
tert-butyl ester consists in the compatibility of the acid-labile side chain protecting groups such 
as a TBS group with the deprotection reaction conditions. To demonstrate this potential, 
conditions for a global deprotection of both the C and N-termini that would not cleave the latter 
protecting groups needed to be found. Compound 89b was a perfect substrate to investigate those 
reaction conditions. 
I.3.B.d. Hydrogenolysis of 89b and synthesis of Fmoc-HPA-OH 62 
To complete the synthesis of HPA from 89b a global deprotection of both protecting 
groups needed to be performed first before the Fmoc protecting group would be installed on the 
N-terminus. After optimization we found that hydrogenolysis of substrate 89b using H2 (75 psi) 
and Pd(OH)2/C as the catalyst afforded the C- and N-deprotected unnatural amino acid HPN. 
The mixture also contained diphenylmethane, a benzophenone imine byproduct, and isopropyl 
benzene. After filtration of the catalyst and evaporation, the crude mixture was subjected to 
standard Fmoc protection conditions with Fmoc(OSu) and 5% NaHCO3 in a dioxane-acetone-
water mixture. Fmoc-HPA-OH 62 was obtained in 77% yield after purification by 
chromatography (Scheme 14). This result presents a great improvement compared to our initial 
method, which required two additional steps: acidic hydrolysis of the tert-butyl ester, and 
reprotection of the pyridine moiety with the TBS group. Gratified by those findings, the 
preparation of Fmoc-HPN-OH 60 from 89f was investigated. 
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Scheme 14: Synthesis of Fmoc-HPA-OH 62 from product 89b 
I.3.B.e. Synthesis of Fmoc-HPN-OH 60 
To complete the improvements of this new methodology we needed to show that 89f 
could be taken forward and coupled with the suitable partner 88 under Sonogashira conditions, 
and then perform a global hydrogenolysis and reduction of the alkyne functionality. The 
Sonogashira coupling of 89f and 88 proceeded cleanly to give 92 in 76% yield. To our delight, 
92 could be fully reduced within 24 hours with H2 (75 psi) and Pd/C to the unprotected unnatural 
amino acid HPN, diphenylmethane and isopropyl benzene. Under similar conditions as for the 
synthesis of 62, Fmoc-HPN-OH (60) was obtained in a 83% yield over the 2 steps (Scheme 15). 
This result is a great improvement compared with the first synthesis of HPN developed in our 
laboratory. The sequence described in Scheme 15 previously took six steps (Scheme 10), three of 
which were protecting group manipulations. 
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Scheme 15: Synthesis of Fmoc-HPN-OH 60 from 89f 
 The syntheses of unnatural amino acids 60 and 62 demonstrate the utility of this new 
methodology. The pyridine moiety in unnatural amino acids HPA and HPN is protected with a 
TBS group. Previous syntheses were based on the enantioselective alkylation of tert-butyl ester-
protected glycine imine forcing harsh deprotection conditions and loss of the TBS group that had 
to be reintroduced in separate steps. The use of the cumyl ester-protected glycine imine enables 
the use of hydrogenolysis for the deprotection step, leaving the TBS group in place. Acid-labile 
side chain protecting groups are thus now compatible with the enantioslective alkylation 
reactions using the Cinchona catalysts. 
I.3.C. Conclusion 
We have developed a novel substrate for a classical reaction that enables quick access to 
a variety of unnatural amino acids. Our method presents an important advantage: electrophiles 
bearing acid-labile protecting groups can be now used, which was not the case previously. We 
expect this method to facilitate the synthesis of Fmoc protected unnatural amino acids in the 
community. 
 The results presented in the Chapter were published in Organic Letters: Respondek T., 
Cueny E., Kodanko J. J, "Cumyl Ester as the C-Terminal Protecting Group in the 
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Enantioselective Alkylation of Glycine Benzophenone Imine" Org. Lett., 2012, 14 (1), pp 150–
153).
129
 
 From a more general perspective, the results presented in this part of this dissertation 
describe a novel approach to building peptide-ligand conjugates. The strategy was designed to 
accelerate the synthesis of full libraries of peptides where the sequence and nature of the ligand 
can be easily modified. It uses the combinatorial approach to build a plethora of molecules for 
testing their properties as metal complexes or biologically active molecules through the use of 
SPPS. The utility of this strategy is based on the use of unnatural amino acids having a TBS 
protected pyridylmethyl moiety that is used for anchoring a diversity of ligands once the desired 
peptide has been constructed. The TBS group and the subsequent ligand attachment are 
chemically compatible with standard Fmoc SPPS synthesis. 
Recognizing that our initial syntheses of unnatural amino acids were not compatible with 
acid-labile protecting groups (the TBS group in this precise example) we have reexamined one of 
the most used methods in the literature for the synthesis of enantiomerically enriched amino 
acids and synthesized an “optimal” substrate for the Cinchona catalyzed phase transfer alkylation 
of glycine benzophenone imine. The new cumyl ester-protected benzophenone glycine imine 
offers the same levels of enantiomeric excess compared to the original studies with very mild 
deprotection conditions, now compatible with acid-labile protecting groups. The conjoined use 
of this methodology with the divergent synthesis of peptide-ligand conjugates gives a very 
straightforward access to a multitude of new molecules in a very efficient manner. We believe 
that the strategies described above will facilitate the study of metal-peptide conjugates as 
potential active molecules with new properties inherited from both the metal complexes and 
peptides. 
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The Kodanko group is actively interested in studying the use of metal complexes as 
potential warheads for biological targets. Metal-peptide conjugates offer a new range of 
opportunities in the areas of directing those metal warheads to site specific areas or through the 
use of caging strategies. The methodologies described in this part of the dissertation contribute to 
the synthesis and evaluation of novel, potentially biologically active molecules. Their syntheses 
and evaluation are underway in our laboratory 
I.3.D. Experimental section 
I.3.D.a. General considerations 
All reagents were purchased from commercial suppliers and used as received. NMR 
spectra were recorded on a Varian FT-NMR Mercury-300, 400 or 500 MHz Spectrometer. Low-
resolution mass spectra were recorded on a Waters ZQ2000 single quadrupole mass spectrometer 
using an electrospray ionization source, while high-resolution mass spectra were recorded on a 
Waters-Micromass LCT Premier XE time of flight mass spectrometer. IR spectra were recorded 
on a Nicolet FT-IR spectrophotometer. Optical rotations were obtained by using a PERKIN-
ELMER 241-MC Polarimeter. HPLC was performed on an Agilent 1200 Preparative Purification 
System equipped with a multi-wavelength detector. Column purifications were performed using 
silica gel flash chromatography unless mentioned otherwise. All reactions were performed under 
ambient atmosphere unless otherwise noted. Anaerobic reactions were performed in Schlenk 
tubes. 
Compounds 90
130
,52
99
, 80
131
 and benzophenone imine
127
 used in this report were synthesized 
according to previously reported literature procedures. All reactions were performed under 
ambient atmosphere unless otherwise noted. Anaerobic reactions were performed in Schlenk 
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tubes. These reactions were deoxygenated by performing five vacuum-backfill cycles with Ar 
and were run under a constant purge of Ar. For anaerobic reactions, Et3N, Hunig’s base and 
CH3CN were distilled over CaH2. All NMR spectra and chromatographs used to determine the ee 
can be found in the Appendix section. 
I.3.D.b. Experimental procedures and tabulated characterization data 
2-phenylpropan-2-yl 2-bromoacetate (87). 
 
 Sodium hydride (60% in oil, 180 mg 4.50 mmol) was suspended in anhydrous ether (4.50 
mL) and a solution of 2-phenyl-2-propanol in ether (6.50 mL) was added dropwise with stirring, 
under an Ar atmosphere. After 20 min the solids have dissolved and the solution was cooled 
down to 0°C. Trichloroacetonitrile (6.82 g, 47.2 mmol) was then added dropwise over 15 min 
and the reaction mixture was allowed to warm up to RT over 60 min. The reaction mixture was 
concentrated to a syrup and pentane (4.50 ml) was added. The resulting solution was filtered on a 
Buchner filtration set-up and washed with pentane (2 4.50 mL). The filtrate was evaporated to 
give the crude imidate that was used as is without further purification. The imidate was stored at 
-20°C as solutions in cyclohexanes (1.00 mmol/1.00 mL) for periods up to 2 months.
125, 126
 
The imidates in cyclohexanes (3.00 mL, 3.00 mmol) were added to bromoacetic acid (417 mg, 
3.00 mmol) in dry CH2Cl2 under Ar at RT and the resulting solution stirred for 12 h. The 
trichloroacetamide was filtered off on a Buchner set-up and washed with CH2Cl2. The solvent 
was evaporated to give a solidifying crude mixture that was purified by flash chromatography on 
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silica (5 to 10% EtOAc in hexanes) to afford the product 87 as an oil (696 mg, 2.71 mmol, 90%): 
1
H NMR (400 MHz, CDCl3)  7.44-7.32 (m, 4H), 7.32-7.25 (m, 1H), 3.80 (s, 2H), 1.82 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  165.8, 145.1, 128.6, 127.6, 124.5, 84.1, 28.6, 27.5; IR (thin film) 
3089, 3061, 3028, 2982, 2935, 2875, 1737, 1603, 1584, 1496, 1468, 1449, 1420, 1384, 1367, 
1285, 1202, 1178, 1139, 1100, 1077, 1030, 960, 938, 909, 827, 764, 699 cm
-1
; HRMS (ESMS) 
calculated for C11H13BrO2Na 278.9997 (M+Na)
+
, found : 279.0003. 
2-phenylpropan-2-yl 2-((diphenylmethylene)amino)acetate (88). 
 
 To a solution of 2-phenylpropan-2-yl 2-bromoacetate 87 (5.80 g, 22.6 mmol) in 
anhydrous CH3CN (23 mL), DIPEA (3.93 mL, 22.56 mmol) and benzophenone imine
127
 ( 4.09 g, 
22.6 mmol) were added under an Ar atmosphere. The resulting solution was stirred for 24 h at 
RT. After the reaction completion (followed by TLC) the crude was filtered through a cotton 
plug, dissolved with 75 mL of CH2Cl2 and 50 mL of 5% NaHCO3 in H2O. The organic layer was 
separated and the aqueous layer extracted with 2 50 mL CH2Cl2. The organic layers were 
combined, dried over Na2SO4, filtered and evaporated. The crude was purified by flash 
chromatography on silica basified with 1% TEA (1% TEA in 4 to 9% EtOAC/hexanes) to give 
product 88 as an oil (6.87g, 19.2 mmol, 85%): 
1
H NMR (400 MHz, CDCl3)  7.71-7.66 (m, 2H), 
7.50-7.45 (m, 3H), 7.43-7.31 (m, 7H), 7.29-7.33 (m, 1H), 7.20-7.15 (m, 2H), 4.26 (s, 2H), 1.82 
(s, 6H); 
13
C NMR (100 MHz, CDCl3)  172.0, 169.3, 145.9, 139.6, 136.3, 130.7, 130.3, 129.1, 
129.0, 128.9, 128.5, 128.3, 128.0, 127.3, 124.6, 82.5, 56.6, 28.9; IR (thin film) 3058, 3026, 2980, 
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2929, 1744, 1659, 1625, 1598, 1577, 1495, 1446, 1383, 1343, 1315, 1274, 1193, 1137, 1102, 
1076, 1029, 1000, 940, 907, 838, 764, 696 cm
-1
; HRMS (ESMS) calculated for C24H24NO2 
358.1807 (M+H)
+
, found : 358.1807. 
General procedure for the asymmetric alkylation of glycine benzophenone imine 88: 
 To a solution of 2-phenylpropan-2-yl 2-((diphenylmethylene)amino)acetate 88 (150 mg, 
0.42 mmol) in Toluene/CHCl3 (7/3, 1.05 mL) in a Schlenk flask was added the catalyst 52 (18.2 
mg, 0.03 mmol) and the resulting solution cooled down to -55 °C. The electrophile (0.30 mmol) 
was then added at -55 °C and the resulting solution stirred for 3 min. CsOH.H2O was then added 
in one portion (504 mg, 3.00 mmol) at -55°C and the resulting solution turned rapidly yellow and 
was stirred at -55 °C for 12-24 h. The completion of the reaction was followed by TLC. The 
crude was then dissolved in 10 mL of H2O and 20 mL of anhydrous ether. The organic layer was 
washed with H2O (2 10 mL). The combined aqueous layers were then extracted with anhydrous 
ether (3 15 mL). All organic layers were combined, dried over Na2SO4 and evaporated. The 
crude was purified by flash chromatography on silica basified with 1% TEA (1% TEA in 4 to 
9% EtOAC/hexanes) to give the alkylation product 89a-f as an oil. 
(S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)-3-phenylpropanoate (89a): 
 
89a was obtained as a yellow oil (115 mg, 0.257 mmol, 86 %): 
1
H NMR (400 MHz, 
CDCl3)  7.70-7.64 (m, 2H), 7.47-7.17 (m, 14H), 7.16-7.09 (m, 2H), 6.71-6.55 (d, J = 5.7, Hz, 
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2H), 4.29-4.22 (dd, J = 8.9, 4.1 Hz, 1H), 3.38-3.20 (m, 2H), 1.85 (s, 3H), 1,80 (s, 3H); 
13
C NMR 
(100 MHz, CDCl3)  170.5, 170.3, 145.9, 139.7, 138.6, 136.5, 130.5, 130.2, 129.0, 128.5, 128.5, 
128.4, 128.4, 128.3, 127.9, 127.3, 126.5, 124.6, 82.7, 68.2, 39.6, 29.2, 28.6; IR (thin film) 3083, 
3060, 3027, 2979, 2927, 2853, 1741, 1623, 1597, 1576, 1495, 1446, 1382, 1365, 1315, 1272, 
1247, 1200, 1180, 1137, 1101, 1076, 1029, 1000, 975, 909, 841, 779, 762, 696, 637 cm
-1
; [α] = -
48.9° (c = 0.922, CHCl3); HRMS (ESMS) calculated for C31H30NO2 448.2277 (M+H)
+
, found : 
448.2266. The enantiomeric excess was determined using HPLC on a Chiralcel OD-H column 
(250  4.6 mm ID) for the racemic and enantioenriched substrates under isocratic conditions 
(100:2 Hexanes-Isopropanol) with a flowrate of 1.0 ml/min. Retention times: 6.98 min and 8.10 
min. Enantiomeric excess: 94%. 
(S)-2-phenylpropan-2-yl 3-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-
((diphenylmethylene)amino)propanoate (89b): 
 
 89b was obtained as a yellow oil (140 mg, 0.237 mmol, 79 %): 
1
H NMR (400 MHz, 
CDCl3)  8.23 (d, J = 1.6 Hz, 1H), 7.64-7.58 (m, 2H), 7.44-7.20 (m, 13H), 6.74-6.60 (d, J = 7.3 
Hz, 2H), 4.21-4.17 (dd, J = 8.9, 4.1 Hz, 1H), 3.28-3.12 (m, 2H), 1.79 (s, 3H), 1,75 (s, 3H), 0.94 
(s, 9H), 0.10 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  171.2, 169.9, 159.5, 150.0, 145.7, 139.3, 
138.3, 136.3, 132.0, 130.6, 129.0, 128.8, 128.6, 128.5, 128.3, 127.7, 127.3, 124.5, 119.7, 82.9, 
67.5, 66.2, 36.4, 29.2, 28.5, 26.2, 18.6, -5.1; IR (thin film) 3445 (broad), 3062, 2954, 2928, 2855, 
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1741, 1622, 1600, 1574, 1488, 1471, 1463, 1447, 1396, 1383, 1366, 1314, 1253, 1199, 1136, 
1102, 1077, 1030, 1006, 838, 778, 763, 697, 667 cm
-1
; [α] = -30.0° (c = 0.3, CHCl3); HRMS 
(ESMS) calculated for C37H45N2O3Si 593.3199 (M+H)
+
, found : 593.3201. The enantiomeric 
excess was determined using HPLC on a Chiralcel OD-H column (250  4.6 mm ID) for the 
racemic and enantioenriched substrates under isocratic conditions (100:2 Hexanes-Isopropanol) 
with a flowrate of 1.0 ml/min. Retention times: 7.21 min and 11.21 min. Enantiomeric excess: 
94%. 
(S)-benzyl 3-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-
((diphenylmethylene)amino)propanoate (91): 
 
The enantiomeric excess was determined using HPLC on a Chiralcel OD-H column (250 
 4.6 mm ID) for the racemic and enantioenriched substrates under isocratic conditions (100:1 
Hexanes-Isopropanol) with a flowrate of 1.0 ml/min. Retention times: 12.31 min and 16.94 min. 
Enantiomeric excess: 80%. 
(S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)propanoate (89c): 
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 89c was obtained as a yellow oil (62 mg, 0.17 mmol, 56 %): 
1
H NMR (400 MHz, CDCl3) 
 7.70-7.64 (m, 2H), 7.49-7.44 (m, 3H), 7.44-7.21 (m, 8H), 7.21-7.15 (m, 2H), 4.14-4.12 (q, J = 
6.5 Hz, 1H), 1.79 (s, 3H), 1.75 (s, 3H), 1.44 (d, J = 6.5 Hz, 3H); 
13
C NMR (100 MHz, CDCl3)  
171.4, 169.7, 146.0, 139.8, 136.7, 130.5, 129.0, 128.8, 128.4, 128.3, 128.0, 127.2, 124.5, 82.3, 
61.5, 29.1, 28.6; 19.2; IR (thin film) 3059, 3026, 2980, 2932, 2870, 1743, 1661, 1623, 1598, 
1577, 1495, 1446, 1382, 1366, 1315, 1273, 1198, 1140, 1121, 1102, 1076, 1030, 1001, 951, 909, 
841, 780, 764, 697 cm
-1
; [α] = -35.8° (c = 1.025, CH2Cl2); HRMS (ESMS) calculated for 
C25H26NO2 372.1964 (M+H)
+
, found : 372.1957. The enantiomeric excess was determined using 
HPLC on a Chiralcel OD-H column (250  4.6 mm ID) for the racemic and enantioenriched 
substrates under isocratic conditions (500:1 Hexanes-Isopropanol) with a flowrate of 1.0 ml/min. 
Retention times: 11.10 min and 12.02 min. Enantiomeric excess: 92%. 
(S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)butanoate (89d): 
 
 89d was obtained as a yellow oil (89 mg, 0.23 mmol, 77 %): 
1
H NMR (400 MHz, CDCl3) 
 7.72-7.65 (m, 2H), 7.49-7.42 (m, 3H), 7.42-7.20 (m, 8H), 7.20-7.12 (m, 2H), 3.99-3.92 (dd, J = 
8.1, 4.9 Hz, 1H), 2.06-1.87 (m, 2H), 1.80 (s, 3H), 1.76 (s, 3H), 0.89 (t, J = 7.3 Hz, 3H); 
13
C 
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NMR (100 MHz, CDCl3)  170.9, 170.3, 146.0, 139.9, 136.9, 130.4, 130.3, 129.0, 128.7, 128.6, 
128.4, 128.3, 128.1, 127.1, 124.6, 82.3, 67.6, 29.1, 28.6; 26.9; 10.9; IR (thin film) 3060, 3027, 
2976, 2932, 2874, 1739, 1660, 1623, 1598, 1577, 1496, 1447, 1383, 1366, 1316, 1276, 1198, 
1139, 1102, 1076, 1030, 1000, 941, 919, 838, 780, 763, 698, 638 cm
-1
; [α] = -56.2° (c = 1.6, 
CHCl3); HRMS (ESMS) calculated for C26H28NO2 386.2120 (M+H)
+
, found : 386.2121. The 
enantiomeric excess was determined using HPLC on a Chiralcel OD-H column (250  4.6 mm 
ID) for the racemic and enantioenriched substrates under isocratic conditions (100:1 Hexanes-
Isopropanol) with a flowrate of 1.0 ml/min. Retention times: 10.10 min and 11.66 min. 
Enantiomeric excess: 85%. 
(S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)pent-4-enoate (89e) : 
 
 89e was obtained as a yellow oil (101 mg, 0.254 mmol, 85 %): 
1
H NMR (400 MHz, 
CDCl3)  7.70-7.64 (m, 2H), 7.47-7.43 (m, 3H), 7.43-7.21 (m, 8H), 7.20-7.13 (m, 2H), 5.80-5.67 
(m, 1H), 5.13-5.01 (m, 2H), 4.14-4.09 (dd, J = 7.3, 2.4 Hz, 1H), 2.78-2.62 (m, 2H), 1.80 (s, 3H), 
1.75 (s, 3H); 
13
C NMR (100 MHz, CDCl3)  170.5, 170.3, 145.9, 139.8, 136.8, 134.9, 130.5, 
129.0, 128.8, 128.7, 128.4, 128.3, 128.2, 127.2, 124.6, 117.7, 82.5, 66.1, 38.1, 29.2, 28.5; IR 
(thin film) 3061, 3025, 2980, 2928, 1741, 1623, 1598, 1576, 1495, 1446, 1414, 1383, 1365, 
1314, 1271, 1245, 1194, 1137, 1102, 1076, 1030, 1000, 915, 839, 780, 763, 697, 651 cm
-1
; [α] = 
-7.6° (c = 1.84, CHCl3); HRMS (ESMS) calculated for C27H28NO2 398.2120 (M+H)
+
, found : 
398.2116. The enantiomeric excess was determined using HPLC on a Chiralcel OD-H column 
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(250  4.6 mm ID) for the racemic and enantioenriched substrates under isocratic conditions 
(500:1.5 Hexanes-Isopropanol) with a flowrate of 1.0 ml/min. Retention times: 10.58 min and 
12.06 min. Enantiomeric excess: 91%. 
(S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)pent-4-ynoate (89f) : 
 
89f was obtained as a yellow oil (108 mg, 0.274 mmol, 91 %): 
1
H NMR (400 MHz, 
CDCl3)  7.73-7.68 (m, 2H), 7.50-7.44 (m, 3H), 7.44-7.21 (m, 10H), 4.31-4.25 (dd, J = 8.1, 4.9 
Hz, 1H), 2.91-2.75 (m, 2H), 1.98 (t, J = 2.4 Hz, 1H), 1.80 (s, 3H), 1.76 (s, 3H); 
13
C NMR (100 
MHz, CDCl3)  171.8, 169.0, 145.6, 139.7, 136.4, 130.7, 129.2, 128.9, 128.7, 128.5, 128.3, 
127.3, 124.6, 83.1, 81.5, 65.0, 29.1, 28.5; 23.4; IR (thin film) 3293, 3059, 3026, 2980, 2924, 
2854, 1740, 1659, 1623, 1598, 1577, 1496, 1447, 1383, 1366, 1316, 1276, 1196, 1138, 1102, 
1076, 1030, 1000, 942, 919, 838, 781, 764, 698, 638 cm
-1
; [α] = -75.4° (c = 1.0, CH2Cl2); HRMS 
(ESMS) calculated for C27H26NO2 396.1964 (M+H)
+
, found : 396.1971. The enantiomeric excess 
was determined using HPLC on a Chiralcel OD-H column (250  4.6 mm ID) for the racemic 
and enantioenriched substrates under isocratic conditions (100:1 Hexanes-Isopropanol) with a 
flowrate of 0.6 ml/min. Retention times: 13.62 min and 15.25 min. Enantiomeric excess: 92%. 
(S)-2-phenylpropan-2-yl 5-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-
((diphenylmethylene)amino)pent-4-ynoate (92) : 
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To a solution of, (S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)pent-4-ynoate 
(99.0 mg, 0.25 mmol) 89f in anhydrous THF (3 mL) in a pressure flask under Ar were added 5-
bromo-2-((tert-butyldimethylsilyloxy)methyl)pyridine 80 (83.0 mg, 0.28 mmol), Pd(PPh3)4 (29.0 
mg, 0.03 mmol), CuI (7.00 mg, 0.04 mmol) and Et3N (350 μL, 2.50 mmol). The solution turned 
quickly brown-black and was heated to 60 °C for 36 h. The completion of the reaction was 
monitored by TLC. After completion of the reaction, the crude was extracted with CH2Cl2 (3 10 
mL, addition of 15 mL of 5% NaHCO3 in H2O). The organic layers were collected, dried over 
Na2SO4 and evaporated. The crude was purified by flash chromatography on silica basified with 
1% TEA (1% TEA in 4% EtOAC/hexanes) to give the coupling product 92 as a yellow oil (117 
mg, 0.19 mmol, 76%): 
1
H NMR (400 MHz, CDCl3)  8.47 (d, J = 2.4 Hz, 1H), 7.74-7.67 (m, 
2H), 7.63 (dd, J = 8.1, 2.4 Hz, 1H) 7.47-7.39 (m, 5H), 7.39-7.31 (m, 4H), 7.31-7.20 (m, 5H), 
4.81 (s, 2H), 4.39-4.34 (dd, J = 8.1, 4.9 Hz, 1H), 3.14-2.98 (m, 2H), 1.82 (s, 3H), 1.78 (s, 3H), 
0.96 (s, 9H), 0.12 (s, 6H); 
13
C NMR (100 MHz, CDCl3)  171.9, 169.1, 160.4, 151.4, 145.6, 
139.7, 139.4, 136.4, 130.7, 129.2, 129.0, 128.7, 128.5, 128.4, 128.3, 127.3, 124.5, 119.5, 118.9, 
90.1, 83.1, 79.4, 66.2, 65.2, 29.1, 28.6, 26.2, 18.6, -5.1; IR (thin film) 3449 (broad), 3060, 3026, 
2953, 2929, 2885, 2856, 1742, 1624, 1595, 1576, 1556, 1485, 1471, 1463, 1447, 1418, 1376, 
1366, 1314, 1258, 1215, 1188, 1136, 1102, 1077, 1029, 1006, 987, 967, 908, 839, 779, 763, 697, 
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640 cm
-1
; [α] = -23.5° (c = 1.18, CHCl3); HRMS (ESMS) calculated for C39H45N2O3Si 617.3199 
(M+H)
+
, found : 617.3180. 
(S)-2-((((9H-fluoren-9-yl)methoxy)carbonylamino)-3-(6-((tert-
butyldimethylsilyl)oxy)methyl)pyridin-3-yl)propanoic acid (62). 
 
 From compound 89b: A mixture of (S)-2-phenylpropan-2-yl 3-(6-(((tert-
butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-((diphenylmethylene)amino)propanoate (89b) 
(88.0 mg, 0.15 mmol), Pd(OH)2/C (13.0 mg, 15% w/w) and MeOH (2.6 mL) was stirred at RT 
under H2 (75 psi) for 12 h. The reaction mixture was filtered through a celite bed or HPLC filter 
to remove Pd/C and the filtrate was concentrated to give the deprotected amino acid (60 mg) as a 
colorless to white solid. An NMR was taken to ensure the completion of the hydrogenolysis step. 
The solid was then dissolved in a 1:1 mixture of H2O and acetone (2.00 mL), NaHCO3 (25.0 mg, 
0.295 mmol) and Fmoc-OSu (54.8 mg, 0.16 mmol) in dioxane (1.00 mL) were added and the 
resulting solution was stirred at RT for 16 h. After completion of the reaction (monitored by 
TLC), the pH of the reaction was brought to pH~4-5 with 10% citric acid in H2O and extracted 
with EtOAC (5 10 mL). The organic layers were collected, dried over Na2SO4 and evaporated. 
The crude was purified by flash chromatography on silica (1 to 10% CH3OH in CH2Cl2) to give 
62 as an amorphous solid. The NMR and optical rotation were matching with the literature 
data.
120
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(S)-2-phenylpropan-2-yl 5-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-
((diphenylmethylene)amino)pentanoate (60). 
 
 From compound 92: A mixture of ((S)-2-phenylpropan-2-yl 5-(6-(((tert-
butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-((diphenylmethylene)amino)pent-4-ynoate (92) 
(100 mg, 0.16 mmol), Pd/C black (15 mg, 15% w/w) and MeOH (2.85 mL) was stirred at RT 
under H2 (75 psi) for 36 h. The reaction mixture was filtered through a celite bed or HPLC filter 
to remove Pd/C and the filtrate was concentrated to give the deprotected amino acid (69 mg) as a 
colorless to white solid. An NMR was taken to ensure the completion of the hydrogenolysis step. 
The solid was then dissolved in a 1:1 mixture of H2O and acetone (2.20 mL), NaHCO3 (27.0 mg, 
0.32 mmol) and Fmoc-OSu (60.3 mg, 0.18 mmol) in dioxane (1.10 mL) were added and the 
resulting solution was stirred at RT for 16 h. After completion of the reaction (monitored by 
TLC), the pH of the reaction was brought to pH~4-5 with 10% citric acid in H2O and extracted 
with EtOAC (5 10 mL). The organic layers were collected, dried over Na2SO4 and evaporated. 
The crude was purified by flash chromatography on silica (1 to 10% CH3OH in CH2CL2) to give 
60 as an amorphous solid. The NMR and optical rotation were matching with the literature 
data.
120
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Part II :  Synthesis and biological evaluation of novel 
light activated cysteine proteases inhibitors caged by 
RuII(bpy)2 
Chapter 1. Introduction: 
II.1.A. Proteases 
 Proteolytic enzymes or proteases are enzymes that facilitate protein degradation by 
hydrolysis of the peptide bond. More than 500 different proteases have been identified in the 
human body to date, and they can be classified between six different categories, namely, serine, 
threonine, cysteine, aspartic, glutamic and metallo proteases.
132, 133
 They are believed to be the 
intracellular turnover police
134
 controlling such processes as cell death and proliferation, DNA 
replication, tissue remodeling etc. Because of the complex role that proteases are involved in, the 
signaling pathways are extremely complicated and disrupting those cascades can create serious 
safety issues.
135
 
 Protease dysregulation leads to serious disease states and has been linked to many 
conditions. Insufficient proteolysis, due to a lack of activation, is often a result of genetic 
anomalies or caused by pathogens.
136, 137
 On the other hand, upregulation of proteolytic activity 
has been closely related to cardiovascular, neurodegenerative, inflammatory and cancer diseases. 
Inhibition of upregulated proteases involved in such states became a popular therapeutic strategy,  
making proteases a viable target.
138
 Because of the complexity in the signaling pathways, the 
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necessity for not disturbing the tightly regulated proteolytic activity in healthy cells, and the 
resemblance between many proteases, achieving inhibitor selectivity has been one of the main 
areas of research leading to successful developments of drug molecules
139
 as well as clinical 
failures.
140, 141
 
 Research in the area of proteases and their inactivation has been extremely abundant and 
nearly 10,000 papers are published every year on the subject.
142
 Thus, only a modest 
introduction, directly related to the projects described in this dissertation will be presented. 
II.1.B. Cysteine cathepsins and cancer 
 Cathepsins are a family of cysteine proteases expressed in humans, animals and plants 
belonging to the papain subfamily.
133
 Most of the 11 cathepsins expressed in humans are 
endopeptidases and found in lysosomes.
143
 For a long time, cathepsins were believed to be only 
involved in protein turnover, however they have been found to be associated with particular 
physiological processes such as brain and skin development
144
 and bone resorption.
145
 Cathepsin 
activity is highly regulated in healthy cells, and many safety mechanisms to avoid dysregulation 
exist. More and more data has directly implied the causal role of cathepsin upregulation in cancer 
where the natural “safety mechanisms” are overridden. Moreover, dyslocalization of cathepsin 
activity to the extracellular milieu has also been reported in cancer cells.
146
 Recent, excellent 
review articles have summarized the overall role of cathepsin upregulation in cancer in general 
and tumor growth, invasion, angiogenesis and metastasis in particular, and thus will not be 
further discussed here.
146-150
  
 Cathepsin K is a lysosomal cysteine protease that is mostly expressed in osteoclasts
151
 
and responsible for collagen I degradation.
152
 Recent publications from the Podgorski laboratory 
link cathepsin K activity to bone marrow metastases from prostate and breast cancers.
153
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Cathepsin K has been shown to process the protein SPARC implicated in bone metastasis and 
inflammation.
154, 155
 
 More recently, cathepsin K levels in bone marrow macrophages (BMM) have been linked 
to tumor progression in bone.
156
 Cathepsin K inhibitors have been known for a few years now to 
have beneficial effects on patients with breast cancer and bone metastases. The selective 
cathepsin K inhibitor drug odanacatib has been shown to reduce bone resorption.
157
 Taken all 
together, these data suggest that cathepsin K inhibition is a viable therapeutic target for 
metastatic bone disease and related conditions.
158
 
II.1.C. Cysteine cathepsin inhibitors 
 Three different classes of small molecule cathepsin inhibitors have so far demonstrated 
efficacy in vivo. All react with the enzymes’s free thiol in the active site, but epoxysuccinyl-
based and vinyl sulfone inhibitors react in an irreversible fashion whereas nitrile-based inhibitors 
are reversible inhibitors. Epoxysuccinyl-based inhibitor E64 was stopped in phase III clinical 
trials because of suboptimal results.
159
 Vinyl sulfone inhibitor K11777 is being clinically tested 
for Chagas disease.
160
 Finally, multiple nitrile-based inhibitors are in development. Clinical 
phase III trials of odanacatib were recently closed early with “a favorable benefit-risk profile” 
and a new study is scheduled for next year.
157
 Excellent review papers summarize the efforts by 
both academia and industry to develop new potent cysteine cathepsin inhibitors.
134, 159, 161-163
 
II.1.D. Metals as therapeutic or biologically relevant agents 
 Since the discovery of cisplatin by Rosenberg in the 1960’s, inorganic complexes have 
gathered a more important role as therapeutic agents in medicine.
164
 As of now, more than 50% 
of cancer treatments involve some use of cisplatin.
165
 Other complexes of platinum, ruthenium 
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and gold have entered clinical trails.
166
 New designs use metals and light to gain spatial and 
temporal control over the delivery of drugs through the use of photodynamic therapy, CALI 
(chromophore-assisted laser inactivation) and caging strategies. The next sections will provide 
some insight into the use of ruthenium complexes in the latter mentioned approaches. 
II.1.D.a. Platinum anticancer drugs 
 Although cisplatin ([cis-diamminedichloro platinum(II)]) 93 was first synthesized and 
characterized more than 150 years ago
167
, its anticancer properties were not discovered until the 
1960s by Rosenberg, while using platinum electrodes with ammonium chloride to study 
Escherichia coli growth.
168
 Cisplatin was subsequently identified as a platinum complexe that 
inhibits sarcoma 180 and leukemia L1210 cells in mice
169
 and approved by the FDA as an 
anticancer drug in 1978. The full mechanism of action is still not completely understood 
although it is clear that one main mode of action is caused by binding of cisplatin to DNA, 
provoking 1,2-intrastrand crosslinks at d(GpG) sites further blocking replication.
170
 Because of 
severe side effects associated with treatments using cisplatin
171
 and intrinsic/acquired resistance, 
new platinum, gold and ruthenium anticancer have been synthesized, entered clinical trials or 
have been approved by the FDA.
172, 173
 (Figure 28 shows FDA approved platinum anticancer 
agents) 
 
Figure 28: FDA approved platinum complexes for cancer treatment 
 Drug resistance is cell-line dependent, usually increases with time and is not fully 
understood. Some of the causes are related to reduced accumulation, increased deactivation by 
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natural cell detoxification operations mediated by glutathione or repair of platinum DNA 
adducts. Related ruthenium complexes have been thought to be less toxic and capable of 
overcoming usual drug resistance pathways.
174
 
II.1.D.b. Ruthenium anticancer drugs 
 The research area of ruthenium complexes with potential anticancer activities has been 
extremely active. Many excellent review articles describe the history of the development of these 
complexes as well as the analogies and differences compared to related platinum complexes and 
challenges for finding actual drug molecules.
173-179
 Only a few major examples will be described 
here. 
 
Figure 29: Early Ru based complexes with anticancer activity 
 Early designs were clearly mimicking known platinum-based drugs as in complex 96,
180, 
181
 but quickly new hypotheses emerged. Scientists believed that ruthenium was a better metal 
anchor to build potential drugs around because three oxidations states could be easily accessible 
under physiological conditions (from Ru(II) to Ru(IV)). Moreover, the octahedral geometry is 
usually preferred for these complexes, offering more geometrical possibilities and opening the 
door for more SAR type studies. To improve water solubility compared to 96, cis- and trans-
Ru(DMSO)4X4 (with X = Cl or Br) were synthesized,
182
 and surprisingly showed that the trans 
isomer was 20 times more cytotoxic than the cis isomer, implying that the DNA binding of Ru 
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complexes was either not following the same mechanism as for Pt complexes or a different mode 
of action was responsible for the cytotoxicity.
183
 
 
Figure 30: Ru complexes being investigated in clinical trials 
 One of the early hypotheses, namely the “activation by reduction”180, 181 led to the 
development of the only two ruthenium based anticancer agents that have entered clinical trials, 
namely NAMI-A by the Sava group and KP1019 by the Keppler group. The theory was based on 
the fact that the environment of cancer cells is mostly hypoxic and pH levels are lower because 
cancer cells divide rapidly to form masses with poor blood circulation and thus force glycolysis 
over the Kreb’s cycle. Taken together, these conditions should be favorable to reduce Ru(III) 
complexes into Ru(II) complexes, giving the possibility to administer less toxic Ru(III) prodrugs 
that would predominately become active in the tumor cell environment by reduction. Although 
the theory could be verified in simplified in vitro setups, it has not been validated in vivo. 
Nonetheless, NAMI-A
184
 and KP1019
185
 have successfully advanced through phase I clinical 
trials. Interestingly, these two molecules show different types of cytotoxicity even though they 
are closely related. NAMI-A shows selectivity towards lung metastases,
186
 whereas KP1019 
shows activity towards cisplatin-resistant human colon carcinoma cell lines
187
 which seems to be 
contradicting the “activation by reduction theory”. A new study aimed at explaining those results 
has shown the ability of certain Ru complexes to mimic Fe complexes and bind to transferrin,
188
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thus facilitating the transport of the molecules into cells.
189-191
 Interactions with other 
biologically relevant molecules including proteins could also contribute to the toxicities of these 
complexes. NAMI-A has, for example, been recently shown to accumulate on RNA in vitro and 
in cellulo.
192
 
 
Figure 31: Examples of Ru-arene complexes with anticancer activity 
 A different family of Ru complexes showing similar selectivity for metastases is the 
ruthenium-arene family (also called “piano-stool” complexes). Ethylenediamine piano 
complexes such as RM175 have similar aquation rates and cytotoxicities to Pt(II) complexes.
193-
195
 The RAPTA-C complex was the first molecule from this family that has shown interesting 
cytoxicity and is still used as a standard for the evaluation of new entities in this family of 
potential anticancer agents. A number of 1,3,5-triaza-7-phosphaadamantane (PTA) containing 
RAPTA complexes have been synthesized and tested.
193, 196
 Early studies have shown that the 
interaction between the aquated ruthenium complex with DNA could be the main mode of action 
of the drug, but lately new interactions such as inhibition of thioredoxin reductase and cathepsin 
B
197
 (in the lower micromolar range) suggest a DNA independent mode of action. 
 Polypyridyl ruthenium complexes have been known for a long time to bind to DNA in a 
site specific fashion depending on the geometry (chirality) of the complex. Barton has shown 
that Ru(phen)2Cl2 binds covalently and selectively to DNA with substantial differences in 
binding between the Δ and the Λ isomers.198, 199 The latter result clearly demonstrated the 
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possibility of binding to DNA leading to new complexes also having toxic effects. Brabec has 
shown that mer-[Ru(terpy)Cl3] (terpy = terpyridine) had particularly high cytotoxic effects in 
murine and human tumor cell lines compared to related [Ru(terpy)(bpy)Cl]Cl and cis-
[Ru(bpy)2Cl2] complexes.
200
 The study also supported that the mechanism involved DNA 
interstand cross-linking. Intercalation of metal complexes with DNA has been thoroughly 
reviewed and will not be discussed further.
201
 
 
Figure 32: Examples of Ru-polypyridyl complexes mimicking cisplatin  
 New classes of polypyridyl ruthenium complexes that lack labile groups (such as Cl, H2O 
or DMSO) have also been shown to have cytotoxic effects comparable to cisplatin. Although, 
DNA interactions are still believed to be the principal mode of action of those complexes, 
intercalation instead of covalent cross linking is postulated as the key type of interaction.
202
 
 The Schatzschneider group showed that cis-[Ru(bpy)2(4,5,9,16-
tetraazadibenzoA[a,c]naphthacene)] 106 presents low micromolar IC50 values against HT-29 and 
MCF-7 cancer cell lines and levels of cellular uptakes suggesting a cell adhesion mediated mode 
of action.
203
 The Liang group has shown various spectrographic data suggesting that the related 
Ru(II) complex, [Ru(phen)2PMIP]
2+
 (PMIP=2-(4-methylphenyl)imidazo[4,5-f]1,10-
phenanthroline) (107) binds to both transfer RNA and calf thymus DNA suggesting intercalation 
as the mode of action.
204
 More recently, the Hall group presented the first ever crystal structure 
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showing a Λ-[Ru(1,4,5,8-tetraazaphenanthrene)2(dipyridophenazine)]
2+
 complex 108 bound to 
duplex DNA resulting in kinking of the double helix due to dppz ligand intercalation. Previous 
studies on the same molecule also suggest a possible semi-intercalation of the TAP ligand, but it 
is not yet clear if both modes of interaction are happening at the same time.
205-207
 
 
Figure 33: New classes of polypyridyl ruthenium complexes that lack labile ligands 
 Other classes of Ru complexes such as Ru-polyaminocarboxylate complexes
208
 or Ru-
arylazopyridine complexes
209
 also show interesting cytotoxic effects in cancer cell lines but will 
not be discussed here. It should be made very clear that this research area is still very much in 
progress, mostly because the modes of action of the different classes of complexes are not well 
understood, thus making rational development of new candidates difficult. 
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II.1.E. Kinetic and spatial control over drug delivery 
 An interesting characteristic of certain Ru complexes is their photoreactivity and 
photodissociation under exposure to light. Ru complexes such as Ru(bpy)3
2+
 generate singlet 
oxygen upon irradiation with visible light
210-215
 and thus constitute viable candidates as a new 
class of inorganic photosensitizers for photodynamic therapy (PDT).
216
 Octahedral Ru 
complexes with distorted geometries decompose upon exposure to light with wavelengths 
corresponding to their metal to ligand charge transfer energies by ligand dissociation.
217, 218
 
These characteristics make Ru complexes interesting scaffolds for either PDT or caging 
strategies in order to gain spatial control over the delivery of the biologically active agent. 
II.1.E.a. Photodynamic therapy (PDT) and chromophore-assisted laser 
inactivation (CALI) strategies 
 Classic PDT strategies use organic photosensitizers to generate reactive oxygen species 
(ROS) to inactivate targets in the vicinity of the sensitizer upon exposition to light (often 
administered using lasers).
219
 Two major reaction pathways include the direct reaction with the 
substrate through radical formation, or generation of highly reactive singlet oxygen.
220
 PDT is 
now a clinically tested and approved therapy for various diseases. Classical approaches based on 
macrocycles such as porphyrins
221-223
 will not be discussed here, as they do not relate directly to 
the work presented in this dissertation, but recent examples where Ru complexes have been used 
will be described in the following section. 
 Chromophore-assisted laser inactivation (CALI) of proteins is a direct application of PDT 
to study biological functions of proteins through their specific inactivation. CALI is based on a 
target specific antibody labeled with a photosensitizer. After binding to the target and activation 
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upon exposure to light using a laser, the target protein is inactivated through oxidative processes. 
Initial CALI strategies used organic sensitizers such as malachite green or fluorescein.
224
 Recent 
developments include more efficient organic photosensitizers such as EGFP or KillerRed.
225-227
 
 The Kodadek group has recently described the use of Ru complexes as photosensitizers 
for CALI.
228
 HaloTag ligands (HT) of the commercially available haloalkane dehalogenase 
HaloTag protein (HTP) were covalently attached to either [Ru(bpy)3]
2+
 or fluorescein (109 and 
110 respectively). The Ru based CALI agent was found to be more than ten times effective at 
inactivating the target protein compared to fluorescein after a 30 min irradiation. Those results 
were attributed to the more efficient quantum yield for the generation of triplet oxygen by 
[Ru(bpy)3]
2+
 compared to fluorescein demonstrating the potential for [Ru(bpy)3]
2+
 to be used as a 
CALI photosensitizer.
214, 229
 
 
Figure 34: Ru(bpy)3
2+
 used as a CALI photosensitizer 
 An impressive application of this strategy was recently disclosed by the Kodadek group. 
Singlet oxygen generating [Ru(bpy)3]
2+
 complex was attached to a highly selective VEGF 
(vascular endothelial growth factor) peptoid antagonist GU40C of the VEGF receptor 2 
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(VEGFR2).
43
 Upon irradiation the CALI reagent was up to 1000 times more active at inhibiting 
the activity of VEGFR2 compared to the same reagent left in the dark. 
 
Figure 35: [Ru(bpy)3]
2+
-GU40C CALI agent 
II.1.E.b. Caging strategies using Ru complexes 
 The photophysical and photochemical properties of Ru and Rh complexes have been 
known and used as DNA probes for years. One of the most studied examples is 
[Ru(phen)2(dppz)]
2+
, a molecule that is naturally luminescent in organic solvents but does not 
luminesce if its ligands participate in H-bonding, for example in water. Upon intercalation, the 
molecule’s luminescence is restored, as molecules of water are unable to H-bond with the ligand 
that is “surrounded” by the DNA duplex.230, 231 The corresponding Rh complex has also been 
shown to initiate strand scission upon irradiation through abstraction of a hydrogen atom from 
the adjacent deoxyribose ring (as in PDT).
166
 
 The possibility of photoactivating covalent binding of Ru complexes with DNA using 
light was first shown by the Turro group. cis-[Ru(bpy)2(NH3)2]
2+
 was effectively 
photodissociated upon irradiation with light wavelengths between 350 and 400 nm and the 
resulting aqua complex bound to DNA. Interestingly, the related cis-
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[Ru(bpy)2(ethylenediamine)]
2+
 complex did not undergo photodissociation.
232
 Similarly, cis-
[Ru(bpy)2(5CNU)2]
2+
 (5CNU = 5-cyanouracil) could be photolyzed with even greater 
efficiencies. The resulting aqua complex was shown to bind to DNA in a fashion similar to 
cisplatin (Figure 36).
233
 
 
Figure 36: Ru complexes used as cages: prodrugs of Ru based, cisplatin like anticancer agents 
 The Bonnet group prepared [Ru(terpy)(bpy)(SRR’)]2+ (with SRR’ being either N-acetyl-
L-methionine or D-biotin), and showed that the thioester could be photoreleased giving the aqua 
adduct that is known to be biologically active.
234
 An impressive result came from the Glazer 
group, where a series of [Ru(bpy)2L]
2+
 complexes were synthesized (with L being phen, 
2,2'dimethylbpy, 2,2'dimethyldpq) (Figure 36) and irradiated with visible light, generating 
molecules that have cytotoxicities comparable to cisplatin after irradiation. The same complexes 
are 100 times less active in the dark and they do not undergo photodissociation.
235, 236
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 The Sadler group has also recently shown the photoactvation of Ru(II) arene complexes 
using the same strategy. [(p-cym)Ru(bpm)(py)][PF6]2 was photodissociated to the corresponding 
aqua complex using white light (400-600 nm), and the latter complex bound 9-ethylguanine (9-
EtG) to form [(p-cym)Ru(bpm)(py)][9-EtG]
2+
 when photolysis was performed in the presence of 
one equivalent of 9-EtG, demonstrating potential anticancer activity through DNA binding.
237
 In 
a subsequent publication, the Sadler and Brabec groups have screened multiple piano-stool Ru 
complexes of the type [(η6-arene)Ru(N,N’)(L)]2+ for their photodissociative abilities and 
anticancer activities. Low micromolar IC50 values against A2780 human ovarian cancer cells 
were shown upon irradiation with light with several of those complexes.
238
 
 
Figure 37: Double directing strategy of a potential anticancer Ru complex [(p-cym)Ru(bpm)(py-
linker-peptide)]
2+ 
 A unique approach consisting of a double directing-caging strategy was also recently 
disclosed by the Sadler group. In addition to the caging strategy described above, the Sadler 
group attached a receptor binding peptide to the photolabile ligand of [(p-
cym)Ru(bpm)(py)][PF6]2 in order to direct the agent towards overexpressed peptide receptors 
present on tumor cells. This strategy is described in the Chapter I.1.B. of this dissertation. The 
authors decided to use either the Arg-Gly-Asp (RGD) sequence as a vector of tumor endothelial 
cells
239
 or octreotide, a somatostatin binding peptide.
240-242
 For both complexes, 
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photodissociation gave the same aqua complex as with complex 116 described above. Complex 
117 bound to DNA model substrate 9-EtG as well as two guanidines in DNA sequences 
5’
dCATGGCT and 
5’
dAGCCATG showing potential anticancer activity.
243
 
 The Ru based caging strategy has been effectively used by others over the last 10 years to 
study neurotransmitters. The Etchenique group has attached diverse amines and 
neurotransmitters to [Ru(bpy)2L2] (with L = neurotransmitters) namely tryptamine, tyramine, 
serotonin, butylamine, 4-aminopyridine and GABA, and shown the ability of the complexes to 
photodissociate upon irradiation with visible light and stimulate neuron response
244, 245
 The same 
group has also shown that a two photon uncaging was possible using wavelengths at the limit of 
the visible-IR range.
246
 Moreover, the replacement of one of the amine ligands with 
triphenylphosphine resulted in an increased quantum yield.
247
 
 
Figure 38: Ru based caging of amine based neurotransmitters 
 Finally, a completely different approach for spatially controlled delivery of biologically 
relevant molecules has been demonstrated by the Mascharak group over the last years. 
Ruthenium-nitrosyl complexes effeciently photorelease NO in the visible range. A recent review 
by Mascharak describes the development of this class of complexes and further details will not 
be described here.
248
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 It is clear from the examples described above that Ru is a great anchor for the caging 
strategy, offering the possibility of spatially and temporarily controlling the delivery of a 
biologically active agent. The mechanistic details describing the photodissociation of such Ru 
complexes are described below. 
II.1.F. Photodissociation of [Ru(bpy)2(X)2](Y)2 complexes 
 The photochemical and photophysical properties of Ru(bpy)3
2+
 have been recognized for 
decades, and the complex has been successfully used as a sensitizer for years.
249
 Studies 
originating in the 1970s suggested that the original photochemistry and photodissociation of the 
complex could be mechanistically explained by a thermally accessible 
3
MC (metal centered, 
3
d-
d* ligand field) state under kinetic equilibrium with a 
3
MLCT (metal to ligand charge transfer) 
state. The 
3
MLCT state is accessible from the 
1
MLCT state by intersystem crossing.
217, 250
 This 
mechanistic picture has been extended to [Ru(bpy)2(X)2]
2+
 complexes.
218
 The much higher 
photostability of Ru(bpy)3
2+
 compared to [Ru(bpy)2(X)2]
2+
 complexes has been attributed to 
efficient ring reclosures.
217
 The general role for metal centered (MC) excited states is now well 
understood and accepted as one of the key components in the design of complexes with 
photooptical properties.
251
 
The recent interest in [Ru(bpy)2(X)2]
2+
 complexes as possible cages for 
neurotransmitters, potential anticancer DNA bonding agents or inhibitors and the advances in 
ultrafast transient absorption spectroscopy
252
 and time resolved X-ray techniques have enabled a 
better depiction of the molecular structures characteristic of the different excited states.
253
 The 
Turro group recently disclosed the study of the photodecomposition of [Ru(bpy)2(MeCN)2]
2+
 in 
H2O showing that ligand exchange generating [Ru(bpy)2(MeCN)(L)]
2+
 proceeds through the 
formation of [Ru(bpy)2(MeCN)(H2O)]
2+
 as the pentacoordinate intermediate 
99 
 
[Ru(bpy)2(MeCN)]
2+
 is too short-lived to permit bimolecular reactions.
254
 The recent work from 
the Lamberti group using OTA (optical transient absorption) and XTA (X-ray transient 
absorption) spectroscopy techniques gives more insight into the geometries of the different 
excited states that were postulated earlier by DFT calculations.
255
 This work shows that the 
geometry of the 
3
MLCT state of cis-[Ru(bpy)2(py)]
2+
 is close to the ground state geometry. 
Elongation of the dissociating Ru-N(py) bond and simultaneous shortening of the trans-Ru-
N(bpy) bond characterize the 
3
MLCT whereas the 
3
MC state shows completely distorted Ru-
N(py) bonds.
256
 
II.1.G. Thesis statement (Part II) 
 Side effects due to drug off-target reactivity are very common and there is a clear need to 
develop strategies to either direct therapeutic agents towards specific sites or selectively activate 
them in the desired areas of the body. Recent developments in ruthenium chemistry offer new 
possibilities for establishing a caging strategy for a controlled delivery of inhibitors. We sought 
to use the cis-[Ru(bpy)2(L)2]
2+
 complex as a platform to deliver nitrile-based inhibitors in a 
spatially controlled fashion. This strategy has been recently demonstrated to cage 
neurotransmitters and ligands such as MeCN that could be photodissociated upon irradiation 
with visible light. Inspired by these reports, we hypothesized that nitrile-based small molecule 
cathepsin inhibitors could be covalently bound to Ru(bpy)2 and released using light. 
 The first goal for this second part of the dissertation was to demonstrate the possibility of 
attaching nitrile-based inhibitors to Ru(bpy)2 to form cis-[Ru(bpy)2(L)2]
2+
 complexes, with L 
being the nitrile-based inhibitors. The metal complexes were fully characterized and the stability 
in the dark and photorelease of the ligands assessed upon synthetic success. Upon completion of 
the first goal, the study of inhibitory properties of the caged inhibitors was undertaken. As a 
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starting point the inhibition of isolated cysteine proteases such as papain and different cathepsins 
was surveyed. Inhibition experiments under conditions in the dark and after photorelease were 
performed and “dark/light” ratios determined. To prove the compatibility of cis-[Ru(bpy)2(L)2]
2+
 
complexes to cage and photorelease inhibitors in biological media, studies on living cells were 
undertaken. Finally, the viability of cells after treatment with ruthenium complexes such as cis-
[Ru(bpy)2(L)2]
2+
 were measured with the hope to demonstrate the lack of toxicity inherent with 
the metal center adducts. Strategies to complete each of the goals as well as all relevant 
experimental data are discussed in the next two chapters. Conclusions and future directions are 
presented at the end of this Part II of this dissertation. 
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Chapter 2. Synthesis and biological testing of the first nitrile 
containing cysteine protease inhibitor caged by Ru
II
(bpy)2 and 
activated by light 
II.2.A. Background and project design 
 The Kodanko group has been interested in developing methodologies for using metal 
complexes as potential biological ”warheads”, as explained in the first part of this dissertation. 
We have disclosed ways of attaching metal ligands to vector peptides with the goal of gaining 
specificity. Recently, we started investigating a different approach using metal complexes to gain 
control over the delivery of biologically active molecules. In this new approach we envisioned 
the use of metal complexes, not as warheads, but rather as a protecting group or cage of the 
inhibitors, that would be able to release the therapeutics with the use of light. As presented in 
Part II Chapter 1, similar strategies were employed to either release neurotransmitters or Ru 
based anticancer agents. We hypothesized that we could use the same cis-[Ru
II
(bpy)2(L)2] metal 
complex to cage nitrile-based inhibitors. 
 One of the main sources of toxicity when delivering a drug is off-target reactivity. To 
contribute to the discussion addressing spatial and temporal drug delivery that would minimize 
off-target reactivity, we set out to build a metal-based construct where known inhibitors would 
be covalently bound to the metal center. The success of this approach would be reached if the 
metal complex was chemically inert in a biological media in the dark so that it does not 
decompose and does not react with the targeted enzyme and, at the same time, could 
photorelease the caged inhibitor upon irradiation with light in a site specific manner. The use of 
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light to activate compounds was demonstrated with the development of PDT and is a clinically 
proven methodology.
216
 With the advances made in this area, it is now possible to reach almost 
any area in the body with light upon the use of lasers and fiber optics.
257
 
 
Figure 39: Light activated release of nitrile containing cysteine proteases 
 We postulated the possibility of caging peptidomimetic nitrile containing cysteine 
proteases inhibitors with Ru
II
(bpy)2 complexes. We indeed realized that [Ru
II
(bpy)2(MeCN)2]
2+
 
is a stable complex in aqueous solutions in the dark. Upon exposure to light (> 400 nm), the 
complex will quickly release two molecules of MeCN and [Ru
II
(bpy)2(H2O)2]
2+
.
254
 We imagined 
that upon replacement of the MeCN ligands by peptidomimetic nitrile containing cysteine 
protease inhibitors (examples are in Phase III clinical studies), we could potentially cage the 
inhibitors and release them upon irradiation with light. Caging bioactive molecules and being 
able to release them with light could be a novel way of gaining kinetic and spatial control over 
their activity that has never been demonstrated. We chose cysteine proteases as they are 
associated with various medical conditions and cancer in particular. A specific family of cysteine 
proteases, namely cathepsins B, K and S has been proposed as a promising target for metastatic 
bone disease (see Part II.1.B. for more details). 
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Many medicinal groups, in academia and industry, have isolated numerous potent and 
specific nitrile-based peptidomimetic cathepsin inhibitors.
134, 159, 161-163
 In our initial studies, we 
have deliberately chosen simple nitrile-based inhibitors that might not be as potent as more 
complex, SAR developed molecules, to show a proof of concept. The next sections describe the 
synthesis of both the organic cathepsin inhibitors and the Ru based cage inhibitors. We disclose 
the metal complexes characterization as well as their stability in the dark and ability to 
photorelease the nitrile inhibitors upon irradiation with light. In the following chapters, a series 
of biological studies on isolated enzymes, in vitro and in cellulo is also presented. 
II.2.B. Results and discussion 
II.2.B.a. Synthesis of nitrile cathepsin inhibitor 119 
 As explained above, the first generation Ru-nitrile inhibitor cages were designed as a 
proof of concept with a very simple to synthesize nitrile inbibitor N-acetyl-L-phenylalanyl-
glycine-nitrile (Ac-Phe-Gly-ψ[C≡N] 119). We chose 119 because of its chemical simplicity and 
ease of synthesis, but also its promising inhibitory activity against both the plant enzyme papain 
and mammalian cathepsins B, K, L and S.
258, 259
 
 The synthesis was straightforward and began with commercially available Boc-protected 
L-phenylalanine 120 that was coupled with glycine amino nitrile under HBTU conditions to give 
the coupled product 121 in a 75% isolated yield. The Boc protecting group could be removed 
with formic acid and the resulting N-terminus was acetylated with acetyl chloride to give the 
nitrile inhibitor 119 with a 70% isolated yield over two steps (Scheme 16). 
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Scheme 16: Synthesis of nitrile inhibitor Ac-Phe-Gly-ψ[C≡N] 119 
II.2.B.b. Syntheisis of cis-[Ru(bpy)2(119)2](PF6)2 
 With 119 in hand, a method for covalently bonding the latter nitrile to Ru
II
(bpy)2 had to 
be devised. The Turro group from the Department of Chemistry at the Ohio State Univeristy has 
demonstrated the use of Ru
II
(bpy)2 as a potential anticancer agent that could be photoreleased 
from diverse complexes such as [Ru
II
(bpy)2(L)2]
2+
. We decided to use the Turro group’s 
expertise in this domain, and started a collaborative effort to synthesize and study Ru-caged 
nitrile inhibitors. A successful synthesis was designed after multiple discussions and trials. 
 
Scheme 17: Syntheis of cis-[Ru
II
(bpy)2(119)2]
2+
 
 When Ru
II
(bpy)2Cl2 was reacted with five equivalents of 119 along with two equivalents 
of AgBF4 in EtOH in the dark, a bright orange solution was observed. After filtration, 
concentration and precipitation from acetone, the NMR of the crude material was consistent with 
the formation of the desired complex and excess 119. The excess of 119 was removed by 
extraction with EtOAc. The complex was then precipitated with a saturated aqueous solution of 
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NH4PF6. The analytically pure complex was obtained by slow recrystalization in a cold 
acetone/DCM mixture. 
II.2.B.c. Characterization of cis-[Ru(bpy)2(119)2](PF6)2 
 The complex 123 was obtained as a racemic mixture of both Λ and Δ diastereoisomers. 
This was expected because the starting material cis-Ru
II
(bpy)2Cl2 122 was a mixture of Λ and Δ 
stereoisomers, and ligand 119 is chiral and enantioenriched (synthesized from enantioenriched L-
phenylalanine with the (S) configuration). The 
1
H NMR spectrum confirmed the presence of two 
diastereoisomers, as two distinct peaks, corresponding to the acetyl groups for each of the 
diastereoisomers. It is important to note that both 119 ligands on each of the diastereoisomer are 
equivalent by C2 symmetry. The methylene hydrogens adjacent to the nitrile functional group 
were shifted by ~ 0.5 ppm between the free ligand and when bonded to the Ru center. 
 
Figure 40: Δ-cis-[Ru(bpy)2(119)2](PF6)2 and Λ-cis-[Ru(bpy)2(119)2](PF6)2 
 
 The IR spectrum for 119 shows the characteristic resonance for CN functional groups at 
νCN = 2250 cm
-1
. The latter resonance is shifted in complex 123 by 30 cm
-1
 to 2280 cm
-1
 
consistent with the nitrile binding to the Ru center.
260
 The UV-Vis spectrum of 123 shows a very 
similar set of electronic absorptions compared to related complexes with a λmax at 281 nm (ε = 
60,000 M
-1
cm
-1
) and 414 nm (ε = 10,700 M-1cm-1).261 The identity of the complex was also 
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confirmed by high resolution mass spectrometry showing a prominent peak at m/z = 452.1366 
and a Ru isotope patern consistent with the dication [Ru(bpy)2(119)2]
2+
 was observed. Elemental 
analysis was consistent with [Ru(bpy)2(119)2](PF6)2·2H2O. With the identity of the caged Ru-
complex confirmed we started investigating the stability of the complex in the dark and the 
photorelease of the nitrile inhibitors. 
II.2.B.d. Stability in the dark and release using light 
 Solutions of 123 (25 μM) in pure DMSO or 0.1 M phosphate buffer pH 6.5 (0.5% 
DMSO) were monitored for decomposition by UV-vis spectroscopy at RT by following 
absorbance at 414 nm. First-order rate constants for decomposition of 123 were calculated using 
slopes of ln A414 vs time graphs. Rate constants were determined to be 2.3x10
-7 
s
-1
 (0.1 M 
phosphate buffer pH 6.5, Figure 41) and 2.8x10
-7
 s
-1
 (DMSO, Figure 42). These values 
correspond to half-lives t1/2 of 35 and 29 days, respectively. 
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Figure 41: Plot of ln A vs t for complex 123 in 0.1M phosphate pH 6.5 buffer at RT. 
 
Figure 42: Plot of ln A vs t for complex 123 in DMSO at RT. 
 Steady-state photolysis experiments were conducted by the Turro group at the Ohio State 
University. The electronic absorption at 414 nm corresponding to the metal to ligand charge 
transfer (MLCT) absorption of the Ru cage 123, was followed by UV-Vis spectroscopy. Upon 
irradiation, the decrease of the intensity of the absorption at 414 nm was associated with the 
advent of absorption at 444 nm within 1 min of irradiation (Figure 43). This new peak is 
hypothesized to correspond to the Ru→bpy MLCT absorption of the mono-aqua complex, cis-
[Ru(bpy)2(119)(H2O)]
2+
. With subsequent irradiation between one and ten minutes, the peak at 
444 nm gradually disappears but a new absorption can be spotted at 490 nm with no additional 
change upon irradiation for more than 10 min. The peak at 490 nm (ε = 9,300 M–1cm–1) is 
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attributed to cis-[Ru(bpy)2(H2O)2]
2+
 according to similar photorelease data from other studies.
218, 
261
 
 
Figure 43: Changes to the electronic absorption spectrum of 30 M cis-[Ru(bpy)2(119)2](PF6)2 
(123) in a 1% DMSO aqueous solution upon irradiation ( irr > 395 nm) at tirr = 0, 2, 3, 4, 5, 6, 
and 7 min; inset: 0, 1 min 
 The quantum yield for the disappearance of the reactant cis-[Ru(bpy)2(119)2]
2+
 (R) to 
form the mono-aqua intermediate (I), R I, was measured at early reaction times to be 0.080(4), 
whereas that determined for the formation of the product cis-[Ru(bpy)2(H2O)2]
2+
 (P) from the 
cis-[Ru(bpy)2(peptide)2]
2+
 starting material, R P, was 0.00091(7). From these values, the 
quantum yield of the second step of the reaction, I P, can be calculated to be 0.011(1). The 
overall photoaquation quantum yield, R P, is significantly smaller than that reported for cis-
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[Ru(bpy)2(CH3CN)2]Cl2, 0.21 ( irr = 400 nm),
254
 but similar to that measured for the formation of 
the mono-aqua species, R I, upon irradiation of cis-[Ru(bpy)2(5cnu)2]Cl2, 0.16
233
 (see Part 
II.2.D.b. for more details). 
 The results shown above complete the initial requirements for a potential Ru-based cage 
of nitrile peptidomimetic cysteine protease inhibitors. The complex demonstrates excellent 
stability in aqueous solutions in the dark, and very fast release of both inhibitors upon irradiation 
with visible light. The complex 123 was then tested in different biological assays to determine if 
the caging strategy can be effectively used to inhibit different families of enzymes. 
II.2.B.e. Biological evaluation of nitrile containing cysteine protease 
inhibitor caged by Ru
II
(bpy)2 against papain 
 The inhibition studies with papain were carried out following a modified procedure by 
Gűtschow.258 Enzyme activity was determined with the chromogenic substrate BAPNA (Z-Phe-
Arg-NHNp, Nα-Benzoyl-L-arginine-4-nitroanilide hydrochloride) and is expressed as a 
percentage, with 100% equal to activity in the absence of inhibitor. Photolysis was conducted for 
10 min (with gentle shaking of the plate every 2-3 min) using a 250 W tungsten halogen lamp 
(Osram Xenophot HLX) powered by a 24 V power supply. The irradiation wavelength was 
selected by placing a bandpass filter (395 nm cutoff) between the lamp and the sample, along 
with a 10 cm water cell to absorb infrared light. Different concentrations of the inhibitor 119 
alone and Ru inhibitor 123 were plated in wells on a 96 well plate in sextuplets (a series of 
triplicates on the right and left side of the plate). Half of the plate was covered with aluminum 
foil to keep one series of triplicates in the dark while the other series was irradiated following the 
set-up described above. 
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 The IC50 for the cysteine protease inhibitor 119 was determined to be 638 nM against 650 
nM papain (red trace, Figure 44). In the dark, the complex 123 has an IC50 of 9.5 μM (black 
trace, Figure 44). A 32 fold enhancement of activity was noticed for the complex 123 after a 10 
min exposure to light (>395 nM) to give an IC50 of 295 nM (blue trace, Figure 44). It is also 
important to notice, that those values suggest that two equivalents of 119 have been released 
upon irradiation (as expected from the photolability studies). 
 
Figure 44: IC50 curves for 119 (red) and 123 (with irradiation, blue, and without, black) against 
the cysteine protease papain. 
 These results suggest that we have effectively caged the nitrile-based inhibitor 119 with 
Ru
II
(bpy)2. To explain the inhibition of papain with 123 in the dark, we postulate that either low 
amounts of 119 were released during the different manipulations (all studies were conducted in 
the dark, but some amount of light in the room was obviously necessary for the manipulations to 
be conducted without error) or 123 acts a weak inhibitor of the enzyme by nonbonding 
interaction of either the Ru
II
(bpy)2 moiety or the caged peptide. Control experiments using cis-
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[Ru
II
(bpy)2(MeCN)2](PF6)2 with or without light did not show any inhibition below 500 μM 
suggesting that cis-[Ru
II
(bpy)2(H2O)2]
2+
 or any other byproduct of the photorelease are not 
responsible for the inhibition. Inhibition by reactive oxygen species such as 
1
O2 are also very 
unlikely because of the very short lifetime of the exited state of the Ru complex
254
 and same 
levels of inhibition in the control experiments with [Ru
II
(bpy)2(MeCN)2](PF6)2 in the dark and 
upon irradiation. 
These exciting results motivated us to conduct more inhibition studies with enzymes 
expressed in human cells. To help us with the studies we started a collaboration with the 
Podgorski group from the Pharmacology department at Wayne State University that specializes 
in the work with different cathepsins and cathepsin K in particular. 
II.2.B.f. Biological evaluation of nitrile containing cysteine protease 
inhibitor caged by Ru
II
(bpy)2 against isolated human cathepsins 
 Inhibition studies with isolated human enzymes were conducted in a very similar fashion 
to the papain inhibition studies. Enzyme activity was determined with the fluorogenic substrates 
Z-Arg-Arg-AMC (cathepsin B), Z-Phe-Arg-AMC (cathepsin K) and Z-Gly-Pro-Arg-AMC 
(cathepsin L) and is expressed as a percentage, with 100% equal to activity in the absence of 
inhibitor. Photolysis was conducted for 10 min (with gentle shaking of the plate every 2-3 min) 
(see Part II.2.D.c. for more details).  
 Inhibitor 119 was a much weaker inhibitor of human cathepsins B, K and L than papain, 
but in all cases we noticed significant enhancement of activity upon irradiation of 123 with 
visible light when compared to 123 left in the dark (Table 8). The data also suggest, once again, 
that two equivalents of the nitrile inhibitor are released from every Ru complex consistent with 
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the photolability studies. To further extend our studies we decided to examine the inhibition of 
cathepsin B expressed in a series of human cell lysates 
compound 119 123 (dark) 123 (light) dark/light ratio 
     
  IC50   
human cathepsin     
B 133 892 63 14.2 
K 12 176 5.4 32.6 
L 72 225 40 5.6 
     
Table 8: IC50 values (μM) for 119 and 123 (with and without irradiation) against isolated human 
cathepsins B, L and K with ratios under light vs. dark conditions 
II.2.B.g. Biological evaluation of nitrile containing cysteine protease 
inhibitor caged by Ru
II
(bpy)2 against cathepsins B in cancer cell lysates 
 Cancer cell lines that are known for overexpressing diverse proteolytic enzymes and 
cathepsin B in particular were chosen to conduct this study. DU145 prostate carcinoma cells 
metastatic to the brain
262
 have been shown to exhibit increased cathepsin B activity,
263
 whereas 
primary human bone marrow stromal cells (hBMSC) have been demonstrated to modulate the 
progression of cancer in bone through cathepsin activity.
153
 In both cases, the levels of expressed 
cathepsin B were much higher than that of cathepsin K and L so we have chosen to study the 
inhibition of cathepsin B with the use of its specific fluorogenic substrate Z-Arg-Arg-AMC. The 
studies followed the same setup as explained previously, with enzyme activity expressed as a 
percentage, with 100% equal to activity in the absence of inhibitor. The photolysis was 
conducted for 10 min (with gentle shaking of the plate every 2-3 min) (see see Part II.2.D.c. for 
more details). 
Similar to the results presented in the previous section, the inhibitor 119 was not a very 
potent inhibitor of cathepsin B, but 123 showed a significant increase (between 6.6 and 8 times 
113 
 
more potent) in potency after irradiation, and once again suggests that two equivalents of 119 
were released from every Ru complex demonstrating the utility of the caging strategy. 
compound 119 123 (dark) 123 (light) dark/light ratio 
     
  IC50   
lysate     
DU145 182 658 82 8.0 
hBMSC 183 580 88 6.6 
     
Table 9: IC50 values (μM) for 119 and 123 (with and without irradiation) against cathepsin B in 
human cell lysates with ratios under light vs. dark conditions 
II.2.C. Conclusions and further directions 
 The results presented in this chapter describe a very efficient way of caging nitrile based 
cathepsin inhibitors and activating them within minutes upon exposure to visible light. This is 
the first example of such a strategy. We believe that this methodology should help us to achieve 
kinetic and spatial control over protease activity. 
 The Ru complex cis-[Ru
II
(bpy)2(119)2]
2+
 shows excellent stability in aqueous solutions in 
the dark (with half lives in the order of ~ 30 days), and the ability to release two equivalents of 
119 upon irradiation with visible light within ten minutes. Inhibition studies with papain and 
human cathepsins B, K and L have shown significant enhancement of the inhibitory activity 
associated with the nitrile based inhibitor, ranging from 5.6 to 33 times upon irradiation with 
visible light. This strategy has also been tested with the inhibition of cathepsin B expressed in 
lysates of cancer cells. We are planning to synthesize new Ru complexes caging more potent 
inhibitors and show that the strategy can be applied to control the activity of proteases in live 
cells. 
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The results presented in this chapter have been published in the Journal of the American 
Chemical Society with fellow collaborators Robert Garner and Claudia Turro from the Ohio 
State University and Mackenzie Herroon and Izabela Podgorski from the Pharmacology 
Department at the Medical School, Wayne State University (Respondek T., Garner R. N., 
Herroon M. K., Podgorski I., Turro C., Kodanko J. J. "Light Activation of a Cysteine Protease 
Inhibitor: Caging of a Peptidomimetic Nitrile with Ru
II
(bpy)2" J. Am. Chem. Soc., 2011, 133(43), 
17164-17167).
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II.2.D. Experimental section 
II.2.D.a. General considerations 
 All reagents were purchased from commercial suppliers and used as received. NMR 
spectra were recorded on a Varian FT-NMR Mercury-400 Spectrometer. Mass spectra were 
recorded on a Time-of-Flight Micromass LCT Premier XE Spectrometer. IR spectra were 
recorded on a Perkin Elmer Spectrum 2000 FT-IR Spectrometer. Enzymatic assays were 
conducted on a Tecan Infinite M200 or Tecan SPECTRAFluor Plus microplate reader. UV-vis 
spectra were recorded on a Varian Cary 50 spectrophotometer. Time-dependent UV-Vis spectra 
were recorded on a Varian Cary 50 spectrophotometer. The photolysis experiments were 
conducted using a 250 W Tungsten Halogen lamp (Osram Xenophot HLX) powered by a 24 V 
power source. The irradiation wavelength was selected by placing a bandpass filter (395 nm 
cutoff) between the lamp and the sample, along with a 10 cm water cell to absorb infrared light. 
All reactions were performed under ambient atmosphere unless otherwise noted. Anaerobic 
reactions were performed by purging the reaction solutions with Ar or N2. 
All NMR, IR and mass spectra be found in the Appendix section. 
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II.2.D.b. Experimental procedures and tabulated characterization data 
(S)-2-acetamido-N-(cyanomethyl)-3-phenylpropanamide (119). 
 
 Compound 119 was prepared by modification of published procedures.
258, 265
 Boc-Phe-
OH (20.0 mmol, 5.31 g) in dry DMF (110 mL) was treated with HBTU (24.0 mmol, 9.10 g), 
aminoacetonitrile hydrochloride (24.0 mmol, 2.22 g) and Et3N (48.0 mmol, 6.76 mL). The 
solution was stirred for 16 h. The crude reaction solution was combined with CH2Cl2 (150 mL) 
and the organic layer was washed with 0.1 M HCl (2 x 50 mL), sat. aqueous NaHCO3 (2 x 50 
mL) and brine (2 x 50 mL). The organic layer was dried (Na2SO4), filtered and concentrated. The 
crude product was analyzed by 
1
H NMR spectroscopy (> 90% purity) and was used without 
further purification. The crude solid was dissolved in formic acid (100 mL) and maintained for 
16 h. Excess formic acid was removed under reduced pressure and the resulting yellowish oil 
dissolved in H2O (100 mL), basified with sat. NaHCO3 and extracted with EtOAc (3 x 100 mL). 
The organic layer was dried (Na2SO4), filtered and concentrated. The resulting solid was treated 
with CH2Cl2 (100 mL), Et3N (48.0 mmol, 6.75 mL) and acetic anhydride (24.0 mmol, 2.27 mL) 
and the solution was stirred for 12 h. The resulting slurry was partitioned between EtOAc (100 
mL) and 0.1 M HCl (100 mL). The aqueous layer was extracted with EtOAc (3 x 100 mL). The 
organic layers were combined, dried (Na2SO4), filtered and concentrated. The crude product was 
recrystallized from hot EtOAc to give 119 as a white powder (2.42 g, 9.81 mmol, 49% over the 3 
steps): 
1
H NMR (400 MHz, DMSO-d6) : 8.71 (t, J = 5.7 Hz, NH), 8.22 (d, J = 8.1 Hz, NH), 
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7.21 (m, 5H), 4.44 (dd, J = 13.0, 4.9 Hz, 1H), 4.10 (d, J = 5.7 Hz 2H), 2.97 (dd, J = 13.8, 4.9 Hz, 
1H), 2.73 (dd, J = 13.9, 9.7 Hz, 1H), 1.75 (s, 3H); [α]D
20
 + 6.4 (c = 0.5, MeOH); 
13
C NMR (100 
MHz, DMSO-d6) : 172.75, 169.93, 138.39, 129.74, 128.80, 127.04, 118.14, 54.50, 38.01, 27.74, 
23.11; IR νmax (cm
-1
): 3302, 3066, 3033, 2978, 2937, 2346, 2251, 1956, 1661, 1639, 1606, 1542, 
1496, 1455, 1431, 1416, 1372, 1343, 1320, 1298, 1281, 1239, 1193, 1106, 1071, 1037, 966, 914, 
893, 791, 747, 731, 702, 618, 600, 565, 519, 472; HRMS (ESMS) calculated for C13H15N3O2Na 
[M+Na]
+
: 268.1062, found: 268.1072. 
Δ-cis-[Ru(bpy)2(119)2](PF6)2.2H2O and Λ-cis-[Ru(bpy)2(119)2](PF6)2·2H2O (123): 
 
 A sealable tube was charged with cis-Ru(bpy)2Cl2 (0.20 mmol 97 mg), AgBF4 (0.80 
mmol, 156 mg) and (S)-2-acetamido-N-(cyanomethyl)-3-phenylpropanamide (119) (1.00 mmol, 
245 mg) and freshly distilled EtOH (40 mL). The resulting solution was sealed under inert 
atmosphere in a glove box, wrapped in aluminum foil and heated to 80°C for 12 h, during which 
it turned from dark violet to bright orange. After cooling the crude solution to rt, the reaction 
mixture was placed in the freezer at -20 °C for 16 h. The reaction mixture was filtered through 
celite to remove precipitated silver salts and the filter cake was washed with cold EtOH. The 
solvents were removed under reduced pressure, resulting in the formation of a yellow solid. The 
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resulting yellow solid was dissolved in acetone (3 mL), layered with Et2O (15 mL) and placed in 
the freezer at -20 °C for 16 h. The yellow solid was isolated by filtration and washed with cold 
Et2O. The resulting solid was dissolved in H2O (25 mL) and the aqueous layer was extracted 
with EtOAc (3 x 20 mL) and MTBE (1 x 20 mL). The aqueous layer was treated with a saturated 
aqueous solution of NH4PF6 (5 mL), resulting in the formation of an orange precipitate that was 
isolated by centrifugation. The precipitate was washed with cold CH2Cl2, then dissolved in a 
mixture of CH2Cl2 and acetone (10:1). After storing this solution for 2 days at -20 °C the 
complex 123 precipitated and was obtained as a microcrystalline bright yellow-orange solid (45 
mg, 37 mol, 19% yield): mp = 110 °C (decomp); 
1
H NMR (400 MHz, acetone-d6) : 9.55 (d, J 
= 5.7 Hz, 1H), 9.51 (d, J = 4.9 Hz, 1H), 8.81 (d, J = 8.1 Hz, 2H), 8.68 (d, J = 8.1 Hz, 2H), 8.43 
(t, J = 8.1 Hz, 2H, NH), 8.20 (t, J = 5.7 Hz, NH), 8.11 (dt, J = 7.7, 1.6 Hz, 2H), 8.03 (t, J = 6.5 
Hz, 2H), 7.87 (d, J = 5.7 Hz, 2H), 7.80 (d, J = 7.3 Hz, NH), 7.60 (d, J = 7.3 Hz, NH), 7.45 (d, J = 
6.1 Hz, 2H ), 7.23 (m, 10H), 4.56 (m, 5H), 4,32 (m, 1H), 3.12 (dd, J = 9.72, 4.9 Hz, 1H), 3.09 
(dd, J = 9.3, 5.3 Hz, 1H), 2.93 (dd, J = 13.8, 7.3, Hz, 1H), 2.91 (dd, J = 13.8, 6.5, Hz, 1H), 1.89 
(s, 3H), 1.85 (s, 3H); IR (KBr) νmax (cm
-1
): 3635, 3415, 3297, 3062, 3031, 2930, 2346, 2289, 
1665, 1605, 1524, 1467, 1448, 1427, 1375, 1342, 1314, 1275, 1243, 1193, 1161, 1125, 1071, 
1031, 961, 839, 766, 741, 731, 702, 663, 648, 558, 488; HRMS (ESMS) calculated for 
C46H46N10O4Ru [M]
2+
: 452.1380, found: 452.1366; Anal. Calcd for C46H50F12N10O6P2Ru 
([Ru(bpy)2(1)2](PF6)2·2H2O): C, 44.92; H, 4.10; N, 11.39. Found: C, 44.79; H, 3.91; N, 11.33.  
General Considerations for the Time Dependent UV-Vis spectra: 
 Time dependent UV-Vis spectra were recorded on a Varian Cary 50 spectrophotometer. 
The photolysis experiments were conducted using a 250 W Tungsten Halogen lamp (Osram 
Xenophot HLX) powered by a 24 V power source. The irradiation wavelength was selected by 
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placing a bandpass filter (395 nm cutoff) between the lamp and the sample, along with a 10 cm 
water cell to absorb infrared light. 
Stability of 123 in 0.1M phosphate buffer pH 6.5 (0.5% DMSO) 
 A 25 μM solution of 123 in 0.1 M phosphate buffer pH 6.5 (0.5% DMSO) was placed in 
a cell, and UV-Vis spectra recorded for 6 h (the cell was shaken to help diffusion). Ln A was 
ploted vs. time and fitted to give a first order reaction rate r = 2.32e-7s
-1
. The half life 
corresponding to this rate was approximately 34.5 days (t1/2 = 0.693/r). 
Stability of 123 in DMSO 
 A 25 μM solution of 123 in DMSO was placed in a cell, and UV-Vis spectra recorded for 
100 h (the cell was shaken to help diffusion).Ln A was ploted vs. time and fitted to give a first 
order reaction rate r = 2.80e-7s
-1
. The half life corresponding to this rate was approximately 28.6 
days (t1/2 = 0.693/r). 
Quantum yield and time dependent UV-vis spectra upon irradiation of 123: 
 Steady-state photolysis experiments for quantum yield determination were conducted 
using a 150 W Xe arc lamp in a PTI housing (Milliarc Compact Lamp Housing) powered by an 
LPS-220 power supply  (PTI) with an LPS-221  igniter (PTI) as a source. The irradiation 
wavelength was selected by placing long-pass colored glass filters (Melles Griot) or bandpass 
filters (Newport) between the lamp and the sample, along with a 10 cm water cell to absorb 
infrared light. Electronic absorption spectra were collected on a diode array spectrometer (HP 
8453) with HP 8453 Win System software.  
 Quantum yields were measured relative to ferrioxalate using a standard procedure
266
. The 
quantum yield of reactant (R) to intermediate (I), R I, was determined by monitoring the 
decease in the MLCT absorption of the reactant at 414 nm up to 5% of the reaction. The 
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quantum yield of reactant (R) to product (P), R P, was determined by monitoring the increase 
in the absorption of the latter with maximum at 490 nm. The quantum yield of intermediate (I) to 
product (P), I P, was calculated using the equation R P = R I • I P.  
 The electronic absorption spectrum of cis-[Ru(bpy)2(119)2](PF6)2 exhibits ligand-
centered (LC) bpy * and Ru bpy metal-to-ligand charge transfer (MLCT) absorption peaks 
at 281 nm (  =  54 430 M
–1
 cm
–1
) and 414 nm (8 760 M
–1
 cm
–1
), respectively, in a 1% DMSO 
aqueous solution. Similar transition energies and intensities have been reported for the related 
complexes cis-[Ru(bpy)2(CH3CN)2](PF)6 and cis-[Ru(bpy)2(5cnu)2]Cl2 (5cnu = 5-cyanouracil). 
The former exhibits absorption maxima at 283 nm (  = 52 500 M
–1
 cm
–1
) and 425 nm (  = 8 590 
M
–1
 cm
–1
) in CH3CN
267
 and at 427 nm (  = 8 900 M
–1
 cm
–1
) in water,
261
 and for the latter 
maxima were reported at 284 nm (  = 48 300 M
–1
 cm
–1
) and 410 nm  = 7 800 M
–1
 cm
–1
) in 
H2O.
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 The changes in the electronic absorption spectrum of a 1% DMSO aqueous solution of 30 
M cis-[Ru(bpy)2(119)2](PF6)2 upon irradiation with visible light ( irr > 395 nm) were used to 
monitor the progress of the photochemical reaction, as shown in Figure 43. A decrease in the 
MLCT absorption of the reactant at 414 is observed with a concomitant appearance of a new 
peak at 444 nm within 1 min of irradiation (Figure 43). This peak is attributed to the Ru bpy 
MLCT absorption of the mono-aqua complex, cis-[Ru(bpy)2(119)(H2O)]
2+
. With continued 
irradiation the absorption at 444 nm decreases with an increase in the intensity of the peak at 490 
nm (  = 9 300 M
–1
cm
–1
) known to correspond to cis-[Ru(bpy)2(H2O)2]
2+
 
268
. The photochemistry 
discussed here is similar to that of numerous  related complexes,
269-271
 including cis-
[Ru(bpy)2(CH3CN)2]
2+ 
 and cis-[Ru(bpy)2(5cnu)2]
2+
.
218, 233, 261
 The quantum yield for the 
disappearance of the reactant cis-[Ru(bpy)2(119)2]
2+
 (R) to form the mono-aqua intermediate (I), 
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R I, was measured at early reaction times to be 0.080(4), whereas that determined for the 
formation of the product cis-[Ru(bpy)2(H2O)2]
2+
 (P) from the cis-[Ru(bpy)2(peptide)2]
2+
 starting 
material, R P, was 0.00091(7). From these values, the quantum yield of the second step of the 
reaction, I P, can be calculated to be 0.011(1). The overall photoaquation quantum yield, 
R P, is significantly smaller than that reported for cis-[Ru(bpy)2(CH3CN)2]Cl2, 0.21 ( irr = 400 
nm),
254
 but similar to that measured for the formation of the mono-aqua species, R I, upon 
irradiation of cis-[Ru(bpy)2(5cnu)2]Cl2, 0.16(4).
233
 
II.2.D.c. Enzyme Inhibition Studies 
Papain Inhibition Studies: 
 The inhibition studies with papain were carried out following a modified procedure by 
Gűtschow.258 Enzyme activity was determined with the chromogenic substrate BAPNA (Z-Phe-
Arg-NHNp) and is expressed as a percentage, with 100% equal to activity in the absence of 
inhibitor. A 0.25 mM papain stock solution was prepared in 0.1 mM HCl and kept frozen. For 
each experiment, the stock solution was diluted 250 times and activated for 45 min at 25 °C with 
a 0.1 M phosphate pH 6.5, 15 mM DTT and 2.5 mM EDTA buffer solution. A 10.0 mM solution 
of BAPNA in DMSO was prepared daily and plated (final concentration 1.0 mM). The inhibitor 
was plated as a 1% DMSO solution in the assay buffer. All 3 experiments in triplicates (119, 123 
in the dark, and 123 photolyzed) were plated on the same 96 well plate. The wells containing 119 
and 123 “dark” were carefully wrapped in aluminum foil and the plate exposed to visible light. 
The photolysis was conducted for 10 min (with gentle shaking of the plate every 2-3 min) using 
a 250 W tungsten halogen lamp (Osram Xenophot HLX) powered by a 24 V power supply. The 
irradiation wavelength was selected by placing a bandpass filter (395 nm cutoff) between the 
lamp and the sample, along with a 10 cm water cell to absorb infrared light. After photolysis, the 
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reaction was initiated by addition of 65 μL of enzyme (final volume 100 μL, final enzyme 
concentration 0.65 μM). The absorbance changes due to the hydrolysis product p-nitroaniline 
(pNA) were measured at 405 nm every 2 min for 14 min (8 measures) at 25 °C. 
Cathepsin Inhibition Studies: 
 Cathepsin enzyme activity was determined from kinetic measurements performed by 
fluorometric detection of the hydrolysis product AMC at 37 °C every 2 min for 14 min (8 
measures). The excitation and emission wavelengths were 360 and 485 nm respectively. 
Selective fluorescent substrate Z-Arg-Arg-AMC for cathepsin B, Z-Phe-Arg-AMC for cathepsin 
L, and Z-Gly-Pro-Arg-AMC for cathepsin K were used at a final concentration of 100 μM (all 
obtained from Bachem). Enzyme activities are expressed as a percentage, with 100% equal to 
activity in the absence of inhibitor. 
Cathepsin B: 
 Purified cathepsin B (human liver) was obtained from Enzo Life Sci and a 5 μM stock 
solution was prepared in 50 mM sodium acetate, pH 5.0, 1 mM EDTA and kept at -80 °C. For 
each experiment the stock solution was diluted 625 times and activated for 15 min at 37 °C with 
a 400 mM sodium acetate, pH 6.0, 4 mM EDTA, 8 mM DTT assay buffer solution. The inhibitor 
was prepared as a 1% DMSO solution in the activated enzyme buffer solution and plated (50 
μL). All 3 experiments in triplicates (119, 123 in the dark, and 123 photolyzed) were plated on 
the same 96 well plate. The wells containing 119 and 123 “dark” were carefully wrapped in 
aluminum foil and the plate was exposed to visible light. The photolysis was conducted for 10 
min (with gentle shaking of the plate every 2-3 min) using a 250 W tungsten halogen lamp 
(Osram Xenophot HLX) powered by a 24 V power supply. The irradiation wavelength was 
selected by placing a bandpass filter (395 nm cutoff) between the lamp and the sample, along 
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with a 10 cm water cell to absorb infrared light. After photolysis, the reaction was initiated by 
addition of 50 μL of 200 μM Z-Arg-Arg-AMC solution in the assay buffer (final volume 100 μL, 
final enzyme concentration 4 nM). Cathepsin enzyme activity was determined from kinetic 
measurements performed by fluorometric detection of the hydrolysis product AMC at 37 °C 
every 2 min for 14 min (8 measures) and MAX RFU slope values used for plotting. 
 
Figure 45: IC50 curve for inhibition of cathepsin B activity with 119 (red), 123 “light” (yellow), 
and 123 “dark” (blue)  
Cathepsin K: 
 Recombinant cathepsin K (human) was obtained from Enzo Life Sci as a 880 nM stock 
solution in 50 mM sodium acetate, pH 5.5, 50 mM NaCl, 0.5 mM EDTA and 5 mM DTT and 
kept at -80 °C. For each experiment the stock solution was diluted 44 times and activated for 15 
min at 37 °C with a 400 mM sodium acetate, pH 5.5, 4 mM EDTA, 8 mM DTT assay buffer 
solution. The inhibitor was prepared as a 1% DMSO solution in the activated enzyme buffer 
solution and plated (50 μL). All 3 experiments in triplicates (119, 123 in the dark, and 123 
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photolyzed) were plated on the same 96 well plate. The wells containing 119 and 123 “dark” 
were carefully wrapped in aluminum foil and the plate exposed to visible light. The photolysis 
was conducted for 10 min (with gentle shaking of the plate every 2-3 min) using a 250 W 
tungsten halogen lamp (Osram Xenophot HLX) powered by a 24 V power supply. The 
irradiation wavelength was selected by placing a bandpass filter (395 nm cutoff) between the 
lamp and the sample, along with a 10 cm water cell to absorb infrared light. After photolysis, the 
reaction was initiated by addition of 50 μL of 200 μM Z-Gly-Pro-Arg-AMC solution in the assay 
buffer (final volume 100 μL, final enzyme concentration 10 nM). Cathepsin enzyme activity was 
determined from kinetic measurements performed by fluorometric detection of the hydrolysis 
product AMC at 37 °C every 2 min for 14 min (8 measures) and MAX RFU slope values used 
for plotting. 
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Figure 46: IC50 curve for inhibition of cathepsin K activity with 119 (red), 123 “light” (yellow), 
and 123 “dark” (blue) 
 
Cathepsin L: 
 Cathepsin L was obtained from Sigma as a 10 μM stock solution in 20 mM malonate, pH 
5.5, 1 mM EDTA, 400 mM NaCl and kept at -80 °C. For each experiment the stock solution was 
diluted 500 times and activated for 15 min at 25 °C with a 400 mM sodium acetate, pH 5.5, 4 
mM EDTA, 8 mM DTT assay buffer solution. The inhibitor was prepared as a 1% DMSO 
solution in the activated enzyme buffer solution and plated (50 μL). All 3 experiments in 
triplicates (119, 123 in the dark, and 123 photolyzed) were plated on the same 96 well plate. The 
wells containing 119 and 123 “dark” were carefully wrapped in aluminum foil and the plate 
exposed to visible light. The photolysis was conducted for 10 min (with gentle shaking of the 
plate every 2-3 min) using a 250 W tungsten halogen lamp (Osram Xenophot HLX) powered by 
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a 24 V power supply. The irradiation wavelength was selected by placing a bandpass filter (395 
nm cutoff) between the lamp and the sample, along with a 10 cm water cell to absorb infrared 
light. After photolysis, the reaction was initiated by addition of 50 μL of 200 μM Z-Phe-Arg-
AMC solution in the assay buffer (final volume 100 μL, final enzyme concentration 10 nM). 
Cathepsin enzyme activity was determined from kinetic measurements performed by 
fluorometric detection of the hydrolysis product AMC at 37 °C every 2 min for 14 min (8 
measures) and MAX RFU slope values used for plotting. 
 
Figure 47: IC50 curve for inhibition of cathepsin L activity with 119 (red), 123 “light” (yellow), 
and 123 “dark” (blue) 
Inhibition Studies in Human Cell Lysates 
 DU145 lysates: DU145 cells were purchased from American Type Culture Collection 
(ATCC; Manassas, VA) and were cultured in Dulbecco’s modified Eagle’s medium (DMEM) 
(Sigma; St. Louis, MO) supplemented with 10% fetal bovine serum (FBS) (Invitrogen; Carlsbad, 
TCA) according to ATCC guidelines. Cells were maintained in a 37 °C humidified incubator 
ventilated with 5% CO2. Lysates were obtained by culturing cells to roughly 80% confluency on 
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uncoated 100-mm
2
 tissue culture dishes. Cells were then washed with phosphate-buffered saline 
(PBS), scraped and collected in 250 mM sucrose, 25 mM MES, 1 mM EDTA, pH 6.5, and 0.1% 
Triton X-100 (SME). Cells were lysed by gentle sonication followed by passing through a 26-
gauge needle. For each experiment the lysates in SME were diluted 8 times with assay buffer 
solution containing 400 mM sodium acetate, pH 5.5, 4 mM EDTA, and 8 mM DTT. The 
inhibitor was prepared as a 1% DMSO solution in the activated lysates buffer solution and plated 
(50 μL). All 3 experiments in triplicates (119, 123 in the dark, and 123 photolyzed) were plated 
on the same 96 well plate. The wells containing 119 and 123 “dark” were carefully wrapped in 
aluminum foil and the plate exposed to visible light. The photolysis was conducted for 10 min 
(with gentle shaking of the plate every 2-3 min) using a 250 W tungsten halogen lamp (Osram 
Xenophot HLX) powered by a 24 V power supply. The irradiation wavelength was selected by 
placing a bandpass filter (395 nm cutoff) between the lamp and the sample, along with a 10 cm 
water cell to absorb infrared light. After photolysis, the reaction was initiated by addition of 50 
μL of 200 μM Z-Arg-Arg-AMC solution in the assay buffer (final volume 100 μL). Cathepsin 
enzyme activity was determined from kinetic measurements performed by fluorometric detection 
of the hydrolysis product AMC at 37 °C every 2 min for 14 min (8 measures) and MAX slope 
values used for plotting. 
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Figure 48: IC50 curve for inhibition of cathepsin B activity from DU145 lysates with 119 (red), 
123 “light” (yellow), and 123 “dark” (blue) 
 Human Bone Marrow Stromal Cell (hBMSC) lysates. Human bone marrow stromal 
cells (hBMSC) were derived from human male fetal femurs as previously described.
153
 Cells 
were cultured in DMEM supplemented with 10% FBS, and maintained in a 37°C humidified 
incubator ventilated with 5% CO2. Lysates were obtained by culturing cells to roughly 80% 
confluency on uncoated 100-mm
2
 tissue culture dishes. Cells were then washed with phosphate-
buffered saline (PBS), scraped and collected in 250 mM sucrose, 25 mM MES, 1 mM EDTA, pH 
6.5, and 0.1% Triton X-100 (SME). Cells were then lysed by sonication and by passing through a 
26-gauge needle. For each experiment the lysates in SME were diluted 8 times with assay buffer 
containing 400 mM sodium acetate, pH 5.5, 4 mM EDTA, and 8 mM DTT. The inhibitor was 
prepared as a 1% DMSO solution in the activated lysates buffer solution and plated (50 μL). All 
3 experiments in triplicates (119, 123 in the dark, and 123 photolyzed) were plated on the same 
96 well plate. The wells containing 119 and 123 “dark” were carefully wrapped in aluminum foil 
and the plate exposed to visible light. The photolysis was conducted for 10 min (with gentle 
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shaking of the plate every 2-3 min) using a 250 W tungsten halogen lamp (Osram Xenophot 
HLX) powered by a 24 V power supply. The irradiation wavelength was selected by placing a 
bandpass filter (395 nm cutoff) between the lamp and the sample, along with a 10 cm water cell 
to absorb infrared light. After photolysis, the reaction was initiated by addition of 50 μL of 200 
μM Z-Arg-Arg-AMC solution in the assay buffer (final volume 100 μL). Cathepsin enzyme 
activity was determined from kinetic measurements performed by fluorometric detection of the 
hydrolysis product AMC at 37 °C every 2 min for 14 min (8 measures) and MAX slope values 
used for plotting. 
 
Figure 49: IC50 curve for inhibition of cathepsin B activity from hBMSC lysates with 119 (red), 
123 “light” (yellow), and 123 “dark” (blue) 
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Chapter 3. Synthesis and biological testing of a second 
generation nitrile containing cathepsin K inhibitor caged by 
Ru
II
(bpy)2 and live cell assays 
II.3.A. Background and project design 
 The collaborative effort between the Kodanko, Podgorski and Turro group leading to the 
first example of a caged nitrile-based protease inhibitor was disclosed in the previous chapter. In 
this “proof of concept” approach we have effectively neutralized the reactivity of a small nitrile-
based inhibitor towards a free thiol by covalently attaching it to a Ru center. The design of the 
complex also enabled us to photorelease two equivalents of the inhibitor upon irradiation with 
visible light for ten minutes.
264
 To extend the study of this new class of Ru cages we sought to 
build a new complex caging a more potent inhibitor for cathepsin K. 
 We chose to target cathepsin K as more and more evidence suggests that cathepsin K 
activity in bone marrow macrophages is associated with abberant proteolysis in prostate cancer 
metastases.
153
 The choice for the new inhibitor was motivated by several factors. The inhibitor 
used in our initial study
264
 (Chapter II.2.B. ) was only a modest inhibitor of cathepsin K with 
literature data suggesting a Ki = 7.5 μM
258
 and our own studies showing an IC50 = 12 μM; the use 
of a more potent inhibitor in this second generation Ru cage was the natural step forward. One of 
the goals of this new series of studies was to demonstrate that our strategy could be used to 
survey protease activity in living cells. The desired inhibitor would preferentially have structural 
similarities to avoid changing too many parameters compared to the initial work. Our choice was 
directed towards inhibitor Cbz-Leu-Gly-ψ[C≡N] 124 that could be easily synthesized from Cbz 
protected L-leucine and shows two hundred times more inhibitory activity compared to 119.
272
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Moreover, 124 has been previously used to inhibit cathepsin K in live cell assays.
273
 The 
synthesis, characterization, stability in the dark and upon exposure to light, enzymatic assays on 
isolated cathepsin K and in cellulo assays as well as cytotoxicity studies of this new Ru-caged 
nitrile-based cathepsin K inhibitor will be presented in the next sections. 
 
Figure 50: Cathepsin K inhibitor chosen for the second generation Ru-caged complex with 
literature reported IC50 and Kivalues 
II.3.B. Results and discussion 
II.3.B.a. Synthesis of nitrile cathepsin K inhibitor 124 
 The synthesis of 124 is even more straightforward than that of 119. Commercially 
available (or accessible in one step from L-leucine) Cbz-protected L-leucine 125 was coupled 
with glycine amino nitrile under HBTU conditions to give the coupled product 124 in a 45 % 
isolated yield over two steps from free L-leucine.  
 
Scheme 18: Synthesis of cathepsin K nitrile inhibitor Cbz-Leu-Gly-ψ[C≡N] 124 
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II.3.B.b. Synthesis of cis-[Ru(bpy)2(124)2]Cl2 
 With the nitrile inhibitor in hand, the method developed in the initial work (presented in 
the previous chapter) was applied to the synthesis of this new Ru complex. When cis-
Ru
II
(bpy)2Cl2 was reacted with four equivalents of 124 along with three equivalents of AgBF4 in 
EtOH in the dark (prepared under N2 atmosphere in a glove box), a quick formation of a dark 
purple-black solution was observed that turned bright orange upon heating to reflux for six hours 
(kept rigorously in the dark). After filtration and concentration, the 
1
H NMR spectrum of the 
crude product indicated clean formation of the final complex and no other Ru-based side 
products. The crude complex was dissolved in EtOAc saturated with n-Bu4NCl and upon cooling 
to -20 °C an oily orange residue was obtained. Several washings with cold Et2O and toluene 
were effective to remove excess n-Bu4NCl and the final complex was precipitated in analytically 
pure form with cold acetone/Et2O.
a
 
                                                 
 
a
 The same complex was resynthesized and isolated in a different manner by Raj Sharma, a colleague from the 
Kodanko group, since this work had been completed. A better purity of the complex was obtained leading to better 
“dark/light” ratios. Investigations to explain the differences in the results are in progress.  
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Scheme 19: Synthesis of cis-[Ru
II
(bpy)2(124)2]Cl2 
II.3.B.c. Characterization of cis-[RuII(bpy)2(124)2]Cl2 
 Similarly to the previously described complex 123, cis-[Ru
II
(bpy)2(124)2]Cl2 (126) was 
obtained as a racemic mixture of both Λ and Δ diastereoisomers. The 1H NMR confirmed this 
observation, and two distinct peaks corresponding to amide protons for each of the 
diastereoisomers were split (see tabulation in experimental section and appendix). 
 
Figure 51: Δ-cis-[Ru(bpy)2(124)2]Cl2 and Λ-cis-[Ru(bpy)2(124)2]Cl2 
 The IR spectrum for 126 shows the characteristic resonance for the CN functional group 
at νCN = 2258 cm
-1
. This resonance is shifted in the complex 126 by 16 cm
-1
 to 2274 cm
-1
 
consistent with the nitrile binding to the Ru center. 
260
 The UV-Vis spectrum of 126 shows a very 
similar set of electronic absorptions compared to related complexes such as cis-
[Ru
II
(bpy)2(MeCN)2]
2+
 and cis-[Ru
II
(bpy)2(119)2]
2+
 with a λmax at 281 nm (ε = 55,600 M
-1
cm
-1
) 
and 412 nm (ε = 9,600 M-1cm-1). Elemental analysis was also consistent with 
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[Ru(bpy)2(124)2]Cl2·3.5H2O. With the identity of the caged Ru-complex confirmed we started 
investigating the stability of the complex in the dark and the photorelease of the nitrile inhibitors. 
II.3.B.d. Stability in the dark and release using light 
 Solutions of 126 (50 μM) in 0.1 M phosphate buffer pH 6.5 (0.5% DMSO) or 400 mM 
sodium acetate, pH 5.5, 4 mM EDTA, 8 mM DTT buffer solution (cathepsin K activity assay) 
(0.5% DMSO) were monitored for decomposition by UV-Vis spectroscopy at RT by following 
the absorbance at 412 nm. First-order rate constants for the decomposition of 126 were 
calculated using slopes of ln A412 vs time graphs. Rate constants were determined to be 1.0x10
-6 
s
-1
 (0.1 M phosphate buffer pH 6.5) and 2.1x10
-6
 s
-1
 (cathepsin K activity assay buffer). These 
values correspond to half-lives t1/2 of ~ 8 and 3.8 days, respectively. 
 Steady-state photolysis experiments were conducted by the Turro group at the Ohio State 
University. The electronic absorption at 412 nm corresponding to the metal to ligand charge 
transfer (MLCT) absorption of the Ru complex 126 at 412 nm was followed by UV-Vis 
spectroscopy. Upon irradiation, the decrease of the intensity of the absorption at 414 nm was 
associated with the advent of an absorption ~ 450 nm within 2-3 minutes of irradiation. This new 
peak is hypothesized to correspond to the Ru→bpy MLCT absorption of the mono-aqua 
complex, cis-[Ru(bpy)2(124)(H2O)]
2+
. With subsequent irradiation up to 15 minutes, the peak ~ 
450 nm gradually disappears but a new absorption can be spotted at 486 nm with no additional 
change upon irradiation for more than 15 minutes. The peak at 486 nm (ε = 9,600 M–1cm–1) is 
attributed to cis-[Ru(bpy)2(H2O)2]
2+
 according to similar photorelease data from other studies.
218, 
261
 The quantum yield of intermediate (I) to product (P), I P, was calculated using the equation 
R P = R I • I P. The quantum yield for the conversion of the reactant (R) 126 to the 
intermediate (I) cis-[Ru(bpy)2(124)(H2O)]
2+
 (ΦR→I) and to the product (P) cis-
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[Ru(bpy)2(H2O)2]
2+
 (ΦR→P) were determined, as previously described for cis-
[Ru(bpy)2(119)2](PF6)2, to be 0.050(6) and 0.0067(4), respectively (λirr = 400 nm). These values 
are significantly lower than those reported for the photoaquation of the related complex cis-
[Ru(bpy)2(MeCN)2]
2+
 
254
 but are similar to those measured for cis-[Ru(bpy)2(119)2](PF6)2 (see 
II.3.D.b. for more details). 
 
Figure 52: Changes to the electronic absorption spectrum of 52 M cis-[Ru(bpy)2(124)2]Cl2 
(126) in a 1% DMSO aqueous solution upon irradiation ( irr > 395 nm) at tirr = 0, 3, 4, 5, 6, 7, 8, 
10 and 15 min; inset: 0, 1 and 2 min 
 The results shown above complete the initial requirements for a potential Ru-based cage 
of a nitrile-based cathepsin K inhibitor. The complex 126 has similar stability properties in 
aqueous solutions to complex 123 in the dark, and dissociates upon irradiation with light under 
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similar conditions (15 minute irradiation is needed versus ten minutes for complex 123). The 
complex 126 was then tested as an inhibitor of cathepsin K activity on the isolated enzyme and 
in living cells. 
II.3.B.e. Biological evaluation of a nitrile containing cathepsin K inhibitor 
124 caged by Ru
II
(bpy)2 (126) against isolated human cathepsin K 
 Inhibition studies with isolated human cathepsin K were conducted according to the 
procedures described in the previous chapter.
264
 Enzyme activity was determined with the 
fluorogenic substrates Z-Phe-Arg-AMC and is expressed as a percentage, with 100% equal to 
activity in the absence of inhibitor. Photolysis was conducted for 15 min (with gentle shaking of 
the plate every 2-3 min) using a 250 W tungsten halogen lamp (Osram Xenophot HLX) powered 
by a 24 V power supply. The irradiation wavelength was selected by placing a bandpass filter 
(395 nm cutoff) between the lamp and the sample, along with a 10 cm water cell to absorb 
infrared light. Different concentrations of the inhibitor 124 alone and Ru complex 126 were 
plated on a 96 well plate in sextuplets (a series of triplicates on the right and left side of the 
plate). Half of the plate was covered with aluminum foil to keep one series of triplicates in the 
dark while the other series was irradiated following the set-up described above. 
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Figure 53: IC50 curves for inhibitor 124 (red, “dark”; green, “light”) and cis-[Ru(bpy)2(124)2]Cl2 
(126) (black, “dark”; blue, “light”) against isolated cathepsin K. 
 Inhibitor 124 was a much more potent inhibitor of human cathepsin K showing an IC50 
value of 550 nM compared to 12 μM for 119. This value was in accordance with the literature 
data giving a Ki = 35 nM that can be converted to IC50 values using a web based tool.
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Significant enhancement of inhibitory activity upon irradiation of 126 with visible light was 
noted once again with IC50 values of 290 nM and 2.4 μM for 126 after irradiation and in the dark 
respectively.
b
 We still hypothesize that the inhibition in the dark is probably due to either 
                                                 
 
b
The same complex has been resynthesized and isolated in a different manner by Raj Sharma, a colleague from the 
Kodanko group, since this work has been completed. A better purity of the complex has been obtained leading to 
better “dark/light” ratios. Investigations to explain the differences in the results are in progress.   
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nonbonding interactions of cis-[Ru
II
(bpy)2(124)2]
2+
 with the enzyme or small amounts of 124 
released during the different manipulations. The latter results are in agreement with our previous 
studies, suggesting that two molecules of nitrile-based inhibitor are released from every molecule 
of the complex and that the new complex is overall a more potent inhibitor of cathepsin K (290 
nM vs. 5.4 μM)264 that should be more suitable for live cell assays. 
II.3.B.f. Biological evaluation of a nitrile containing cathepsin K inhibitor 
124 caged by Ru
II
(bpy)2 (126) in live cells 
 To show the full potential of our caging strategy we were interested in the possibility of 
inhibiting cathepsin K activity in live cells. Bone macrophage cells (BMM) differentiated as pre-
osteoclast were chosen as the target cells because they express high levels of cathepsin K and 
have been recently linked to inflammatory, osteolytic and tumor cell-driven events in bone-
tumor microenvironments.
156
 We chose an established live cell assay to monitor the activity of 
cathepsin K that combines the power of confocal microscopy
275
 with a modified substrate, 
namely Z-Gly-Pro-Arg-4-methoxy- -naphthylamide (Z-Gly-Pro-Arg-4MβNA) that leads to 4-
methoxy- -naphthylamine.
273
 The latter is precipitated upon reaction with nitrosalicylaldehyde 
and can be detected and quantified by fluorescence measurements. Because cathepsin B is 
usually expressed in higher concentration than cathepsin K, the cells were treated with 1 μM 
epoxide-based cathepsin B specific inhibitor CA074 to ensure that only activity due to cathepsin 
K was assessed. 
 Cells were treated with four concentrations of 126 from 1 nM to 10 μM and 1 μM CA074 
and incubated for 30 minutes. After a thorough wash, to remove all extracellular inhibitors, the 
cells were split in two and either irradiated with visible light for 15 minutes or kept in the dark. 
The cells were then treated with 1.0 mM Z-Gly-Pro-Arg-4MβNA and 0.5 mM 
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nitrosalicylaldehyde for 30 minutes and after a second wash, fixed with 1% formaldehyde. The 
activity was measured using a confocal laser scanning microscope (Zeiss LSM 510) and DAPI 
was used as the nuclear dye. Controls with cells treated with buffer only or cis-
[Ru
II
(bpy)2(MeCN)2](PF6)2 were examined in the same way. Activity was detected by a green 
coloration whereas the nuclei were colored in blue (DAPI). The upper left quadrant corresponds 
to the activity due to cathepsin K (green coloration), the lower left denotes the nuclei stained 
with DAPI (blue coloration), the lower right is the superposition of the two left quadrants and 
finally the upper right quadrant corresponds to the raw image (Figure 54). 
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Figure 54: Confocal microscopy images of mouse bone marrow macrophages cells treated with 
250 nM complex 126 plus CA074 (1 μM) for measuring specific Cat K activity, with or without 
irradiation, plus controls 
 To our delight, cells treated with 250 nM 126 and irradiated with light did not show any 
activity associated with cathepsin K whereas cells treated with the same concentration of 
inhibitor 126 and left in the dark showed activity levels comparable to cells treated with the 
buffer solution alone. Moreover, all activity for the cells left in the dark (green) was associated 
around the nuclei (blue) suggesting that the intracellular activity of cathepsin K could be 
knocked down using our light activated inhibitor 126. 
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Figure 55: Quantitative analysis of cathepsin K inhibition by cis-[Ru(bpy)2(124)2]Cl2 (126) in 
live bone marrow macrophages (BMMs) under the dark and light conditions 
(All data were analyzed using Graph Prizm software and are shown as mean  S.D. * indicates p 
= 0.08; ** indicates p = 0.02; and *** indicates p = 0.003; p values < 0.05 are considered 
statistically significant. Results are representative of at least 3 experiments) 
 The fluorescence data was quantified to give a better assessment of the efficacy of 126 to 
inhibit the activity of cathepsin K. Four snapshots were taken per microscope plate (each 
corresponding to different conditions) and the images of control and complex 126-treated BMMs 
(4 images/treatment) were analyzed using MetaMorph software. Integrated intensities of green 
fluorescence were normalized to the number of nuclei (DAPI). Graph A shows CTSK activity in 
BMMs in the absence (control) or presence of increasing concentrations of complex 126 after 
exposure to light (Figure 55). Integrated intensity/nuclei values were normalized to controls and 
expressed as percent activity in the dark. A dose-dependent inhibition of cathepsin K activity is 
observed with increasing concentrations of complex 126 and is completely abolished at 250 nM. 
Graph B shows cathepsin K activity in BMMs treated with 250 nM and 1 μM complex 
concentrations of 126 under dark and light conditions. Data are shown as percent activity under 
control conditions. At 250 nM complex 126 completely inhibits cathepsin K activity with light 
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but not dark exposure. At 1 μM concentration, inhibition of cathepsin K is observed under both, 
light and dark conditions (Figure 55). 
 These data strongly suggest that light activation of the nitrile-based inhibitor 126 has 
been accomplished in a dose-dependent fashion. Cathepsin K activity can be thus controlled with 
light demonstrating the usefulness of this strategy to study the effects of activity/inhibition of 
activity of cathepsin K on different disease states in a spatially controlled fashion. Ideally this 
strategy could enable spatial knockdown of cathepsin K in selected cells/areas of living 
organisms. To further demonstrate the robustness of the Ru
II
(bpy)2 cage strategy, we decided to 
investigate cell viability after treatment with our Ru complex 126 
II.3.B.g. Toxicity evaluation of a nitrile containing cathepsin K inhibitor 
124 caged by Ru
II
(bpy)2 (126) 
 As a final complement to this study, we were interested in gaining insight into the 
possible toxic effects of the ruthenium complexes on the cells under both light and dark 
conditions. The possible product of the photorelease, namely cis-[Ru
II
(bpy)2(H2O)2]
2+
 is a 
potential anticancer agent, with a mode of action mimicking that of cisplatin by covalently 
bonding to DNA.
232, 233, 235, 236
 To address this question, it was decided to test the viability of the 
same BMM cells as the ones used in the previous live cell assay using the MTT (3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, a yellow tetrazole) assay. Cells were 
treated with concentrations of 126 and cis-[Ru
II
(bpy)2(MeCN)2]Cl2 between 1 nM and 100 μM, 
incubated for 30 min, washed thoroughly and irradiated for 15 minutes or left in the dark 
(following the same procedure as in the live cell assay). Cell viability was assessed after 24 
hours using the MTT assay, showing no cytotoxicity for any of the compounds at any 
concentration.  
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Figure 56: BMM cell viability 24 hours after treatment with various concentrations of 126 or 
cis-[Ru
II
(bpy)2(MeCN)2]Cl2 assayed using the MTT assay 
 Because growth inhibitory effects have been reported in the literature for certain Ru 
complexes with treatments extended to 72 hours,
203
 we repeated the latter study with PC3 cells 
(BMM cells were unfortunately not well suited for a prolonged study). Following the same 
protocol as described previously, PC3 cells were assessed for viability using the MTT assay after 
72 hours and once again did not show any signs of cytotoxicity. 
 
Figure 57: PC3 cell viability 72 hours after treatment with various concentrations of 126 or cis-
[Ru
II
(bpy)2(MeCN)2]Cl2 assayed using the MTT assay 
 
 The lack of cytotoxicity underlines even more the potential of the Ru cage strategy. The 
cage does not seem to have any toxic side effects upon treatment with high micromolar 
concentrations of 126 or control Ru complex cis-[Ru
II
(bpy)2(MeCN)2]Cl2 and has been shown in 
the previous section to be effective at inhibiting the activity of cathepsin K in high nanomolar 
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concentrations. Further studies with extended treatment times might be required to completely 
rule out any toxic effects associated with the Ru
II
(bpy)2 cage. 
Also, studies that could clarify the pharmacokinetics of Ru complexes such as 126 or cis-
[Ru
II
(bpy)2(MeCN)2]Cl2 need to be designed. It is not clear if the Ru complexes penetrate the 
cell membranes. The effective inhibition of cathepsin K could be explained through at least two 
scenarios where either the Ru cage penetrates the cells, and then releases the nitrile-based 
inhibitors inside or only associates with cell membranes releasing the nitrile-based inhibitor 
outside of the cell, followed by inhibitor penetration. Because complexes like 126 are not 
luminescent at RT,
276
 we have not been able to determine the fate of the complexes so far. We 
have tried to investigate potential Ru accumulation in cells, that was analyzed by atomic 
absorption, but the low concentrations found did not provide conclusive results .
203
 Knowing the 
faith of the Ru complexes could bring more understanding to their potential toxic effects. 
II.3.C. Conclusions and further directions 
 The results presented in this chapter describe an efficient way of caging nitrile based 
cathepsin inhibitors and activating them within minutes upon exposure to visible light. We have 
extended our initial studies on isolated enzymes to living cells. We demonstrated a dose-
dependent inactivation of cathepsin K with our Ru complex 126 and the nitrile-based inhibitor 
124 that is released upon irradiation with visible light at high nanomolar concentrations. 
Moreover, the Ru
II
(bpy)2 did not show any toxic effects with high micromolar concentrations 
highlighting the usefulness of this strategy to selectively inhibit targets with spatial and kinetic 
control. We believe this strategy can be an extremely useful tool to study aberrant proteolysis in 
cancer models as well as animal models. This successful study also opens a number of doors for 
new and challenging analyses as number of parameters need to be addressed and improved. 
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 We chose to use a moderate inhibitor of cathepsin K in this study as cathepsin K has 
become a very alluring target for various disease states and bone tumor growth in particular. 
Cathepsin K is largely overexpressed in metastases to the bone from prostate
277
 and breast 
cancers
278
 and bone lesions from such metastases are very severe and often irreversible.
279
 The 
use of this caging strategy might be a very interesting tool in the study of the effects of cathepsin 
K inhibition in bone marrow macrophages and osteoclasts that have been demonstrated to highly 
overexpress cathepsin K.
153
 Because proteases in general, and cathepsins in particular, are such 
an attractive therapeutic target, several families of very potent inhibitors have been designed by 
SAR studies. Molecules such as odanacatib
157
 have successfully entered clinical trials offering a 
wide variety of potential nitrile-based inhibitors that can be used in our caging strategy. The 
variety of motifs already synthesized and tested by others might be a very helpful benefit to 
modulate the pharmacokinetics and pharmacodynamics of future complexes. 
 Families of targets other than cathepsins such as caspases are also effectively inhibited by 
nitrile-based inhibitors. We strongly believe that the strategy described here could be a general 
methodology to study protease inactivation in a light controlled fashion. To achieve this goal, 
further studies are in progress in the Kodanko, Podgorski and Turro laboratories. We are actively 
caging new, more potent inhibitors and trying to improve the dark/light activation ratios. The 
modulation of the bpy moieties should have a direct influence on the MLCT absorption band. 
We are hoping to improve the photodissociation quantum yields and shift the necessary 
irradiation wavelengths towards the near-IR wavelengths as light with longer wavelengths 
penetrates deeper within tissues and is less toxic. Finally, we are designing new complexes that 
could allow us to study their biological fate after cell treatment and photodissociation. Building 
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complexes that are luminescent at RT or using flow cytometry are some of the strategies that we 
have envisioned so far. 
 In conclusion, this part of the dissertation described the first metal based caging strategy 
for nitrile-based inhibitors. In our initial study, we built “proof of concept” RuII(bpy)2 cages that 
effectively deliver and inhibit cysteine proteases upon delivery of nitrile-based inhibitors 
triggered by light. After fully characterizing the new complexes and their behavior in aqueous 
solutions in the dark and upon irradiation with visible light we have shown high dark/light 
inactivation ratios on isolated enzymes and have extended the applications to the inactivation of 
cathepsin K in living cells in the latest study. By showing that no toxic effects are associated 
with the use of Ru
II
(bpy)2 as a cage, further studies will be carried out to establish this 
methodology as a general method to study proteolysis in a spatially controlled fashion in vivo. 
The results presented in this chapter will be published in due time (Respondek T., Sharma 
R., Garner R. N., Herroon M. K., Podgorski I., Turro C., Kodanko J. J.): “Targeting intracellular 
proteolysis with a light-activated cathepsin K inhibitor” Manuscript in preparation. 
II.3.D. Experimental section 
II.3.D.a. General considerations 
 All reagents were purchased from commercial suppliers and used as received. NMR 
spectra were recorded on a Varian FT-NMR Mercury-400 Spectrometer. Mass spectra were 
recorded on a Waters ZQ2000 single quadrupole mass spectrometer using an electrospray 
ionization source. IR spectra were recorded on a Perkin Elmer Spectrum 2000 FT-IR 
Spectrometer. Enzymatic assays (CatK inhibition, MTT and Bradford) were conducted on a 
Tecan Infinite M200 or Tecan SPECTRAFluor Plus microplate reader. UV-vis spectra were 
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recorded on a Varian Cary 50 spectrophotometer. Time-dependent UV-Vis spectra were 
recorded on a Varian Cary 50 spectrophotometer. The photolysis experiments were conducted 
using a 250 W Tungsten Halogen lamp (Osram Xenophot HLX) powered by a 24 V power 
source. The irradiation wavelength was selected by placing a bandpass filter (395 nm cutoff) 
between the lamp and the sample, along with a 10 cm water cell to absorb infrared light. The 
confocal microscopy was performed with a Zeiss 510 Laser Scanning Microscope. All reactions 
were performed under ambient atmosphere unless otherwise noted. Anaerobic reactions were 
performed by purging the reaction solutions with Ar or N2. 
 All NMR, IR and mass spectra can be found in the Appendix section. 
II.3.D.b. Experimental procedures and tabulated characterization data 
(S)-benzyl (1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-yl)carbamate (124). 
 
 124 was prepared by a modification of published procedures.
258, 272
 L-leucine (15.0 
mmol, 1.97 g) was dissolved in 18.5 mL of 2.0 M NaOH and cooled to 0°C. Benzyl 
chloroformate (17.3 mmol, 2.46 mL) was added in small portions over 30 min and the resulting 
solution stirred at RT for 12 h. The crude reaction solution was then acidified with 6.0 N HCl 
and extracted with EtOAc (3 x 30 mL). The organic layers were combined, dried over Na2SO4, 
filtered and concentrated to give 3.82 g of a sticky white solid. The crude product Cbz-Leu-OH 
was analyzed by 
1
H NMR spectroscopy (> 90% purity) and was used without further 
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purification. Crude Cbz-Leu-OH (7.00 mmol, 1.86 g) was dissolved in dry DMF (10.0 mL). 
Aminoacetonitrile HCl (8.40 mmol, 777 mg) was mixed with HBTU (8.4 mmol, 3.19 g) and 
Et3N (16.8 mmol, 2.36 mL) and dissolved in dry DMF (30.0 mL). Both solutions were combined 
and the resulting solution stirred under N2 for 16 h. The crude reaction solution was combined 
with CH2Cl2 (75 mL) and the organic layer was washed with 0.1 M HCl (2 x 30 mL), 1.0 M HCl 
(1 x 30 mL), sat. aqueous NaHCO3 (2 x 30 mL) and brine (2 x 30 mL). The organic layer was 
dried over Na2SO4, filtered and concentrated. The crude product was recrystallized from hot 
EtOAc/Hexanes to give 124 as a white powder (950 mg, 45% from the first crop over the 2 
steps). Mother liquors can be further recrystalized or purified by flash chromatography on silica. 
1
H NMR (400MHz CD2Cl2-d6 ) 7.33 (m, 5H), 7.06 (br, s, NH, 1H), 5.39 (br, s, NH, 1H), 5.0 
(Aq, 2H), 4.21 (br, s, 1H), 4.05 (d, J = 3.9 Hz, 2H), 1.63 (m, 2H), 1.52 (m, 1H), 0.91 (d, J = 6.4 
Hz, 3H), 0.89 (d, J = 5.9 Hz, 3H); 
13
C NMR (100MHz CD2Cl2-d6 ) 172.68, 156.48, 136.22, 
128.52, 128.21, 127.89, 116.07, 67.20, 40.66, 27.48, 24.62, 22.63, 21.48; [α]D
20
 – 33.9 (c 1.0, 
CH2Cl2); mp 125.5-127 °C; IR νmax (thin film, cm
-1
): 3306, 3065, 3036, 2958, 2872, 2258, 1693, 
1673, 1531, 1537, 1469, 1455, 1411, 1388, 1369, 1342, 1261, 1238, 1172, 1121, 1043, 1028, 
964, 909, 778, 739, 697; LRMS (ESMS) calculated for C16H22N3O3 [M+H]
+
: 304.2, found: 
304.5. 
Δ-cis-[Ru(bpy)2(124)2]Cl2 3.5H2O and Λ-cis-[Ru(bpy)2(124)2]Cl2·3.5H2O (126): 
148 
 
 
 In the glove box, a shlenk flask was charged with cis-Ru(bpy)2Cl2 (0.1 mmol 48.4 mg), 
AgBF4 ( 0.4 mmol 77.9 mg) and (S)-benzyl (1-((cyanomethyl)amino)-4-methyl-1-oxopentan-2-
yl)carbamate (124) (0.6 mmol 91.0 mg) and 20.0 ml of freshly distilled EtOH. The resulting 
solution was wrapped in aluminum foil and heated to 80°C for 6 h during which it turned from 
dark violet to bright orange. After cooling the crude solution to RT, it was placed in the freezer at 
-20°C for 16 h. The precipitated silver salts were filtered off on celite and washed with cold 
EtOH. The solvents were removed under reduced pressure and an NMR taken to monitor the 
completion of the reaction and formation of Ru by-products. The resulting yellow solid was 
dissolved in ~2 ml of acetone and layered with ~10 ml of Et2O and placed in the freezer at -20°C 
for 16 h. The solid was filtered off and washed with cold Et2O. The resulting solid was dissolved 
in ~15 ml of EtOAc and extracted 3 times with 15 ml H2O. The organic layer was then 
precipitated (oily residue) with 2 ml of sat. n-Bu4NCl in EtOAc at -20°C. The oily residue was 
spun out and washed with cold EtOAc (3 times), and then cold Toluene (7 times). It was finally 
dissolved in a minimum amount of acetone and layered with Et2O and placed -20°C for 16 h. 
The resulting solid was washed with Et2O to give the title compound as an orange solid in 
analytically pure form (21.0 mg, 0.019 mmol, 19%): 
1
H NMR (400MHz CD2Cl2-d2 ) 9.93 (s, 
br, 2H), 9.54 (d, J = 4.9 Hz, 1H), 9.51 (d, J = 4.9 Hz, 1H), 8.53 (d, J = 8.1 Hz, 1H), 8.45 (d, J = 
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8.1 Hz, 2H), 8.36 (d, J = 8.1 Hz, 1H), 8.15 (m, 2H), 8.02 (m, 2H ), 7.93 (m, 2H), 7.54 (d, J = 5.9 
Hz, 2H), 7.32 (m, 8H), 7.25 (m, 2H), 6.86 (d, J = 9.7 Hz, 1H, NH), 6.74 (d, J = 8.1 Hz, 1H, NH), 
5.04 (m, 3H), 4.16 (d, J = 12.2, 1H), 4.28 (m, 6H), 1.08 (under the H2O peak, m, 4H), 0.91 (m, 
12H); IR (KBr) νmax (cm
-1
): 3419, 3029, 2957, 2870, 2347, 2274, 1714, 1676, 1604, 1523, 1466, 
1446, 1424, 1386, 1337, 1246, 1170, 1122, 1047, 917, 771, 731, 698, 670; LRMS (ESMS) 
calculated for C52H58N10O6Ru [M]
2+
: 510.2, found: 510.1; Anal. Calcd for C52H65Cl2N10O9.5Ru 
([Ru(bpy)2(1)2]Cl2.3.5H2O): C, 54.12; H, 5.68; N, 12.14. Found: C, 54.16; H, 5.46; N, 12.13.  
General Considerations for the Time Dependent UV-Vis spectra: 
 Time dependent UV-Vis spectra were recorded on a Varian Cary 50 spectrophotometer. 
The photolysis experiments were conducted using a 250 W Tungsten Halogen lamp (Osram 
Xenophot HLX) powered by a 24 V power source. The irradiation wavelength was selected by 
placing a bandpass filter (395 nm cutoff) between the lamp and the sample, along with a 10 cm 
water cell to absorb infrared light. 
Stability of 126 in 0.1M pH 6.5 phosphate buffer: 
 A 50 μM solution of 126 in a 0.1M pH 6.5 phosphate buffer (1.0% DMSO) was placed in 
a cell, and UV-Vis spectra recorded for 12 h (the cell was shaken to help diffusion before the 
start of the experiment). Ln A was plotted vs. time and fitted to give a first order reaction rate r = 
0.00006026 min
-1
. The half life corresponding to this rate was approximately 11500 min ~ 8.0 
days (t1/2 = -0.693/r). 
Stability of 126 in CatK assay buffer: 
 A 50 μM solution of 126 in a 400 mM sodium acetate, pH 5.5, 4 mM EDTA, 8 mM DTT 
buffer solution (0.5% DMSO) was placed in a cell, and UV-Vis spectra recorded for 6 h (the cell 
was shaken to help diffusion). Ln A was plotted vs. time and fitted to give a first order reaction 
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rate r = 0.00012802 min
-1
. The half life corresponding to this rate was approximately 5413 min ~ 
3.75 days (t1/2 = 0.693/r). 
Quantum yield and time dependent UV-vis spectra upon irradiation of 126: 
 Steady-state photolysis experiments for quantum yield determination were conducted 
using a 150 W Xe arc lamp in a PTI housing (Milliarc Compact Lamp Housing) powered by an 
LPS-220 power supply  (PTI) with an LPS-221 igniter (PTI) as a source. The irradiation 
wavelength was selected by placing long-pass colored glass filters (Melles Griot) or bandpass 
filters (Newport) between the lamp and the sample, along with a 10 cm water cell to absorb 
infrared light. Electronic absorption spectra were collected on a diode array spectrometer (HP 
8453) with HP 8453 Win System software. 
 Quantum yields were measured relative to ferrioxalate using a standard procedure.
266
 The 
quantum yield of reactant (R) to intermediate (I), R I, was determined by monitoring the 
decease in the MLCT absorption of the reactant at 414 nm up to 5% of the reaction. The 
quantum yield of reactant (R) to product (P), R P, was determined by monitoring the increase 
in the absorption of the latter with maximum at 490 nm. The quantum yield of intermediate (I) to 
product (P), I P, was calculated using the equation R P = R I • I P.  The quantum yield 
for the conversion of the reactant (R) 126 to the intermediate (I) cis-[Ru(bpy)2(124)(H2O)]
2+
 
(ΦR→I) and to the product (P) cis-[Ru(bpy)2(H2O)2]
2+
 (ΦR→P) were determined, as previously 
described for cis-[Ru(bpy)2(119)2](PF6)2,
264
 to be 0.050(6) and 0.0067(4), respectively (λirr = 400 
nm). These values are significantly lower than those reported for the photoaquation of the related 
complex cis-[Ru(bpy)2(CH3CN)2]
2+
,
254
 but are similar to those measured for cis-
[Ru(bpy)2(119)2](PF6)2.
264
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II.3.D.c. Cathepsin K inhibition studies 
Cathepsin K inhibition studies. 
 Cathepsin enzyme activity was determined from kinetic measurements performed by 
fluorimetric detection of the hydrolysis product AMC at 37°C every 2 min for 14 min (8 
measures). The excitation and emission wavelengths were 360 and 485 nm respectively. The 
selective fluorescent substrate Z-Phe-Arg-AMC was used at a final concentration of 100 μM 
(obtained from Bachem, Torrance, CA). Enzyme activities are expressed as a percentage, with 
100% equal to activity in the absence of inhibitor. Recombinant cathepsin K (human) was 
obtained from Enzo Life Sciences (Farmingdale, NY). An 880 nM stock solution was prepared 
in 50 mM sodium acetate, pH 5.5, 50 mM NaCl, 0.5 mM EDTA and 5 mM DTT and kept at -
80°C. For each experiment the stock solution was diluted 440 times and activated for 15 min at 
37°C with a 400 mM sodium acetate, pH 5.5, 4 mM EDTA, 8 mM DTT assay buffer solution. 
The inhibitor was prepared as a 1% DMSO solution in the activated enzyme buffer solution and 
plated (Corning® 96 Well Flat Clear Bottom Black Polystyrene TC-Treated Microplates, 50 
μL/well). Three experiments in triplicates (124 or 126, light or dark) were carried out on the 
same 96 well plate. The wells containing 124 and 126 “dark” were carefully wrapped in 
aluminum foil and the plate was exposed to visible light. The photolysis was conducted for 15 
min (with gentle shaking of the plate every 2-3 min) using a 250 W tungsten halogen lamp 
(Osram Xenophot HLX) powered by a 24 V power supply. The irradiation wavelength was 
selected by placing a bandpass filter (395 nm cutoff) between the lamp and the sample, along 
with a 10 cm water cell to absorb infrared light. After photolysis, the reaction was initiated by 
addition of 50 μL of 200 μM Z-Phe-Arg-AMC solution in the assay buffer (final volume 100 μL, 
final enzyme concentration 1 nM). Cathepsin enzyme activity was determined from kinetic 
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measurements performed by fluorimetric detection of the hydrolysis product AMC at 37°C every 
2 min for 14 min (8 measures) and MAX RFU slope values used for plotting  
Cell Assays and Imaging. 
 The live cell cathepsin K activity staining assays were performed following a method 
described previously.
275
 Briefly, bone marrow macrophages (BMMs) were derived from FVBN 
mice as previously described.
156
 BMMs were cultured in 24-well plates on acid-washed 
coverslips in MEMα media (Sigma) containing 10% fetal bovine serum (FBS), 10 ng/ml 
RANKL (R&D Systems), and 20 ng/ml MCSF (R&D Systems) to induce pre-osteoclast 
differentiation. After 48 hours, media containing fresh RANKL and MCSF was replenished and 
cells were cultured for additional 24 hours. On the day of experiment cells were incubated for 30 
min at 37°C with 250 μL of reaction buffer (0.2 M sodium acetate, pH 6.0, 0.1 mM EDTA and 
0.125 mM BME) containing 124 or 126 (1- 1000 nM, +/- 1μM CA074, a cathepsin B inhibitor) 
in 1% DMSO. After 30 min, the cells were carefully washed with and left in PBS (phosphate 
buffered saline), the “dark” plate was wrapped in aluminum foil, whereas the “light” plate was 
exposed to visible light. The photolysis was conducted for 15 min (with gentle shaking of the 
plate every 2-3 min) using a 250 W tungsten halogen lamp (Osram Xenophot HLX) powered by 
a 24 V power supply, using bandpass and water filters, as described previously. The cells were 
washed with PBS, and treated with 250 μL of substrate solution in reaction buffer consisting of 
1.0 mM Z-Gly-Pro-Arg-4MβNA (cathepsin K substrate), and 1.0 mM nitrosalicylaldehyde 
(precipitating agent). The reaction was allowed to occur for 30 min at 37°C. Controls were 
incubated in the same manner but without substrate (with or without 1.0 μM CA074). After 30 
min, the cells were washed and fixed with 1% formaldehyde for 20 min minutes at RT. After 
being washed with PBS and distilled water, the coverslips were mounted on microscope slides 
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and viewed with a confocal laser scanning microscope (Zeiss LSM 510). DAPI was used as the 
nuclear dye. For quantitative studies, cells were fixed and images captured with Zeiss 510 laser 
confocal microscope using a 40x oil immersion lens. Images of control and complex 3-treated 
BMMs (4 images/treatment) were analyzed using MetaMorph software. Integrated intensities of 
green fluorescence were normalized to the number of nuclei (DAPI). 
II.3.D.d. Cell Viability Determinations.  
 The cell viability of BMM and PC3 prostate carcinoma cells in the presence of 124, 126 
and cis-[Ru(bpy)2(CH3CN)2]
2+
was measured using the MTT assay according to the 
manufacturer’s instructions (Invitrogen, Grand Island, NY). Briefly, the cells were grown in a 96 
well plate for 48 h. After removing the media, the cells were treated with 50 μL solutions of 124, 
126 or cis-[Ru(bpy)2(MeCN)2]Cl2 in the appropriate culture media and incubated for 30 min at 
37°C. The media was then removed, and the cells were washed 3 times and left in PBS buffer. 
The “dark” plate was wrapped in aluminum foil while the “light” plate was exposed to visible 
light. The photolysis was conducted for 15 min (with gentle shaking of the plate every 2-3 min) 
using a 250 W tungsten halogen lamp (Osram Xenophot HLX) powered by a 24 V power supply, 
using bandpass and water filters, as described previously. The cells were washed 6 times with 
PBS buffer. New media was then added and the cells were incubated for 24 h or 72 h in the dark 
under a 5% CO2 atmosphere and 37°C. After the incubation time, the media was removed and 
100 μL of new media was added. 10 μL of a 12 mM MTT stock solution (5 mg of MTT 
dissolved in 1.0 mL of sterile PBS) was then added to each well. The cells were covered and 
incubated for 4 h. A negative control consisting of 10 μL of stock MTT solution added to 100 μL 
media in empty wells was also prepared. 85 μL was then removed form each well and was 
replaced by 50 μL of DMSO, and thoroughly mixed. Absorbance measurements at 540 nM were 
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collected on a microplate reader. Cell viabilities were expressed as a percentage, with 100% 
equal to activity in the absence of any Ru complex. 
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Purity of 77: HPLC chromatogram 
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(S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)-3-phenylpropanoate (89a) : 
 
 
 
174 
 
(S)-benzyl 3-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-
((diphenylmethylene)amino)propanoate (91) : 
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(S)-2-phenylpropan-2-yl 3-(6-(((tert-butyldimethylsilyl)oxy)methyl)pyridin-3-yl)-2-
((diphenylmethylene)amino)propanoate (89b) : 
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(S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)propanoate (89c): 
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(S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)butanoate (89d): 
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(S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)pent-4-enoate (89e) : 
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(S)-2-phenylpropan-2-yl 2-((diphenylmethylene)amino)pent-4-ynoate (89f) : 
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IR spectrum of 123 
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HRMS of 123 and Ru patern for 123 
183 
 
 
 
 
184 
 
 
 
LRMS of 126 
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LRMS of 126: Isotope pattern 
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ABSTRACT 
METHODOLOGIES FOR ATTACHING POLYPYRIDYL LIGANDS INTO AMINO 
ACIDS 
AND 
SYNTHESIS AND BIOLOGICAL EVALUATION OF NOVEL LIGHT ACTIVATED 
PEPTIDOMIMETIC CYSTEINE PROTEASE INHIBITORS 
CAGED BY Ru
II
(bpy)2 
 
by 
 
TOMASZ RESPONDEK 
August 2013 
Advisor: Jeremy J. Kodanko, Ph.D. 
Major: Chemistry (Organic) 
Degree: Doctor of Philosophy 
 Two separate subjects are described in this dissertation. The first part describes novel 
methodologies for attaching polypyridyl ligands into unnatural amino acids. The first chapter 
describes the different possibilities for attaching metal ligands to peptides and their applications 
as potential imaging and therapeutic agents covered so far in the literature. It is followed in the 
second chapter by the description of a new method for the construction of metal-peptide 
conjugates through the use of three unnatural amino acids, and their adaptation to solid phase 
synthesis. The third chapter describes the synthesis of a novel, “optimal” substrate for the 
enantioselective alkylation reaction of glycine benzophenone imine derivatives. Optimization of 
the enantiomeric excess, scope and compatibility with acid-labile containing protecting groups 
are disclosed. 
 The second chapter presents the synthesis of the first caged cysteine protease inhibitor. 
After an introductory survey of different Ru and Pt complexes used as potential therapeutic 
cancer agents, cysteine protease inhibitors are described. The syntheses of Ru
II
(bpy)2 complexes 
209 
 
caging cathepsin inhibitors are revealed with full characterization in the following chapters. The 
stability of the complexes in the dark in aqueous solutions and their ability to release the 
inhibitors upon irradiation with visible light are shown, followed by cathepsin activity inhibition 
studies, in vitro and in cellulo. Finally, the toxicity of the complexes is evaluated in cell viability 
studies.  
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